PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

C12N 9/96 // C11D 3/386, A61K 47/48

 $\mathbf{A1}$

(11) International Publication Number:

WO 00/22103

(43) International Publication Date:

20 April 2000 (20.04.00)

(21) International Application Number:

PCT/DK99/00542

(22) International Filing Date:

12 October 1999 (12.10.99)

(30) Priority Data:

PA 1998 01301 PA 1999 01418 13 October 1998 (13.10.98) DK 4 October 1999 (04.10.99)

DK

(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).

(72) Inventors: OLSEN, Arne, Agerlin; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). VON DER OSTEN, Claus; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). ANDERSEN, Kim, Vilbour; Tåsingegade 31, 4.th, DK-2100 Copenhagen Ø (DK). ERNST, Steffen; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). ROGGEN, Erwin, Ludo; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: A MODIFIED POLYPEPTIDE WITH REDUCED IMMUNE RESPONSE

(57) Abstract

The present invention relates to polypeptides with reduced immune response including reduced allergenicity having one or more amino acid residues being substituted with other amino acid residues and/or having coupled one or more polymeric molecules in the vicinity of the polypeptides metal binding site, a method for preparing modified polypeptides of the invention, the use of said polypeptide for reducing the immunogenicity and allergenicity and compositions comprising said polypeptide.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

							· ·
AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	\mathbf{SZ}	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
\mathbf{BE}	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
\mathbf{BF}	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
\mathbf{CZ}	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		•
$\mathbf{E}\mathbf{E}$	Estonia	LR	Liberia	SG	Singapore		

Title: A MODIFIED POLYPEPTIDE WITH REDUCED IMMUNE RESPONSE

FIELD OF THE INVENTION

The present invention relates to polypeptides having substituted one or more amino acid residues to said polypeptide and/or having coupled polymeric molecules on the surface of the 3-dimensional structure of the polypeptide, a method for preparing modified polypeptides of the invention, the use of said modified polypeptides for reducing the immunogenicity and allergenicity, and compositions comprising said polypeptide.

BACKGROUND OF THE INVENTION

use of polypeptides, including enzymes, 15 circulatory system to obtain a particular physiological effect is well-known in the medical arts. Further, within the arts of industrial applications, such as laundry washing, bleaching, personal care, contact lens cleaning, and food and feed preparation enzymes are used as a functional ingredient. 20 One of the important differences between pharmaceutical and industrial application is that for the latter applications (i.e. industrial applications) the polypeptides (often enzymes) are not intended to enter into the circulatory system of the body.

5 Certain polypeptides and enzymes have an unsatisfactory stability and may under certain circumstances - dependent on the way of challenge - cause an immune response, typically an IgG and/or IgE response.

It is today generally recognized that the stability of polypeptides is improved and the immune response is reduced when polypeptides, such as enzymes, are coupled to polymeric molecules. It is believed that the reduced immune response is a result of the shielding of (the) epitope(s) on the surface of the polypeptide responsible for the immune response leading to antibody formation by the coupled polymeric molecules.

Techniques for conjugating polymeric molecules to polypeptides are well-known in the art.

One of the first suitable commercially techniques was described back in the early 1970'ies and disclosed in e.g. US patent no. 4,179,337. Said patent concerns non-immunogenic polypeptides, such as enzymes and peptide hormones coupled to polyethylene glycol (PEG) or polypropylene glycol (PPG). At least 15% of the polypeptides' physiological activity is maintained.

GB patent no. 1,183,257 (Crook et al.) describes chemistry for conjugation of enzymes to polysaccharides via a triazine 10 ring.

Further, techniques for maintaining of the enzymatic activity of enzyme-polymer conjugates are also known in the art.

WO 93/15189 (Veronese et al.) concerns a method for maintaining the activity in polyethylene glycol-modified proteolytic enzymes by linking the proteolytic enzyme to a macromolecularized inhibitor. The conjugates are intended for medical applications.

It has been found that the attachment of polymeric molecules to a polypeptide often has the effect of reducing the activity of the polypeptide by interfering with the interaction between the polypeptide and its substrate. EP 183 503 (Beecham Group PLC) discloses a development of the above concept by providing conjugates comprising pharmaceutically useful proteins linked to at least one water-soluble polymer by means of a reversible linking group.

EP 471,125 (Kanebo) discloses skin care products comprising a parent protease (*Bacillus* protease with the trade name Esperase®) coupled to polysaccharides through a triazine ring to improve the thermal and preservation stability. The coupling technique used is also described in the above mentioned GB patent no. 1,183,257 (Crook et al.).

JP 3083908 describes a skin cosmetic material which contains a transglutaminase from guinea pig liver modified with one or more water-soluble substance such as PEG, starch, cellulose etc. The modification is performed by activating the polymeric molecules and coupling them to the enzyme. The composition is stated to be mild to the skin.

WO 98/35026 (Novo Nordisk A/S) describes polypeptide-

3

polymer conjugates having added and/or removed one or more attachment groups for coupling polymeric molecules on the surface of the polypeptide structure. The conjugates have reduced immunogenicity and allergenicity.

5

SUMMARY OF THE INVENTION

It is the object of the present invention to provide improved polypeptides suitable for industrial and pharmaceutical applications.

The term "improved polypeptides" means in the context of the present invention polypeptides having a reduced immune response in humans and animals. As will be described further below the immune response is dependent on the way of challenge.

The present inventors have found that polypeptides, such as enzymes, may be made less immunogenic and/or allergenic by substituting one or more amino acid residues on the surface of the polypeptide with other amino acid residues and/or by coupling polymeric molecules on the surface of the enzyme in the vicinity of a bound ligand of the enzyme e.g. a metal ion substantially without affecting the enzymatic activity.

When introducing pharmaceutical polypeptide directly into the circulatory system (i.e. bloodstream) the potential risk is an immunogenic response in the form of mainly IgG, IgA and/or IgM antibodies. In contrast hereto, industrial polypeptides, such as enzymes used as a functional ingredient in e.g. detergents, are not intended to enter the circulatory system. The potential risk in connection with industrial polypeptides is inhalation causing an allergenic response in the form of mainly IgE antibody formation.

Therefore, in connection with industrial polypeptides the potential risk is respiratory allergenicity caused by inhalation, intratracheal and intranasal presentation of polypeptides.

The main potential risk of pharmaceutical polypeptides is immunogenicity caused by intradermal, intravenous or subcutaneous presentation of the polypeptide.

The term "immunogenicity" used in connection with the present invention may be referred to as allergic contact

dermatitis in a clinical setting and is a cell mediated delayed immune response to chemicals that contact and penetrate the skin. This cell mediated reaction is also termed delayed contact hypersensitivity (type IV reaction according to Gell and Combs classification of immune mechanisms in tissue damage).

The term "allergenicity" or "respiratory allergenicity" is initially an immediate anaphylactic reaction (type I antibody-mediated reaction according to Gell and Combs) following inhalation of e.g. polypeptides.

According to the present invention it is possible to provide polypeptides with a reduced immune response, which has a substantially retained residual activity.

The allergic and the immunogenic response are in one term, at least in the context of the present invention called the "immune response".

In the first aspect the invention relates to a polypeptide with reduced immune response, having one or more amino acid residues modified, wherein the C^{α} -atoms of said amino acid residues are located less than 15 Å from the ligand bound to said polypeptide.

The reduced immune response is preferably reduced allergenicity.

The modification of the polypeptide is conducted by substituting one or more amino acid residues in the parent polypeptide with other amino acid residues to said polypeptide, and/or by selecting variants from a diverse library of variants of the parent polypeptide and/or by coupling a polymeric molecule to the surface of the parent polypeptide.

The term "parent polypeptide" refers to the polypeptide to

be modified by coupling to polymeric molecules or by
substituting amino acid residues. The parent polypeptide may be
a naturally-occurring (or wild-type) polypeptide or may be a
variant thereof prepared by any suitable means. For instance,
the parent polypeptide may be a variant of a naturally-occurring

polypeptide which has been modified by substitution, deletion or
truncation of one or more amino acid residues or by addition or
insertion of one or more amino acid residues to the amino acid
sequence of a naturally-occurring polypeptide.

A "suitable attachment group" means in the context of the present invention any amino acid residue group on the surface of the polypeptide capable of coupling to the polymeric molecule in question.

Preferred attachment groups are amino groups of Lysine residues and the N-terminal amino group. Polymeric molecules may also be coupled to the carboxylic acid groups (-COOH) of amino acid residues in the polypeptide chain located on the surface. Carboxylic acid attachment groups may be the carboxylic acid group of Aspartate or Glutamate and the C-terminal COOH-group. Another attachment group is SH-groups in Cysteine.

An "active site" means any amino acid residues and/or molecules which are known to be essential for the performance of the polypeptide, such as catalytic activity, e.g. the catalytic triad residues, Histidine, Aspartate and Serine in Serine proteases, or e.g. the heme group and the distal and proximal Histidines in a peroxidase such as the Arthromyces ramosus peroxidase.

A "ligand", means in the context of the present invention a netal or metal ion or a cofactor.

In the context of the present invention "modification of amino acid residues" means that amino acid residues are substituted with other amino acid residues and/or a polymeric molecule is coupled to the amino acid residue. The polypeptide of the present invention may according to the invention be modified by substitution alone, by coupling of a polymeric molecule alone or by a combination of substitution and coupling.

In the context of the present invention "located" means the shortest distance from any atom in the ligand to the relevant C- atom in the amino acid residue.

Furthermore, in the context of the present invention e.g. "R250K" means that the amino acid Arginine in position 250 of the polypeptide has been substituted with the amino acid Lysine according to the one-letter-code of amino acids.

In the second aspect the invention relates to a method for preparing polypeptides with reduced immune response comprising the steps of:

a) identifying amino acid residues located on the surface of the

6

3-dimensional structure of the parent polypeptide in question,

- b) selecting target amino acid residues on the surface of said
 3-dimensional structure of said parent polypeptide to be modified,
- 5 c) substituting one or more amino acid residues selected in step
 - b) with other amino acid residue, and/or
 - d) coupling polymeric molecules to the amino acid residues in step b) and/or step c).

The invention also relates to the use of a modified polypeptide of the invention and the method of the invention for reducing the immunogenicity of pharmaceuticals and reducing the allergenicity of industrial products.

Finally the invention relates to compositions comprising a modified polypeptide of the invention and further ingredients used in industrial products or pharmaceuticals.

BRIEF DESCRIPTION OG THE DRAWINGS

Figure 1 shows integrated IgE antibudy levels in rats. Figure 2 shows integrated specific IgE levels in mice.

20

DETAILED DESCRIPTION OF THE INVENTION

It is the object of the present invention to provide improved polypeptides suitable for industrial and pharmaceutical applications.

Even though polypeptides used for pharmaceutical applications and industrial application can be quite different the principle of the present invention may be tailored to the specific type of parent polypeptide (i.e. enzyme, hormone peptides etc.).

The present inventors have found that polypeptides, such as enzymes, may be made less immunogenic and/or less allergenic by substituting amino acid residues in the vicinity of the ligand e.g. metal ion at the metal ion binding site and/or by coupling one or more polymeric molecules on the surface of the parent polypeptide. In addition thereto the inventors have found that a high percentage of maintained residual catalytic activity may be maintained in these modified polypeptides.

In the first aspect the invention relates to an improved polypeptide having one or more amino acid residues modified,

wherein the C^{α} -atom of said amino acid residues is located less than 15 Å from the ligand bound to said polypeptide.

The substitution of amino acid residues and coupling of polymeric molecule may be carried out in a conventional manner sas described below.

Reduced immune response vs. maintained residual enzymatic activity

For enzymes, there is a conflict between reducing the immune 10 response and maintaining a substantial residual enzymatic activity.

Without being limited to any theory it is believed that the loss of enzymatic activity of enzyme-polymer conjugates might be a consequence of impeded access of the substrate to the active site in the form of spatial hindrance of the substrate by especially bulky and/or heavy polymeric molecules to the catalytic cleft. It might also, at least partly, be caused by disadvantageous minor structural changes of the 3-dimensional structure of the enzyme due to the stress made by the coupling of the polymeric molecules.

Also, polypeptides modified by substituting one or more amino acid residues may have reduced enzymatic activity.

Maintained residual activity

A modified polypeptide of the invention has a substantially maintained catalytic activity.

A "substantially" maintained catalytic activity is in the context of the present invention defined as an activity which is above 20%, at least between 20% and 30%, preferably between 30% and 40%, more preferably between 40% and 60%, better from 60% up to 80%, even better from 80% up to about 100%, in comparison to the activity of the modified polypeptide prepared on the basis of corresponding parent polypeptides.

In the case of polypeptide-polymer conjugates of the invention where no polymeric molecules are coupled at or close to the active site(s) the residual activity may even be up to 100% or very close thereto. If attachment group(s) of the parent polypeptide is(are) removed from the active site the activity

might even be more than 100% in comparison to modified (i.e. polymer coupled) parent polypeptide conjugate.

The attachment group

Virtually all ionized groups, such as the amino groups of Lysine residues, are located on the surface of the polypeptide molecule (see for instance Thomas E. Creighton, (1993), "Proteins", W.H. Freeman and Company, New York).

Therefore, the number of readily accessible attachment groups (e.g. amino groups) on a modified or parent polypeptide equals generally the number of Lysine residues in the primary structure of the polypeptide plus the N-terminus amino group.

The chemistry of coupling polymeric molecules to amino groups is quite simple and well established in the art.

Therefore, it is preferred to add Lysine residues (i.e. attachment groups) to the parent polypeptide in question to obtain improved conjugates with reduced immunogenicity and/or allergenicity and/or improved stability and/or high percentage maintained catalytic activity.

Polymeric molecules may also be coupled to the carboxylic groups (-COOH) of amino acid residues on the surface of the polypeptide. Therefore, if using carboxylic groups (including the C-terminal group) as attachment groups addition and/or removal of Aspartate and Glutamate residues may also be a suitable according to the invention.

If using other attachment groups, such as -SH groups, they may be added and/or removed analogously.

Substitution of the amino acid residues is preferred over insertion, as the impact on the 3-dimensional structure of the polypeptide normally will be less pronounced.

The parent polypeptide

In the context of the present invention, the term polypeptides" includes proteins, peptides and/or enzymes for pharmaceutical or industrial applications. Typically the polypeptides in question have a molecular weight in the range between about 1 to 1000 kDa, preferred 4 to 100 kDa, more

9

preferred 12 to 60 kDa.

Pharmaceutical polypeptides

The term "pharmaceutical polypeptides" is defined as polypep-5 tides, including peptides, such as peptide hormones, proteins and/or enzymes, being physiologically active when introduced into the circulatory system of the body of humans and/or animals.

Pharmaceutical polypeptides are potentially immunogenic as they are introduced into the circulatory system.

Examples of "pharmaceutical polypeptides" contemplated according to the invention include insulin, ACTH, glucagon, somatostatin, somatotropin, thymosin, parathyroid hormone, pigmentary hormones, somatomedin, erythropoietin, luteinizing hormone, chorionic gonadotropin, hypothalmic releasing factors, antidiuretic hormones, thyroid stimulating hormone, relaxin, interferon, thrombopoietin (TPO) and prolactin.

Industrial polypeptides

Polypeptides used for industrial applications often have an enzymatic activity. Industrial polypeptides (e.g. enzymes) are (in contrast to pharmaceutical polypeptides) not intended to be introduced into the circulatory system of the body.

It is not very like that industrial polypeptides, such as enzymes used as ingredients in industrial compositions and/or products, such as detergents and personal care products, including cosmetics, come into direct contact with the circulatory system of the body of humans or animals, as such enzymes (or products comprising such enzymes) are not injected (or the like) into the bloodstream.

Therefore, in the case of the industrial polypeptide the potential risk is respiratory allergy (i.e. IgE response) as a consequence of inhalation of polypeptides through the respiratory passage.

In the context of the present invention "industrial polypeptides" are defined as polypeptides, including peptides, proteins and/or enzymes, which are not intended to be administered to humans and/or animals.

10

Examples of such polypeptides are polypeptides, especially enzymes, used in products such as detergents, household article products, agrochemicals, personal care products, such as skin care products, including cosmetics and toiletries, oral and dermal pharmaceuticals, composition use for processing textiles, compositions for hard surface cleaning, and compositions used for manufacturing food and feed etc.

Enzymatic activity

Pharmaceutical or industrial polypeptides exhibiting enzymatic activity will often belong to one of the following groups of enzymes including Oxidoreductases (E.C. 1, "Enzyme Nomenclature, (1992), Academic Press, Inc.), such as laccase and Superoxide dismutase (SOD); Transferases, (E.C. 2), such as transglutaminases (TGases); Hydrolases (E.C. 3), including proteases, especially subtilisins, and lipolytic enzymes; Isomerases (E.C. 5), such as Protein disulfide Isomerases (PDI).

Hydrolases

20 Proteolytic enzymes

Contemplated proteolytic enzymes include proteases selected from the group of Aspartic proteases, such as pepsins, Cysteine proteases, such as Papain, Serine proteases, such as subtilisins, or metallo proteases, such as Neutrase[®].

Specific examples of parent proteases include PD498 (WO 93/24623 and SEQ ID NO. 2), Savinase® (von der Osten et al., (1993), Journal of Biotechnology, 28, p. 55+, SEQ ID NO 3), Proteinase K (Gunkel et al., (1989), Eur. J. Biochem, 179, p. 185-194), Proteinase R (Samal et al., (1990), Mol. Microbiol, 4, p. 1789-1792), Proteinase T (Samal et al., (1989), Gene, 85, p. 329-333), Subtilisin DY (Betzel et al. (1993), Arch. Biophys, 302, no. 2, p. 499-502), Lion Y (JP 04197182-A), Rennilase® (Available from Novo Nordisk A/S), JA16 (WO 92/17576), Alcalase® (a natural subtilisin Carlberg variant) (von der Osten et al., 1993), Journal of Biotechnology, 28, p. 55+), Subtilisin BPN´J. Mol. Biol. 178:389-413 (1984); Hirono S., Akagawa H., Mitsui Y., Iitaka Y. (Available from Novo Nordisk A/S).

11

Carbohydrases

Parent carbohydrases may be defined as all enzymes capable of hydrolyzing carbohydrate chains (e.g. starches) of especially five and six member ring structures (i.e. enzymes classified under the Enzyme Classification number E.C. 3.2 (glycosidases) in accordance with the Recommendations (1992) of the International Union of Biochemistry and Molecular Biology (IUBMB)). Examples include carbohydrases selected from those classified under the Enzyme Classification (E.C.) numbers:

a-amylase (3.2.1.1) b-amylase (3.2.1.2), glucan 1,4-aglucosidase (3.2.1.3), cellulase (3.2.1.4), endo-1,3(4)-bglucanase (3.2.1.6), endo-1,4-b-xylanase (3.2.1.8), dextranase
(3.2.1.11), chitinase (3.2.1.14), polygalacturonase (3.2.1.15),
lysozyme (3.2.1.17), b-glucosidase (3.2.1.21), a-galactosidase
(3.2.1.22), b-galactosidase (3.2.1.23), amylo-1,6-glucosidase
(3.2.1.33), xylan 1,4-b-xylosidase (3.2.1.37), glucan endo-1,3b-D-glucosidase (3.2.1.39), a-dextrin endo-1,6-glucosidase
(3.2.1.41), sucrose a-glucosidase (3.2.1.48), glucan endo-1,3-aglucosidase (3.2.1.59), glucan 1,4-b-glucosidase (3.2.1.74),
glucan endo-1,6-b-glucosidase (3.2.1.75), arabinan endo-1,5-aarabinosidase (3.2.1.99), lactase (3.2.1.108), chitonanase
(3.2.1.132).

25

Examples of relevant carbohydrases include a-1,3-glucanases derived from Trichoderma harzianum; a-1,6-glucanases derived from a strain of Paecilomyces; b-glucanases derived from Bacillus subtilis; b-glucanases derived from Humicola insolens; 30 b-glucanases derived from Aspergillus niger; b-glucanases derived from a strain of Trichoderma; b-glucanases derived from a strain of Oerskovia xanthineolytica; exo-1,4-a-D-glucosidases (glucoamylases) derived from Aspergillus niger; a-amylases derived from Bacillus subtilis; a-amylases derived from Bacillus 35 amyloliquefaciens; a-amylases derived from Bacillus stearothermophilus; a-amylases derived from Aspergillus oryzae; a-amylases derived from non-pathogenic microorganisms; galactosidases derived from Aspergillus niger; Pentosanases,

12

xylanases, cellobiases, cellulases, hemi-cellulases deriver from
Humicola insolens; cellulases derived from Trichoderma reesei;
cellulases derived from non-pathogenic mold; pectinases,
cellulases, arabinases, hemi-celluloses derived from Aspergillus
niger; dextranases derived from Penicillium lilacinum; endoglucanase derived from non-pathogenic mold; pullulanases derived
from Bacillus acidopullyticus; b-galactosidases derived from
Kluyveromyces fragilis; xylanases derived from Trichoderma
reesei;

10

Specific examples of readily available commercial carbohydrases include Alpha-Galô, Bio-Feedô Alpha, Bio-Feedô Beta, Bio-Feedô Plus, Bio-Feedô Plus, Novozyme® 188, Carezyme®, Celluclast®, Cellusoft®, Ceremyl®, Citrozymô, Denimaxô, Dezymeô, Dextrozymeô, Einizym®, Fungamylô, Gamanaseô, Glucanex®, Lactozym®, Maltogenaseô, Pentopanô, Pectinexô, Promozyme®, Pulpzymeô, Novamylô, Termamyl®, AMG (Amyloglucosidase Novo), Maltogenase®, Aquazym®, Natalase® (all enzymes available from Novo Nordisk A/S). Other carbohydrases are available from other companies.

20

It is to be understood that also carbohydrase variants are contemplated as the parent enzyme.

The activity of carbohydrases can be determined as described in "Methods of Enzymatic Analysis", third edition, 1984, Verlag Chemie, Weinheim, vol. 4.

Oxidoreductases

30 Laccases

Contemplated laccases include *Polyporus pinisitus* laccase (WO 96/00290), Myceliophthora laccase (WO 95/33836), Schytalidium laccase (WO 95/338337), and *Pyricularia oryzae laccase* (Available from Sigma).

35

Peroxidase

Contemplated peroxidases include *B. pumilus* peroxidases (WO 91/05858), *Myxococcaceae* peroxidase (WO 95/11964), *Coprinus*

13

cinereus (WO 95/10602) and Arthromyces ramosus peroxidase (Kunishima et al. (1994), J. Mol. Biol. 235, p. 331-344).

Transferases

5 Transqlutaminases

Suitable transferases include any transglutaminases disclosed in WO 96/06931 (Novo Nordisk A/S) and WO 96/22366 (Novo Nordisk A/S).

10 Isomerases

Protein Disulfide Isomerase

Without being limited thereto suitable protein disulfide isomerases include PDIs described in WO 95/01425 (Novo Nordisk A/S).

5 Contemplated isomerases include xylose/glucose Isomerase (5.3.1.5) including Sweetzyme®.

Lyases

Suitable lyases include Polysaccharide lyases: Pectate lyases 20 (4.2.2.2) and pectin lyases (4.2.2.10), such as those from Bacillus licheniformis disclosed in WO 99/27083.

The polymeric molecule

The polymeric molecules coupled to the polypeptide may be any suitable polymeric molecule, including natural and synthetic homo-polymers, such as polyols (i.e. poly-OH), polyamines (i.e. poly-NH₂) and polycarboxyl acids (i.e. poly-COOH), and further hetero-polymers i.e. polymers comprising one or more different coupling groups e.g. a hydroxyl group and amine groups.

Examples of suitable polymeric molecules include polymeric molecules selected from the group comprising polyalkylene oxides (PAO), such as polyalkylene glycols (PAG), including polyethylene glycols (PEG), methoxypolyethylene glycols (mPEG) and polypropylen glycols, PEG-glycidyl ethers (Epox-PEG), PEG-oxycarbonylimidazole (CDI-PEG), Branced PEGs, poly-vinyl alcohol (PVA), poly-carboxylates, poly-(vinylpyrolidone), poly-D,L-amino acids, polyethylene-co-maleic acid anhydride, polystyrene-co-

14

malic acid anhydrid, dextrans including carboxymethyl-dextrans, albumin, homologous celluloses, including heparin, carboxymethylcellulose, ethylcellulose, methylcellulose, carboxyethylcellulose hydroxyethylcellulose 5 hydroxypropylcellulose, hydrolysates of chitosan, starches such as hydroxyethyl-straches and hydroxy propyl-starches, glycogen, agaroses and derivates thereof, guar gum, pullulan, xanthan gum, carrageenin, pectin, alginic acid hydrolysates and bio-polymers.

Preferred polymeric molecules are non-toxic polymeric molecules such as (m)polyethylene glycol ((m)PEG) which further requires a relatively simple chemistry for its covalently coupling to attachment groups on the enzyme's surface.

Generally seen polyalkylene oxides (PAO), such as polyethylene oxides, such as PEG and especially mPEG, are the preferred polymeric molecules, as these polymeric molecules, in comparison to polysaccharides such as dextran, pullulan and the like, have few reactive groups capable of cross-linking.

Even though all of the above mentioned polymeric molecules may be used according to the invention the methoxypolyethylene glycols (mPEG) may advantageously be used. This arise from the fact that methoxyethylene glycols have only one reactive end capable of conjugating with the enzyme. Consequently, the risk of cross-linking is less pronounced. Further, it makes the product more homogeneous and the reaction of the polymeric molecules with the enzyme easier to control.

An example of a branched PEG conjugate is Branched PEG2-NHS-ester of Lysine (available from Shearwater).

30

Activation and coupling of polymers to polypeptides

If the polymeric molecules to be conjugated with the polypeptide in question are not active, they must be activated by the use of a suitable technique. It is also contemplated according to the invention to couple the polymeric molecules to the polypeptide through a linker. Suitable linkers are well-known to the skilled person.

Methods and chemistry for activation of polymeric molecules as well as for conjugation of polypeptides are intensively literature. Commonly used methods described in the insoluble polymers include activation activation of bromide, groups with cyanogen 5 functional biepoxides, epichlorohydrin, divinylsulfone, glutaraldehyde, carbodiimide, sulfonyl halides, trichlorotriazine etc. (see R.F. immobilisation. Fundamental and (1991), "Protein Taylor, S.S. Dekker, N.Y.; Wonq, applications", Marcel 10 "Chemistry of Protein Conjugation and Crosslinking", CRC Press, Boca Raton; G.T. Hermanson et al., (1993), "Immobilized Affinity Ligand Techniques", Academic Press, N.Y.). Some of the methods concern activation of insoluble polymers but are also applicable activation of soluble polymers e.g. periodate, 15 trichlorotriazine, sulfonylhalides, divinylsulfone, carbodiimide The functional groups being amino, hydroxyl, carboxyl, aldehyde or sulfydryl on the polymer and the chosen attachment group on the protein must be considered in choosing the activation and conjugation chemistry which normally consist 20 of i) activation of polymer, ii) conjugation, and iii) blocking of residual active groups.

In the following a number of suitable polymer activation methods will be described shortly. However, it is to be understood that also other methods may be used.

Coupling polymeric molecules to the free acid groups of polymeptides may be performed with the aid of diimide and for example amino-PEG or hydrazino-PEG (Pollak et al., (1976), J. Amr. Chem. Soc., 98, 289-291) or diazoacetate/amide (Wong et al., (1992), "Chemistry of Protein Conjugation and Crosslinking", CRC Press).

Coupling polymeric molecules to hydroxy groups are generally very difficult as it must be performed in water. Usually hydrolysis predominates over reaction with hydroxyl groups.

Coupling polymeric molecules to free sulfhydryl groups can be reached with special groups like maleimido or the *orthopyridyl* disulfide. Also vinylsulfone (US patent no. 5,414,135, (1995), Snow et al.) has a preference for sulfhydryl groups but is not as selective as the other mentioned.

Accessible Arginine residues in the polypeptide chain may be targeted by groups comprising two vicinal carbonyl groups.

Techniques involving coupling electrophilically activated PEGs to the amino groups of Lysines may also be useful. Many of the usual leaving groups for alcohols give rise to an amine linkage. For instance, alkyl sulfonates, such as tresylates (Nilsson et al., (1984), Methods in Enzymology vol. 104, Jacoby, W. B., Ed., Academic Press: Orlando, p. 56-66; Nilsson et al., (1987), Methods in Enzymology vol. 135; Mosbach, K., Ed.; Academic Press: Orlando, pp. 65-79; Scouten et al., (1987), Methods in Enzymology vol. 135, Mosbach, K., Ed., Academic Press: Orlando, 1987; pp 79-84; Crossland et al., (1971), J. Amr. Chem. Soc. 1971, 93, pp. 4217-4219), mesylates (Harris, (1985), supra; Harris et al., (1984), J. Polym. Sci. Polym. Chem. Ed. 22, pp 341-352), aryl sulfonates like tosylates, and para-nitrobenzene sulfonates can be used.

Organic sulfonyl chlorides, e.g. Tresyl chloride, effectively converts hydroxy groups in a number of polymers, e.g. PEG, into good leaving groups (sulfonates) that, when reacted with nucleophiles like amino groups in polypeptides allow stable linkages to be formed between polymer and polypeptide. In addition to high conjugation yields, the reaction conditions are in general mild (neutral or slightly alkaline pH, to avoid denaturation and little or no disruption of activity), and satisfy the non-destructive requirements to the polypeptide.

Tosylate is more reactive than the mesylate but also more unstable decomposing into PEG, dioxane, and sulfonic acid (Zalipsky, (1995), Bioconjugate Chem., 6, 150-165). Epoxides may also been used for creating amine bonds but are much less reactive than the above mentioned groups.

Converting PEG into a chloroformate with phosgene gives rise to carbamate linkages to Lysines. This theme can be played in many variants substituting the chlorine with N-hydroxy succinimide (US patent no. 5,122,614, (1992); Zalipsky et al., (1992), Biotechnol. Appl. Biochem., 15, p. 100-114; Monfardini et al., (1995), Bioconjugate Chem., 6, 62-69, with imidazole (Allen et al., (1991), Carbohydr. Res., 213, pp 309-319), with

para-nitrophenol, DMAP (EP 632 082 A1, (1993), Looze, Y.) etc. The derivatives are usually made by reacting the chloroformate with the desired leaving group. All these groups give rise to carbamate linkages to the peptide.

Furthermore, isocyanates and isothiocyanates may be employed yielding ureas and thioureas, respectively.

Amides may be obtained from PEG acids using the same leaving groups as mentioned above and cyclic imid thrones (US patent no. 5,349,001, (1994), Greenwald et al.). The reactivity of these compounds are very high but may make the hydrolysis to fast.

PEG succinate made from reaction with succinic anhydride can also be used. The hereby comprised ester group make the conjugate much more susceptible to hydrolysis (US patent no. 5,122,614, (1992), Zalipsky). This group may be activated with N-hydroxy succinimide.

Furthermore, a special linker can be introduced. The most commonly used is cyanuric chloride (Abuchowski et al., (1977), J. Biol. Chem., 252, 3578-3581; US patent no. 4,179,337, (1979), Davis et al.; Shafer et al., (1986), J. Polym. Sci. Polym. Chem. 20 Ed., 24, 375-378.

Coupling of PEG to an aromatic amine followed by diazotation yields a very reactive diazonium salt which in situ can be reacted with a peptide. An amide linkage may also be obtained by reacting an azlactone derivative of PEG (US patent no. 5,321,095, (1994), Greenwald, R. B.) thus introducing an additional amide linkage.

As some peptides do not comprise many Lysines it may be advantageous to attach more than one PEG to the same Lysine. This can be done e.g. by the use of 1,3-diamino-2-propanol.

PEGs may also be attached to the amino-groups of the enzyme with carbamate linkages (WO 95/11924, Greenwald et al.). Lysine residues may also be used as the backbone.

The coupling technique used in the examples is the N-succinimidyl carbonate conjugation technique descried in WO 35 90/13590 (Enzon).

Method for preparing improved polypeptides

It is also an object of the invention to provide a method for preparing improved polypeptides comprising the steps of:

- a) identifying amino acid residues located on the surface of the3-dimensional structure of the parent polypeptide in question,
- 5 b) selecting target amino acid residues on the surface of said 3-dimensional structure of said parent polypeptide to be modified,
 - c) substituting one or more amino acid residues selected in step
 - b) with other amino acid residue, and/or
- 10 d) coupling polymeric molecules to the amino acid residues in step b) and/or step c).

Step a) Identifying amino acid residues located on the surface of the parent polypeptide

15

3-dimensional structure

To perform the method of the invention a 3-dimensional structure of the parent polypeptide in question is required. This structure may for example be an X-ray structure, an NMR structure or a model-built structure. The Brookhaven Databank is a source of X-ray- and NMR-structures.

A model-built structure may be produced by the person skilled in the art if one or more 3-dimensional structure(s) exist(s) of homologous polypeptide(s) sharing at least 30% sequence identity with the polypeptide in question. Several software packages exist which may be employed to construct a model structure. One example is the Homology 95.0 package from MSI Inc.

Typical actions required for the construction of a model structure are: alignment of homologous sequences for which 3-dimensional structures exist, definition of Structurally Conserved Regions (SCRs), assignment of coordinates to SCRs, search for structural fragments/loops in structure databases to replace Variable Regions, assignment of coordinates to these regions, and structural refinement by energy minimization. Regions containing large inserts (≥3 residues) relative to the known 3-dimensional structures are known to be quite difficult

to model, and structural predictions must be considered with care.

Having obtained the 3-dimensional structure of the polypeptide in question, or a model of the structure based on 5 homology to known structures, this structure serves as an essential prerequisite for the fulfillment of the method described below.

Step b) Selection of target amino acid residues

Target amino acid residues to be modified are according to the invention selected from those amino acid residues, wherein the C^{α} -atom is located less than 15 Å from a ligand. In a preferred embodiment a possible C^{β} -atom should be closer to the ligand than the C^{α} -atom. In a more preferred embodiment the C^{α} -atom of the amino acid residue is located less than 10 Å from the ligand and said amino acid residues have an accessibility of at least 15%, preferably at least 20% and more preferably at least 30%.

20 Step c) Substitution

WO 00/22103

Conservative substitution

It is preferred to make conservative substitutions in the polypeptide when the polypeptide has to be conjugated, as conservative substitutions secure that the impact of the substitution on the polypeptide structure is limited.

In the case of providing additional amino groups this may be done by substitution of Arginine to Lysine, both residues being positively charged, but only the Lysine having a free amino group suitable as an attachment groups.

In the case of providing additional carboxylic acid groups the conservative substitution may for instance be an Asparagine to Aspartic acid or Glutamine to Glutamic acid substitution. These residues resemble each other in size and shape, except from the carboxylic groups being present on the acidic residues.

In the case of providing SH-groups the conservative substitution may be done by substitution of Threonine or Serine to Cysteine.

Which amino acids to substitute depends in principle on the coupling chemistry to be applied.

When no coupling is performed after substitution there is in general no limit on the selection of amino acids for substitution. However, preferred amino acids for substitutions are substitutions to polar residues e.g. K, R, D, E, H, Q, N, S, T, C. Also substitutions to residues with short side chains G and A are preferred.

Further, when no coupling is to be performed, the changes may be in the form of addition or deletion of at least one amino acid for which the C^{α} atom is located within 15Å from the bound ligand, preferably deleting an amino acid. Furthermore, the parent protein may be changed by substituting some amino acids and deleting/adding other.

Only substitutions which provide polypeptides with reduced immune response when evaluated in animal models are within the concept of the present invention.

The mutation(s) performed in step c) may be performed by standard techniques well known in the art, such as site-directed mutagenesis (see, e.g., Sambrook et al. (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, NY.

A general description of nucleotide substitution can be found in e.g. Ford et al., 1991, Protein Expression and Purification 2, p. 95-107.

In a preferred embodiment of the invention, more than one amino acid residue is substituted, added or deleted, these amino acids possibly being located close to different bound ligands. In that case, it may be difficult to assess a priori how well the functionality of the protein is maintained while antigenicity, immunogenicity and/or allergenicity is reduced. This can be achieved by establishing a library of diversified mutants each having one or more changed amino acids introduced and selecting those variants which show good retention of function and at the same time a good reduction in antigenicity. In the case of protease, this can be tested by assaying the

secreted variants for enzyme activity (as described below in the experimental section) and for antigen binding (e.g. by competitive ELISA using methods known in the art. (see e.g J. Clausen, Immunochemical Techniques For The Identification and 5 Estimation of Macromolecules, Elsevier, Amsterdam, 1988 pp.187-188). Specifically, the competivity ELISA can be performed with the wild-type protease coated on ELISA plates, and incubated with specific polyclonal anti-protease antiserum from rabbits in the presence of protease variant. The scope of these 10 embodiments of the invention is by no means limited to serves only to provide protease, which an example. diversified library can be established by a range of techniques known to the person skilled in the art (Reetz MT; Jaeger KE, in Biocatalysis - from Discovery to Application edited by Fessner Vol. 200, pp. 31-57 (1999); Stemmer, Nature, vol. 370, p.389-391, 1994; Zhao and Arnold, Proc. Natl. Acad. Sci., USA, vol. 94, pp. 7997-8000, 1997; or Yano et al., Proc. Natl. Acad. Sci., USA, vol. 95, pp 5511-5515, 1998). In a more preferable embodiment, substitutions are found by a method comprising the 20 following steps: 1) a range of substitutions, additions, and/or deletions are listed, 2) a library is designed which introduces a randomized subset of these changes in the amino acid sequence into the target gene, e.g. by random mutagenesis, 3) the library is expressed, and preferred variants are selected. In a 25 most preferred embodiment, this method is supplemented with additional rounds of screening and/or family shuffling of hits from the first round of screening (J.E. Ness, et al, Nature Biotechnology, vol. 17, pp. 893-896, 1999) and/or combination with other methods of reducing allergenicity by genetic means 30 (such as that disclosed in WO92/10755).

Generation of site directed mutations

Prior to mutagenesis the gene encoding the polypeptide of interest must be cloned in a suitable vector. Methods for generating mutations in specific sites is described below.

Once the polypeptide-encoding gene has been cloned, desirable sites for mutation identified, and the residue(s) to

22

substitute for the original one(s) have been decided, these mutations can be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites; mutant nucleotides are inserted during oligo-nucleotide synthesis. In a preferred method, Site-directed mutagenesis is carried out by SOE-PCR mutagenesis technique described by Kammann et al. (1989) Nucleic Acids Research 17(13), 5404, and by Sarkar G. and Sommer, S.S. (1990); Biotechniques 8, 404-407.

10

Step d) Coupling polymeric molecules to the optionally modified parent enzyme

Polypeptide-polymer conjugates of the invention may be prepared by any coupling method known in the art including the above mentioned techniques.

Preparation of enzyme variants

Enzyme variants to be conjugated may be constructed by any suitable method. A number of methods are well established in the art. For instance enzyme variants according to the 20 invention may be generated using the same materials and methods described in e.g. WO 89/06279 (Novo Nordisk A/S), EP 130,756 (Novo Nordisk A/S), EΡ (Genentech), EP479,870 (Henkel), WO 87/04461 (Amgen), WO 87/05050 (Genex), EP application no. 87303761 (Genentech), EP 260,105 (Genencor), 25 88/06624 (Gist-Brocades NV), WO 88/07578 (Genentech), 88/08028 (Genex), WO 88/08033 (Amgen), WO 88/08164 (Genex), Thomas et al. (1985) Nature, 318 375-376; Thomas et al. (1987) J. Mol. Biol., 193, 803-813; Russel and Fersht (1987) Nature 328 496-500.

30

Coupling of polymeric molecules to the polypeptide in question See previous paragraphs

35 Immunogenicity and Allergenicity

"Immunogenicity" is a wider term than "antigenicity" and "allergenicity", and expresses the immune system's response to the presence of foreign substances. Said foreign substances are

23

called immunogens, antigens and allergens depending of the type of immune response the elicit.

An "immunogen" may be defined as a substance which, when introduced into circulatory system of animals and humans, is capable of stimulating an immunologic response resulting in formation of immunoglobulin.

The term "antigen" refers to substances which by themselves are capable of generating antibodies when recognized as a non-self molecule.

Further, an "allergen" may be defined as an antigen which may give rise to allergic sensitization or an allergic response by IgE antibodies (in humans, and molecules with comparable effects in animals).

15 Assessment of immunogencity

Assessment of the immunogenicity may be made by injecting animal subcutaneously to enter the immunogen into the circulation system and comparing the response with the response of the corresponding parent polypeptide.

The "circulatory system" of the body of humans and animals means, in the context of the present invention, the system which mainly consists of the heart and blood vessels. The heart delivers the necessary energy for maintaining blood circulation in the vascular system. The circulation system functions as the organism's transportation system, when the blood transports O2, nutritious matter, hormones, and other substances of importance for the cell regulation into the tissue. Further the blood removes CO2 from the tissue to the lungs and residual substances to e.g. the kidneys. Furthermore, the blood is of importance for the temperature regulation and the defence mechanisms of the body, which include the immune system.

A number of *in vivo* animal models exist for assessment of the immunogenic potential of polypeptides. Some of these models give a suitable basis for hazard assessment in man. Suitable models include a mice model.

This model seek to identify the immunogenic response in the form of the IgG response in Balb/C mice being injected subcutaneously with modified and unmodified polypeptides.

Also other animal models can be used for assessment of the immunogenic potential.

A polypeptide having "reduced immunogenicity" according to the invention indicates that the amount of produced antibodies, se.g. immunoglobulin in humans, and molecules with comparable effects in specific animals, which can lead to an immune response, is significantly decreased, when introduced into the circulatory system, in comparison to the corresponding parent polypeptide.

For Balb/C mice the IgG response gives a good indication of the immuniquenic potential of polypeptides.

Assessment of allergenicity

Assessment of allergenicity may be made by inhalation tests, comparing the effect of intratracheally (into the trachea) administrated parent enzymes with the corresponding modified enzymes according to the invention.

A number of in vivo animal models exist for assessment of the allegenicity of enzymes. Some of these models give a suitable basis for hazard assessment in man. Suitable models include a guinea pig model and a mouse model. These models seek to identify respiratory allergens as a function of elicitation reactions induced in previously sensitised animals. According to these models the alleged allergens are introduced intratracheally into the animals.

A suitable strain of guinea pigs, the Dunkin Hartley strain, do not as humans, produce IgE antibodies in connection with the allergic response. However, they produce another type of antibody the IgG1A and IgG1B (see e.g. Prentø, ATLA, 19, p. 8-14, 1991), which are responsible for their allergenic response to inhaled polypeptides including enzymes. Therefore, when using the Dunkin Hartley animal model, the relative amount of IgG1A and IgG1B is a measure of the allergenicity level.

The Balb/C mice strain is suitable for intratracheal, intredermal or subcutaneous exposure. Balb/C mice produce IgE as the allergic response.

More details on assessing respiratory allergens in guinea pigs and mice is described by Kimber et al., (1996), Fundamental and

25

Applied Toxicology, 33, p. 1-10.

Other animals such as rats, rabbits etc. may also be used for comparable studies.

5 Composition

The invention relates to a composition comprising a modified polypeptide of the invention.

The composition may be a pharmaceutical or industrial composition.

The composition may further comprise other polypeptides, proteins or enzymes and/or ingredients normally used in e.g. detergents, including soap bars, household articles, agrochemicals, personal care products, including skin care compositions, cleaning compositions for e.g. contact lenses, oral and dermal pharmaceuticals, composition use for treating textiles, compositions used for manufacturing food, e.g. baking, and food/feed etc.

Use of the polypeptide

The invention also relates to the use of the method of the invention for reducing the immune response of polypeptides.

It is also an object of the invention to use the polypeptide-polymer conjugate or the polypeptide otherwise modified according to the invention to reduce the allergenicity of industrial products, such as detergents, such as laundry, disk wash and hard surface cleaning detergents, food or feed products, personal care products and textile products.

30 MATERIAL AND METHODS

Materials

Enzymes:

PD498: Protease of subtilisin type shown in WO 93/24623. The sequence of PD498 is shown in SEQ ID NO. 1 and 2.

Savinase®: The sequence is shown in SEQ ID NO 3 (Available from Novo Nordisk A/S)

Subtilisin BPN': The sequence can be found in the SWISS-PROT database. The sequence is also disclosed in:

26

GALLAGHER T., OLIVER J., BOTT R., BETZEL C., GILLILAND G.L.;
"Subtilisin BPN' at 1.6-A resolution: analysis for discrete disorder and comparison of crystal forms."; Acta Crystallogr. D 52:1125-1135(1996). The enzyme is available from Novo Nordisk 5 A/S.

Amylase AA560: The alkaline α -amylase may be derived from a strain of Bacillus sp. DSM 12649. The strain was deposited on 25th January 1999 by the inventors under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at Deutshe Sammmlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig DE.The sequence is shown in SEQ ID NO. 4.

15 Strains:

- B. subtilis 309 and 147 are variants of Bacillus lentus, deposited with the NCIB and accorded the accession numbers NCIB 10309 and 10147, and described in US Patent No. 3,723,250 incorporated by reference herein.
- E. coli MC 1000 (M.J. Casadaban and S.N. Cohen (1980); J. Mol. Biol. 138 179-207), was made r-,m+ by conventional methods and is also described in US Patent Application Serial No. 039,298.

25 Vectors:

pPD498: E. coli - B. subtilis shuttle vector (described in US patent No. 5,621,089 under section 6.2.1.6) containing the wild-type gene encoding for PD498 protease (SEQ ID NO. 2). The same vector is use for mutagenesis in E. coli as well as for expression in B. subtilis.

35 Materials, chemicals and solutions:

Horse Radish Peroxidase labeled anti-rat-Ig (Dako, DK, P162, # 031; dilution 1:1000).

27

Mouse anti-rat IgE (Serotec MCA193; dilution 1:200).

Rat anti-mouse IgE (Serotec MCA419; dilution 1:100).

Biotin-labeled mouse anti-rat IgG1 monoclonal antibody (Zymed 03-9140; dilution 1:1000)

5 Biotin-labeled rat anti-mouse IgG1 monoclonal antibody (Serotec MCA336B; dilution 1:1000)

Streptavidin-horse radish peroxidase (Kirkegård & Perry 14-30-00; dilution 1:1000).

CovaLink NH₂ plates (Nunc, Cat# 459439)

10 Cyanuric chloride (Aldrich)

Acetone (Merck)

Rat anti-Mouse IgG1, biotin (SeroTec, Cat# MCA336B)

Streptavidin, peroxidase (KPL)

Ortho-Phenylene-diamine (OPD) (Kem-en-Tec, Cat# 4260)

15 H_2O_2 , 30% (Merck)

Tween 20 (Merck)

Skim Milk powder (Difco)

H₂SO₄ (Merck)

20 Buffers and Solutions:

Carbonate buffer (0.1 M, pH 10 (1 liter)) Na_2CO_3 10.60 g

PBS (pH 7.2 (1 liter)) NaCl 8.00 g

KCl 0.20 q

 K_2HPO_4 1.04 g

 $KH_{2}PO_{4}$ 0.32 g

Washing buffer PBS, 0.05% (v/v) Tween 20

Blocking buffer PBS, 2% (wt/v) Skim Milk powder

Dilution buffer PBS, 0.05% (v/v) Tween 20, 0.5% (wt/v) Skim Milk powder

30 Citrate buffer (0.1M, pH 5.0-5.2 (1 liter))NaCitrate 20.60 g

Citric acid 6.30 g

Sodium Borate, borax (Sigma)

3,3-Dimethyl glutaric acid (Sigma)

CaCl, (Sigma)

35 Tresyl chloride (2,2,2-triflouroethansulfonyl chloride) (Fluka) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (Fluka)

N-Hydroxy succinimide (Fluka art. 56480))

28

Phosgene (Fluka art. 79380)

Lactose (Merck 7656)

PMSF (phenyl methyl sulfonyl flouride) from Sigma

Succinyl-Alanine-Alanine-Proline-Phenylalanine-para-nitroanilide

5 (Suc-AAPF-pNP) Sigma no. S-7388, Mw 624.6 g/mole.

Activation of CovaLink plates:

- · Make a fresh stock solution of 10 mg cyanuric chloride per ml acetone.
- 10 · Just before use, dilute the cyanuric chloride stock solution into PBS, while stirring, to a final concentration of lmg/ml.
 - \cdot Add 100 ml of the dilution to each well of the CovaLink NH2 plates, and incubate for 5 minutes at room temperature.
 - · Wash 3 times with PBS.
- 15 · Dry the freshly prepared activated plates at 50°C for 30 minutes.
 - · Immediately seal each plate with sealing tape.
 - · Preactivated plates can be stored at room temperature for 3 weeks when kept in a plastic bag.

20

Test Animals:

Female Balb/C mice (about 20 grams) purchased from Bomholdtgaard, Ry, Denmark.

Female Brown-Norway rats, weighing on the average 180 g

25

Equipment:

XCEL II (Novex)

ELISA reader (UVmax, Molecular Devices)

HPLC (Waters)

30 PFLC (Pharmacia)

Superdex-75 column, Mono-Q, Mono S from Pharmacia, SW.

SLT: Fotometer from SLT LabInstruments

Size-exclusion chromatograph (Spherogel TSK-G2000 SW).

Size-exclusion chromatograph (Superdex 200, Pharmacia, SW)

35 Amicon Cell

Enzymes for DNA manipulations

Unless otherwise mentioned all enzymes for DNA manipulations, such as e.g. restriction endonucleases, ligases etc., are obtained from New England Biolabs. Inc.

5

Media:

BPX: Composition (per liter)

Potato starch 100g

Ground barley 50g

10 Soybean flour 20g

 $Na_2HPO_4 X 12 H_2O 9g$

Pluronic 0.1g

Sodium caseinate 10g

The starch in the medium is liquefied with α -amylase and the medium is sterilized by heating at 120°C for 45 minutes. After sterilization the pH of the medium is adjusted to 9 by addition of NaHCO $_3$ to 0.1 M.

20 Methods

General molecular biology methods:

Unless otherwise mentioned the DNA manipulations and transformations were performed using standard methods of molecular biology (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., and Cutting, S. M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons, 1990).

30 Enzymes for DNA manipulations were used according to the specifications of the suppliers.

Fermentation of PD498 variants

Fermentation of PD498 variants in B. subtilis are performed at 30°C on a rotary shaking table (300 r.p.m.) in 500 ml baffled Erlenmeyer flasks containing 100 ml BPX medium for 5 days. In order to make an e.g. 2 liter broth 20 Erlenmeyer flasks are fermented simultaneously.

30

Purification of PD498 variants

Approximately 1.6 litres of PD498 variant fermentation broth are centrifuged at 5000 rpm for 35 minutes in 1 litre 5 beakers. The supernatants are adjusted to pH 7.0 using 10% acetic acid and filtered on Seitz Supra S100 filter plates. The filtrates are concentrated to approximately 400 ml using an Amicon CH2A UF unit equipped with an Amicon S1Y10 UF cartridge. The UF concentrate is centrifuged and filtered prior to absorption at room temperature on a Bacitracin affinity column at pH 7. The PD498 variant is eluted from the Bacitracin column at room temperature using 25% 2-propanol and 1 M sodium chloride in a buffer solution with 0.01 dime-thyl-glutaric acid, 0.1 M boric acid and 0.002 M calcium chloride adjusted to pH 7.

The fractions with protease activity from the Bacitracin purification step are combined and applied to a 750 ml Sephadex G25 column (5 cm diameter) equilibrated with a buffer containing 0.01 dimethylglutaric acid, 0.1 M boric acid and 0.002 M calcium chloride adjusted to pH 6.0.

Fractions with proteolytic activity from the Sephadex G25 column are combined and applied to a 150 ml CM Sepharose CL 6B cat-ion exchange column (5 cm diameter) equilibrated with a buffer containing 0.01 M dimethylglutaric acid, 0.1 M boric acid, and 0.002 M calcium chloride adjusted to pH 6.0.

The protease is eluted using a linear gradient of 0-0.5 M sodium chloride in 1 litres of the same buffer.

Protease containing fractions from the CM Sepharose column are combined and filtered through a 2μ filter.

30

Determination of the molecule weight

Electrophoretic separation of proteins was performed by standard methods using 4-20% gradient SDS poly acrylamide gels (Novex). Proteins were detected by silver staining. The molecule weight was measured relative to the mobility of Mark-12® wide range molecule weight standards from Novex.

Protease activity

31

Analysis with Suc-Ala-Ala-Pro-Phe-pNa:

Proteases cleave the bond between the peptide and pnitroaniline to give a visible yellow colour absorbing at 405 nm.

Buffer: e.g. Britton and Robinson buffer pH 8.3
Substrate: 100 mg suc-AAPF-pNa is dissolved into 1 ml dimethyl sulfoxide (DMSO). 100 ml of this is diluted into 10 ml with Britton and Robinson buffer.

The substrate and protease solution is mixed and the absorbance is monitored at 405 nm as a function of time and $ABS_{405\ nm}/min$. The temperature should be controlled (20-50°C depending on protease). This is a measure of the protease activity in the sample.

15 Proteolytic Activity

35

In the context of this invention proteolytic activity is expressed in Kilo NOVO Protease Units (KNPU). The activity is determined relatively to an enzyme standard (SAVINASE_), and the determination is based on the digestion of a dimethyl casein (DMC) solution by the proteolytic enzyme at standard conditions, i.e. 50°C, pH 8.3, 9 min. reaction time, 3 min. measuring time. A folder AF 220/1 is available upon request to Novo Nordisk A/S, Denmark, which folder is hereby included by reference.

A GU is a Glycine Unit, defined as the proteolytic enzyme activity which, under standard conditions, during a 15-minutes' incubation at 40°C, with N-acetyl casein as substrate, produces an amount of $\rm NH_2$ -group equivalent to 1 mmole of glycine.

Enzyme activity can also be measured using the PNA assay, according to reaction with the soluble substrate succinylalanine-alanine-proline-phenylalanine-para-nitrophenol, which is described in the Journal of American Oil Chemists Society, Rothgeb, T.M., Goodlander, B.D., Garrison, P.H., and Smith, L.A., (1988).

ELISA IqE test system (for Brown Norway rats):

A three layer sandwich ELISA is used to determine relative concentrations of specific antibodies.

The immunizing molecule is used as coating antigen with 10 mg per ml and 50 ml per well, in neutral phosphate buffer, incubated overnight at 4°C. All remaining binding spots on the well surface are blocked in 2 % skim milk, 200 ml per well in 5 phosphate buffer for at least 30 minutes at room temperature (RT). All seras to be tested with this antigen are added at 50 ml per well to this plate using a 8-channel pipette in dilution series from 10 x diluted followed by 3-fold dilutions. Dilutions are made in phosphate buffer with 0.5 % skim milk and 0.05% 10 Tween20, incubated 2 hours on agitation platform at RT. "tracer" molecule is biotinylated Mouse anti Rat IgE 50 ml per well and diluted 2000 x in phosphate buffer with 0.5 % skim milk and 0.05% Tween 20, incubated 2 hours on an agitation platform at RT. Control (blank) was identical sequence but without rat 15 sera. 50 ml per well streptavidin horse raddish peroxidase, diluted 2000 x was incubated 1 hour on an agitation platform. Colouring substrate at 50 ml per well is OPD (6 mg) and H,O, (4 ml of a 30% solution) per 10 ml citrate buffer pH 5.2. The reaction is stopped using 100 ml per well 2 N H, SO4. All 20 readings on SLT at 486 nm and 620 nm as reference. Data is calculated and presented in Lotus.

ELISA procedure to determine relative concentrations of IgE antibodies in BALB/C mice

- A three layer sandwich ELISA is used to determine relative concentrations of specific IgE serum antibodies.
 - 1) Coat the ELISA-plate with 10 mg rat anti-mouse IgE or mouse anti-rat IgE/ml buffer 1.
 - 50 ml/well. Incubate over night at 4°C.
- 30 2) Empty the plates and block with Blocking buffer at least ½ hour at room temperature.
 - 200 ml/well. Shake gently. Wash the plates 3 times with Washing Buffer.
- 3) Incubate with mouse/rat sera, starting from undiluted and
 continue with 2-fold dilutions. Keep
 some wells free for buffer 4 only (blanks). 50 ml/well.
 Incubate for 30 minutes at room temperature. Shake gently. Wash
 the plates 3 times in Washing Buffer.

4) Dilute the enzyme in Dilution buffer to the appropriate protein concentration. 50ml/well.

Incubate for 30 minutes at room temperature. Shake gently. Wash the plates 3 times in Washing Buffer.

- 5 5) Dilute specific polyclonal anti-enzyme antiserum serum (pIg) for detecting bound antibody in Dilution buffer. 50ml/well. Incubate for 30 minutes at room temperature. Shake gently. Wash the plates 3 times in Washing Buffer.
 - 6) Dilute Horseradish Peroxidase-conjugated anti-pIg-antibody in Dilution buffer. 50 ml/well.

Incubate at room temperature for 30 minutes. Shake gently. Wash the plates 3 times in Washing Buffer.

- 7) Mix 0.6 mg ODP/ml + 0.4 μ l H_2O_2/m l in substrate Buffer. Make the solution just before use. Incubate for 10 minutes. 50 μ l/well.
 - 8) To stop the reaction: add Stop Solution. 50 μ l/well.
 - 9) Read the plates at 492 nm with 620 nm as reference. Data is calculated and presented in Lotus.

20

EXAMPLES

Example 1

25

Subtilisin BPN'

In order to identify the residues to be modified, a distance and a directional criteria are applied.

As disclosed earlier residues having their C^{α} -atom closer than 15 Å to a ligand are targets for modification. Preferably, residues having their C^{β} -atom closer to the ligand bound than the C^{α} -atom, thereby allowing a potential side chain to point in the direction of the ligand, are targets for modification.

The relevant distance can easily be measured using e.g. molecular graphics programs like InsightII from Molecular Simulations INC.

Especially surface exposed residues, defined as having

ACC>0 when applying the DSSP program to the relevant protein part of the structure, are targets for modification. The DSSP program is disclosed in W. Kabsch and C. Sander, BIOPOLYMERS 22 (1983) pp. 2577-2637.

In Thomas E. Creighton, PROTEINS; Structure and Molecular Priciples, WH Freeman and Company, NY, ISBN: 0-7167-1566-X (1984) is disclosed a table listing the accessible surface areas of individual amino acid residues. In the table below 15% and 20% accessibility has been determined.

_	•
-3	
	u

20

	Total	20% of	15% of
	ACC	Total	Total
AA	AxA	ÅxÅ	AxA
Ala	115	23,0	17,3
Arg	225	45,0	33,8
Asn	160	32,0	24,0
Asp	150	30,0	22,5
Cys	135	27,0	20,3
Gln	180	36,0	27,0
Glu	190	38,0	28,5
Gly	75	15,0	11,3
His	195	39,0	29,3
Ile	175	35,0	26,3
Leu	170	34,0	25,5
Lys	200	40,0	30,0
Met	185	37,0	27,8
Phe	210	42,0	31,5
Pro	145	29,0	21,8
Ser	115	23,0	17,3
Thr	140	28,0	21,0
Trp	255	51,0	38,3
Tyr	230	46,0	34,5
Val	155	31,0	23,3

When dividing the found accessible surface area (ACC) for each amino acid of the protein with the accessible surface area for that individual amino acid (found in the Creighton table) the accessibility value in percent is obtained.

In order to find residues to modify, the method described above was applied to the X-ray structure of Subtilisin BPN' in complex with the inhibitor CI-2 (entry 2SNI in the Brookhaven Protein Data Bank).

Only the Subtilisin BPN' and the two metal ions in the

structure was used for the analysis. Both ions are calcium ions. They are found in site 1 and site 2.

The results of the analysis are seen in the tables below. The columns shows the distance in Å from the metal ion to the 5 C^{α} and C^{β} as well as the accessibility as determined by DSSP for each residue to modify.

Site 1:

Dice i	pice 1.							
resid	res.no	$dist(C^{\alpha})$	$dist(C^{\beta})$	ACC	ACC			
				(ÅxÅ)	(%)			
GLY	80	4.40		14	18.67			
ASN	77	4.68	4.57	62	38.75			
ASP	41	5.14	4.36	0				
GLN	2	5.46	4.64	47	26.11			
ALA	74	5.57	5.12	0				
GLY	83	7.80		0				
PRO	86	8.44	7.42	8				
GLY	70	9.04		1				
THR	208	9.38	8.66	0				
HIS	39	10.41	9.97	3				
PRO	5	10.46	10.17	18	12.41			
LYS	43	10.62	10.53	137	68.50			
TYR	214	10.68	9.62	75	32.61			
GLN	206	11.79	11.27	88	48.89			
VAL	8	12.42	10.89	2				
THR	22	13.14	12.12	22	15.71			
GLY	215	13.52		14	18.67			
PRO	14	13.53	13.29	45	31.03			
HIS	17	13.64	12.25	28	14.36			
THR	66	13.80	13.76	0				
SER	9	14.40	14.22	58	50.43			
ALA	13	14.66	13.53	0				
GLY	7	14.74		0				
LEU	90	14.79	13.38	1				
ASP	36	14.87	14.57	20	13.33			
GLY	211	14.88		45	60.00			

Site 2:

Site 2	Site 2:						
resid	resno	$dist(C^{\alpha})$	$dist(C^{\beta})$	ACC	ACC		
				(ÅxÅ)	(%)		
GLU	195	4.44	4.28	48	25.26		
ALA	176	4.67	3.85	0			
GLY	169	5.16		0			
ASP	197	5.90	5.14	21	14.00		
VAL	165	8.35	6.96	6			
ALA	1 51	8.54	8.04	0			
GLY	166	9.43		14	18.67		
GLY	193	9.46		0			
GLY	264	9.63		7			
VAL	149	9.85	9.50	3			
GLY	178	10.74		0			
VAL	139	10.95	9.63	0			
GLY	154	11.31		17	22.67		
SER	163	11.34	10.12	29	25.22		
ARG	247	11.35	10.32	47	20.89		
LYS	265	11.66	11.35	76	38.00		
GLN	251	11.74	10.57	26	14.44		
SER	191	11.83	11.04	0			
SER	224	12.34	12.02	0			
VAL	143	12.36	10.91	41	26.45		
MET	124	12.43	11.71	0			
GLY	127	12.44		61	81.33		
SER	260	12.47	12.12	72	62.61		
GLY	131	12.69		29	38.67		
VAL	227	13.37	11.90	0			
THR	220	13.55	12.34	3			
LEU	250	13.58	12.73	3			
LEU	135	13.60	13.21	6			
GLY	266	13.93		0			
GLY	128	14.04		16	21.33		
SER	190	14.12	14.09	0			
ALA	142	14.13	13.36	0			

ILE	122	14.17	13.65	0	
ALA	223	14.44	13.70	0	
ASN	243	14.50	13.94	21	13.13
ALA	200	14.63	14.15	0	

The table below shows functional preferred substitutions in site 1 and 2 of the BPN'. For Gly 80 the substitution G to S/T G to N/Q and G to K/D means that Glycine in position 80 may 5 preferably be substituted with Serine/Threonine or Asparagine/Glutamine or Lysine/Aspartic acid.

SITE1		Subtilisin BPN'	
G ly-80	G to S/T	G to N/Q	G to K/D
Asn-77	N to D/E	N to K/R	N to A/C
G In-2	Q to D/E	Q to K/R	Q to A/C
Pro-5	P to G/A	P to C/S	P to K/D
Lys-43	K to S/T/C	K to D/E/R	K to Q/N
Tyr-214	Y to N/Q	Y to A/G/C	Y to K/H
G In-206	Q to D/E	Q to K/R	Q to A/C
Thr-22	T to K/R	T to Q/N/A	T to D/E/C
G ly-215	G to S/T	G to N/Q	G to K/D
Pro-14	P to G/A	P to C/S	P to K/D
Ser-9	S to K/R	S to Q/N/A	S to D/E/C
G ly-211	G to S/T	G to N/Q	G to K/D

10

SITE2		Subtilisin BPN'	
G lu-195	G to S/T	G to N/Q	G to K/D
G ly-166	G to S/T	G to N/Q	G to K/D
G ly-154	G to S/T	G to N/Q	G to K/D
Ser-163	S to K/R	S to Q/N/A	S to D/E/C
Arg-247	R to K/H	R to Q/N	R to A/C/E
Lys-265	K to S/T/C	K to D/E/R	K to Q/N
Val-143	V to A/G/H	V to Q/E/C	V to T/S/K
G ly-127	G to S/T	G to N/Q	G to K/D
Ser-260	S to K/R	S to Q/N/A	S to D/E/C
G ly-131	G to S/T	G to N/Q	G to K/D
G ly-128	G to S/T	G to N/Q	G to K/D

Example 2

15

PD498

The 3-dimensional structure of PD 498 as determined by X-ray

crystallography in Brookhaven Protein Data Bank (PDB) format

The sequence which was used to elucidate the three-dimensional structure forming the basis for the present invention consists of the 280 amino acids derived from *Bacillus* 5 sp. PD498, NCIMB No. 40484 as disclosed in sequence ID No. 2.

The structure of PD498 was solved in accordance with the principle for X-ray crystallographic methods given in "X-Ray Structure Determination", Stout, G.K. and Jensen, L.H., John Wiley & Sons, inc. NY, 1989 and "Protein Crystallography" by Blundell, T.L. and Johnson, L.N., Academic Press, London, 1990. The structural coordinates for the solved crystal structure of PD 498 at 2.2 Å resolution using the isomorphous replacement method are given in a standard PDB format (Brookhaven Protein Data Base) in Appendix 1. It is to be understood that Appendix 1 forms part of the present application.

In Appendix 1 the amino acid residues of the enzyme are identified by three-letter amino acid code (capitalized letters).

PD498 has three bound metal ions. Site 1 is equivalent to site 1 in subtilisin BPN' and contains a calcium ion. Site 2 does not have an equivalent in subtilisin BPN' and contains a calcium ion. Site 3 is in the same region as the 2nd site in subtilisin BPN' and does here contain a sodium ion and a monopropylene glycol ligand.

25 Applying the above method disclosed in example 1 results in:

Site 1:

	residue	resno	$dist(C^{\alpha})$	$dist(C^\beta)$	ACC	(ÅxÅ)	ACC	(웅)
	GLY	89	4.26			4		
	ASP	5	5.02	3.92		0		
	ASP	48	5.10	4.36		0		
35	ASN	86	5.15	4.73		33		20.63
	ALA	82	5.84	4.97		0		
	GLY	87	6.05			41		54.67

39

	GLY	92	7.33		0	
	TYR	8	7.87	7.12	12	
	TYR	7	8.01	7.63	89	38.70
	PRO	47	8.13	8.09	59	40.69
5	PRO	3	8.61	7.55	9	
	GLY	78	8.69		0	
	THR	213	9.19	8.55	0	
	ARG	51	10.39	9.61	162	72.00
	HIS	46	10.41	9.93	1	
10	LYS	52	10.56	9.41	10	
	TYR	219	10.74	9.79	56	24.35
	ALA	211	11.55	11.03	9	
	GLN	12	11.67	10.44	22	12.22
	GLY	218	12.00		18	24.00
15	ALA	10	12.35	12.15	65	56.52
	TYR	11	12.46	12.00	121	47.45
	VAL	53	13.30	13.18	18	11.61
	PRO	15	13.52	12.10	0	
	ARG	28	13.77	12.93	103	45.78
20	ILE	99	14.16	13.16	0	
	ASP	43	14.36	14.04	8	
	TRP	1	14.43	13.90	71	27.84
	GLY	14	14.60		1	
	GLY	234	14.85		0	
25	GLY	29	14.97		13	17.33

30 Site 2:

	resid	resno	$\text{dist}(C^{\alpha})$	$dist(C^{\beta})$	ACC (ÅxÅ)	ACC (%)
	ASN	65	4.25	4.04	65	40.63
	ASP	61	4.98	3.62	88	58.67
35	ASP	63	5.30	4.43	46	30.67
	ASP	58	5.39	3.87	0	
	MET	67	5.53	5.42	42	22.70

40

ILE	60	7.09	6.76	48	27.43
ARG	103	7.67	6.23	4	
GLY	41	8.03		1	
LEU	69	8.99	8.35	114	67.06
GLY	56	10.02		2	
LYS	55	10.15	9.43	115	57.50
ALA	101	11.02	10.20	0	
TYR	44	11.83	11.14	35	15.22
GLY	73	13.18		0	
ASN	45	13.57	13.14	114	71.25
GLY	119	13.62		0	
GLY	111	13.75		36	48.00
GLY	71	13.78		4	
SER	115	13.82	12.77	24	20.87
GLY	109	13.90		32	42.67
THR	74	13.96	13.69	0	
PRO	215	14.41	13.20	30	20.69
VAL	53	14.70	13.64	18	11.61
VAL	37	14.80	14.62	1	
	ARG GLY LEU GLY LYS ALA TYR GLY ASN GLY GLY GLY GLY THR PRO VAL	ARG 103 GLY 41 LEU 69 GLY 56 LYS 55 ALA 101 TYR 44 GLY 73 ASN 45 GLY 119 GLY 111 GLY 71 SER 115 GLY 109 THR 74 PRO 215 VAL 53	ARG 103 7.67 GLY 41 8.03 LEU 69 8.99 GLY 56 10.02 LYS 55 10.15 ALA 101 11.02 TYR 44 11.83 GLY 73 13.18 ASN 45 13.57 GLY 119 13.62 GLY 111 13.75 GLY 71 13.78 SER 115 13.82 GLY 109 13.90 THR 74 13.96 PRO 215 14.41 VAL 53 14.70	ARG 103 7.67 6.23 GLY 41 8.03 LEU 69 8.99 8.35 GLY 56 10.02 LYS 55 10.15 9.43 ALA 101 11.02 10.20 TYR 44 11.83 11.14 GLY 73 13.18 ASN 45 13.57 13.14 GLY 119 13.62 GLY 111 13.75 GLY 71 13.78 SER 115 13.82 12.77 GLY 109 13.90 THR 74 13.96 13.69 PRO 215 14.41 13.20 VAL 53 14.70 13.64	ARG 103 7.67 6.23 4 GLY 41 8.03 1 LEU 69 8.99 8.35 114 GLY 56 10.02 2 LYS 55 10.15 9.43 115 ALA 101 11.02 10.20 0 TYR 44 11.83 11.14 35 GLY 73 13.18 0 ASN 45 13.57 13.14 114 GLY 119 13.62 0 GLY 111 13.75 36 GLY 71 33.78 4 SER 115 13.82 12.77 24 GLY 109 13.90 32 THR 74 13.96 13.69 0 PRO 215 14.41 13.20 30 VAL 53 14.70 13.64 18

Site 3:

	resid	resno	$\operatorname{dist}(\mathtt{C}^{lpha})$	$dist(C\beta)$	ACC (ÅxÅ)	ACC (%)
25	ALA	179	4.07	4.05	0	
	ALA	181	4.65	4.11	0	
	TRP	200	6.65	6.57	46	18.04
	ASP	202	6.86	6.02	19	12.67
	ALA	160	7.85	7.10	0	
30	VAL	158	8.84	8.28	0	
	THR	170	9.23	8.58	65	46.43
	VAL	148	10.12	8.77	0	
	LYS	268	10.74	9.64	108	54.00
	ARG	250	11.05	10.04	30	13.33
35	GLY	183	11.15		2	
	GLY	198	11.37		8	
	TRP	152	11.64	10.35	35	13.73

1	7	
4	1.	

	LEU	133	11.65	10.63	0	
	GLU	254	11.66	10.63	15	7.89
	GLY	136	11.84		39	52.00
	TYR	269	12.12	11.37	45	19.57
5	GLY	163	12.15		11	14.67
	SER	229	12.16	11.65	0	
	LEU	144	13.01	12.62	2	
	ASN	196	13.01	12.00	1	
	VAL	232	13.12	11.71	0	
10	LEU	131	13.25	12.69	0	
	ILE	253	13.27	12.22	1	
	ALA	151	13.59	12.87	0	
	THR	225	13.88	12.66	1	
	ASN	246	14.04	13.33	17	10.63
15	GLY	270	14.22		0	
	ILE	249	14.51	14.36	4	
	ALA	228	14.65	14.00	0	
	SER	141	14.78	14.70	21	18.26
	ALA	236	14.93	13.63	0	

WO 00/22103

The table below shows the preferred functional substitutions in site 1, 2 and 3 of PD498.

SITE1		PD498	
Asn-86	N to D/E	N to K/R	N to A/C
G ly-87	G to S/T	G to N/Q	G to K/D
Tyr-7	Y to N/Q	Y to A/G/C	Y to K/H
Pro-47	P to G/A	P to C/S	P to K/D
Arg-51	R to K/H	R to Q/N	R to A/C/E
Tyr-219	Y to N/Q	Y to A/G/C	Y to K/H
Gly-218	G to S/T	G to N/Q	G to K/D
Ala-10	A to N/Q	A to K/R	A to D/E
Tyr-11	Y to N/Q	Y to A/G/C	Y to K/H
Arg-28	R to K/H	R to Q/N	R to A/C/E
Trp-1	W to N/Q	W to A/G/C	W to K/H
Gly-29	G to S/T	G to N/Q	G to K/D

SITE2	- "	PD 498	
Asn-65	N to D/E	N to K/R	N to A/C
Asp-61	D to N/Q	D to K/H	D to A/G/C
Asp-63	D to N/Q	D to K/H	D to A/G/C
M et-67	M to A/G/H	M to Q/E/C	M to T/S/K
lle-60	I to A/G/H	I to Q/E/C	I to T/S/K
Leu-69	L to A/G/H	L to Q/E/C	L to T/S/K
Lys-55	K to S/T/C	K to D/E/R	K to Q/N
T yr-44	Y to N/Q	Y to A/G/C	Y to K/H
Asn-45	N to D/E	N to K/R	N to A/C
G ly-111	G to S/T	G to N/Q	G to K/D
Ser-115	S to K/R	S to Q/N/A	S to D/E/C
G ly-109	G to S/T	G to N/Q	G to K/D
Pro-215	P to G/A	P to C/S	P to K/D

SITE3	PD498			
Trp-200	W to N/Q	W to A/G/C	W to K/H	
Thr-170	T to K/R	T to Q/N/A	T to D/E/C	
Lys-268	K to S/T/C	K to D/E/R	K to Q/N	
Gly-136	G to S/T	G to N/Q	G to K/D	
Tyr-269	Y to N/Q	Y to A/G/C	Y to K/H	
Ser-141	S to K/R	S to Q/N/A	S to D/E/C	

Example 3

Savinase

For this example the X-ray structure entry 1SVN in the Brookhaven Protein Data Bank was used. This structure contains two metal ions. Site 1 contains a calcium ion and is at a position equivalent to site 1 in subtilisin BPN'. Site 2 contains a calcium ion at a position equivalent to site 2 in subtilisin BPN'. In the following list a SEQUENTIAL numbering have been applied and NOT the numbering system used in the structure file.

Site 1:

resid	resno	$dist(C^{\alpha})$	$dist(C^{\beta})$	ACC	ACC
				(ÅxÅ)) (왕)

				43	
GLY	78	4.28		14	18.67
ASN	75	4.74	4.64	61	38.13
ASP	40	5.08	4.34	0	
GLN	2	5.39	4.59	45	25.0
ALA	72	5.49	4.99	0	
GLY	81	7.68		0	
PRO	84	8.28	7.29	5	
GLY	68	8.88		1	
THR	202	9.19	8.67	0	
HIS	38	10.40	9.89	13	
PRO	5	10.47	10.26	14	9.66
ASN	42	10.55	10.50	94	58.75
TYR	208	10.72	9.76	65	28.26
GLN	200	11.75	11.39	82	45.56
ILE	8	12.10	10.58	3	
PRO	14	12.91	12.63	49	33.79
THR	22	13.01	12.24	29	20.71
HIS	17	13.44	12.07	29	14.87
ALA	13	13.78	12.63	0	
GLY	7	14.60		2	
LEU	88	14.86	13.68	0	
GLY	223	14.89		0	

Site 2:

GLY 23 14.93

resid	resno	dist(C ^a)	$dist(C^{\beta})$	ACC (ÅxÅ)	ACC (%)
ALA	170	4.88	4.24	0	
GLY	189	5.10		46	61.33
ASP	191	7.22	6.52	6	
ALA	149	7.79	7.05	0	
ILE	159	8.29	6.89	1	
VAL	147	8.98	8.40	0	
VAL	137	9.81	8.44	0	
GLY	187	10.71		3	
GLY	258	10.85		3	

			•	4 4	
ARG	241	10.90	9.77	39	17.33
GLY	172	11.27		0	
GLY	125	11.66		46	61.33
THR	141	11.72	10.47	20	14.29
LEU	122	11.73	10.70	0	
GLY	152	11.96		8	
LEU	133	12.29	11.70	3	
GLN	185	12.41	11.63	14	7.74
THR	218	12.51	11.95	0	
LYS	245	12.79	11.71	48	24.00
SER	259	12.93	12.67	35	30.43
ASN	237	13.34	12.53	22	13.75
ALA	120	13.49	13.00	0	
THR	254	13.53	13.19	100	71.43
VAL	221	13.62	12.14	0	
ALA	140	13.65	13.13	0	
VAL	145	13.91	13.88	0	
THR	214	14.00	12.84	2	
GLY	157	14.11		42	56.00
LEU	244	14.27	13.26	0	
ALA	217	14.97	14.17	0	

The table below shows the preferred functional substitutions in site 1 and 2 of Savinase.

SITE1	Savinase		
G ly-78	G to S/T	G to N/Q	G to K/D
Asn-75	N to D/E	N to K/R	N to A/C
Gln-2	Q to D/E	Q to K/R	Q to A/C
Asn-42	N to D/E	N to K/R	N to A/C
Tyr-208	Y to N/Q	Y to A/G/C	Y to K/H
G In-200	Q to D/E	Q to K/R	Q to A/C
Pro-14	P to G/A	P to C/S	P to K/D
Thr-22	T to K/R	T to Q/N/A	T to D/E/C
H is -17	H to S/T/C	H to D/E	H to Q/N

SITE2	Savinase			
Gly-189	G to S/T	G to N/Q	G to K/D	
Arg-241	R to K/H	R to Q/N	R to A/C/E	
Gly-125	G to S/T	G to N/Q	G to K/D	
Lys-245	K to S/T/C	K to D/E/R	K to Q/N	
Ser-259	S to K/R	S to Q/N/A	S to D/E/C	
Thr-254	T to K/R	T to Q/N/A	T to D/E/C	
Gly-157	G to S/T	G to N/Q	G to K/D	

Example 4

5

Amylase (AA560)

For this example the structure of AA560 has been found by homology modelling using the BAN/Termamyl α -amylase structure disclosed in WO 96/23874 which is hereby incorporated by reference. This structure contains two metal ions. Both site 1 and 2 contain a calcium ion.

The example shows how a 3-dimensional structure determined by model building using coordinates from a homologous structure, can be used to identify residues of the ligand binding site, which may be modified in order to reduce the immune response.

Applying the method disclosed above results in:

Site 1:

$\boldsymbol{\neg}$	\sim

Res		ACC	ACC
		(ÅxÅ)	()
TYR	58:CA	23	10.00
GLY	59:CA	4	
ALA	60:CA	0	
VAL	103:CA	0	
VAL	104:CA	1	
MET	105:CA	6	
	106:CA	1	
HIS	107:CA	6	
LYS	108:CA	14	
GLY	109:CA	2	
VAL	122:CA	3	
PRO	124:CA	27	18.62
ASN	126:CA	28	17.50

ARG 127:CA	17	
ASN 128:CA	107	66.88
THR 141:CA	0	
TRP 159:CA	75	29.41
TYR 160:CA	96	41.74
HIS 161:CA	2	
PHE 162:CA	0	
ASP 163:CA	1	
GLY 164:CA	10	
VAL 165:CA	6	
ASP 166:CA5	64	42.67
ILE 177:CA	12	
TYR 178:CA	10	
LYS 179:CA	27	13.50
PHE 180:CA	10	1
LYS 185:CA	36	18.00
GLY 186:CA	24	32.00
TRP 187:CA	27	10.59
ASP 188:CA	0	
TRP 189:CA	136	53.33
GLU 190:CA	39	20.53
VAL 191:CA	0	
ASP 192:CA	111	
THR 193:CA	84	60.00
GLU 194:CA	88	46.32
ASN 195:CA	36	22.50
GLY 196:CA	27	36.00
ASN 197:CA	8	
TYR 198:CA	41	17.83
ASP 199:CA	1	
TYR 200:CA	2	
LEU 201:CA	50	29.41
MET 202:CA	72	38.92
TYR 203:CA	93	40.43
ALA 204:CA	2	1.0.1.0
ASP 205:CA	0	
ILE 206:CA	4	
ASP 207:CA	6	
MET 208:CA	5	-
ASP 209:CA	74	49.33
HIS 210:CA	39	20.00
VAL 213:CA	0	120.00
VAL 214:CA	26	16.77
LEU 217:CA	4	10.77
ILE 235:CA	0	-
ASP 236:CA	15	1
ALA 237:CA	5	-
VAL 238:CA	0	-
LYS 239:CA	14	
HIS 240:CA	13	-
ILE 241:CA	13	
1116 Z41:CA		

LYS 242:C	A	44	22.00
TYR 243:C	A	5	
SER 244:C	A	40	34.78
PHE 245:C	A	10	
THR 246:C	A	0	
ARG 247:C	A	60	26.67
TRP 249:C	A	0	
ALA 265:C	A	0	
GLU 266:C	A	17	8.95
PHE 267:C	A	2	
TRP 268:C	A	27	10.59

site 2:

Ē

Res			ACC (ÅxÅ)	ACC ()
ASN	296:	CA	25	15.63
LEU	297:	CA	1	
TYR	298:	CA	68	29.57
ASN	299:	CA	72	45.00
ALA	300:	CA	0	
SER	301:	CA	0	
LYS	302:	CA	117	58.50
SER	303:	CA	43	37.39
GLY			70	93.33
GLY	305:	CA	8	10.67
ASN			149	93.13
TYR	307:	CA	49	21.30
ASP	308:	CA	59	39.33
MET	309:	CA	0	
ARG	310:	CA	143	63.56
GLN	311:	CA	99	55.00
ILE	312:	CA	3	
PHE	313:	CA	17	8.10
ASN	314:	CA	76	47.50
GLU		CA	73	38.42
TRP			89	38.70
1	348:	CA	2	
LEU		CA	2	
ALA	352:		0	
TYR	404:		32	13.91
LEU		CA	35	20.59
ASP	406:	CA	78	52.00
HIS	407:	CA	69	35.38
HIS	408:	CA	100	51.28
ASN	409:	CA	31	19.38
ILE	410:	CA	19	10.86
ILE	411:	CA	0	
GLY	412:	CA	0	
ILE	429:	CA	0	

430:	CA	5	
431:	CA	0	
432:	CA	5	
433:	CA	19	25.33
434:	CA	73	63.48
435:	CA	35	46.67
436:	CA	21	28.00
437:	CA	86	53.75
474:	CA	0	
475:	CA	53	33.13
476:	CA	41	54.67
477:	CA	29	38.67
478:	CA	18	15.65
479:	CA	2	
	431: 432: 433: 434: 435: 436: 437: 474: 475: 476: 477: 478:	431: CA 432: CA 433: CA 434: CA 435: CA 436: CA 437: CA 474: CA 475: CA 476: CA 477: CA 478: CA	431: CA 0 432: CA 5 433: CA 19 434: CA 73 435: CA 35 436: CA 21 437: CA 86 474: CA 0 475: CA 53 476: CA 41 477: CA 29 478: CA 18

The table below shows functional preferred substitutions in site 1 and 2 of the amylase AA560. For ASN 126 the substitution N to D/E means that Asparagine in position 126 may preferably be substituted with Aspartic acid or Glutamic acid, Lysine or Arginine, or Alanine or Cysteine.

Funtional pro	eferred substi	itutions					
Site 1				Site 2			
ASN 126	N to D/E	Nto K/R	N to A/C	LYS 302	K to S/T/C	Kto D/E	K to Q/N
ASN 128	N to D/E	N to K/R	N to A/C	SER 303	StoK/R	S to Q/N/A	S to D/E/C
TRP 159	WtoNQ	W to A/G/C	W to K/H	ASN 306	N to D/E	N to K/R	NtoAC
TYR 160	Y to N/Q	Y to A/G/C	Y to K/H	TYR 307	Y to N/Q	Y to A/G/C	Y to K/H
ASP 166	D to N/Q	DtoK/H	D to A/G/C	ASP 308	D to N/Q	D to K/H	D to A/G/C
LYS 185	K to S/T/C	Kto D/E	K to Q/N	ARG 310	R to K/H	R to Q/N	R to A/C/E
TRP 189	W to N/Q	W to A/G/C	W to K/H	GLN 311	Q to D/E	Q to K/R	Q to A/C
GLU 190	E to N/Q	E to K/H	E to A/G/C	ASN 314	N to D/E	N to K/R	N to A/C
ASP 209	D to N/Q	DtoK/H	D to A/G/C	GLU 345	E to N/Q	E to K/H	E to A/G/C
HIS 210	H to S/T/C	H to D/E	H to Q/N	TRP 347	W to N/Q	W to A/G/C	W to K/H
VAL 214	V to Q/N	V to G/A/C	V to K/H/D	ASP 406	D to N/Q	D to K/H	D to A/G/C
LYS 242	K to S/T/C	K to D/E	K to Q/N	HIS 407	H to S/T/C	H to D/E	H to Q/N
SER 244	StoK/R	S to Q/N/A	S to D/E/C	HIS 408	H to S/T/C	H to D/E	H to Q/N
ARG 247	R to K/H	R to Q/N	R to AC/E	ALA 434	A to N/Q	A to K/R	A to D/E
				ASN 437	N to D/E	N to K/R	N to A/C
				ASN 475	N to D/E	N to K/R	N to A/C
				GLY 476	G to S/T	GtoNQ	G to K/D
				SER 478	StoK/R	S to Q/N/A	S to D/E/C

49

Example 5

Conjugation of Savinase variant R241K with activated bis-PEG-1000

5

228 mg of the Savinase variant was incubated in 50 mM Sodium Borate pH 9.5 with 510 mg of N-succinimidyl carbonate activated bis-PEG 1000 in a reaction volume of approximately 30 ml. The reaction was carried out at ambient temperature using magnetic stirring while keeping the pH within the interval 9.0-9.5 by addition of 0.5 M NaOH. The reaction time was 2 hours. The reaction was stopped by adding 1M HCl to a final pH of 6.0. Reagent excess was removed by ultra filtration using a Filtron-Ultrasette and the final product stored at -20°C, in 50 mM Sodium Borate, 150 mM NaCl, 1 mM CaCl2, 50% mono propylene glycol at H 6.0.

Compared to the parent enzyme, residual activity was close to 100% towards a peptide substrate (succinyl-Ala-Ala-Pro-Phe-p-nitro-anilide).

20

Example 6

25 Conjugation of Savinase variant R241K with activated bis-PEG-2000

353 mg of the Savinase variant was incubated in 50 mM Sodium Borate pH 9.5 with 1621 mg of N-succinimidyl carbonate activated bis-PEG 2000 in a reaction volume of approximately 35 ml. The reaction was carried out at ambient temperature using magnetic stirring while keeping the pH within the interval 9.0-9.5 by addition of 0.5 M NaOH. The reaction time was 2 hours. The reaction was stopped by adding 1M HCl to a final pH of 6.0. Reagent excess was removed by ultra filtration using a Filtron-Ultrasette and the final product stored at -20°C, in 50 mM Sodium Borate, 150 mM NaCl, 1 mM CaCl2, 50% mono propylene glycol at H 6.0.

Compared to the parent enzyme, residual activity was close to 100% towards a peptide substrate (succinyl-Ala-Ala-Pro-Phe-p-nitro-anilide).

5 Example 7

Determination of IgE levels in rats of R241KbPEG1000 and R241KbPEG2000

10 Methods:

Sample Management: Each sample was diluted to 0.075 mg protein/ml, and aliquoted in 1.5 ml. These fractions were sent to the stables for storage at -20° C until use. Additionally, 100 μ l of the respective fractions were stored in the lab- freezer at -20° C for immunochemical analysis at the beginning, halfway and at the end of the study. For each immunization and each analysis a new fraction was taken.

Immunization: Twenty intratracheal immunizations were performed weekly with 100 μ l 0.9% (wt/vol) NaCl (control group), or 100 μ l of the protein dilution mentioned before. (group 5 unmodified R241K variant of Savinase, group 6 R241K-bis-S-PEG1000, and group 7 R241K-bis-S-PEG2000. Each group contained 10 rats. Blood samples (2 ml) were collected from the eye one week after every second immunization. Serum was obtained by blood clothing, and centrifugation.

ELISA: Specific IgE levels were determined using the ELISA's specific for rat IgE. The sera were titrated at ½ dilutions, starting from undiluted. Optical densities were measured at 492/620 nm.

The results are shown in figure 1. As can be seen the IgE levels of the conjugated savinase variants R241K are reduced compared to the savinase variant R241K.

35 Example 8

51

R2410, R241E, R241H and R241K.

Female Balb/c mice, 9 weeks of age were immunised subcutaneously for 20 consecutive weeks, with wild type savinase, and with variants having single mutations in position R241 (R241Q, R241E, R241H, R241K). Every other week, IgG1 and IgE serum levels were determined by ELISA.

Sample Management: Each sample was diluted to 0.010 mg protein/ml, and aliquoted in 1.5 ml. These fractions were sent to the stables for storage at -20°C until use. Additionally, 100

 μl of the respective fractions were stored in the lab-freezer at -20°C for immunochemical analysis at the beginning, halfway and at the end of the study. For each immunization and each analysis a new fraction was taken.

Immunization: Twenty subcutanuous immunizations were performed weekly with 100 μ l 0.9% (wt/vol) NaCl (control group), or 100 μ l of the protein dilution mentioned before. Thus, group 1 received wild type Savinase, group 2 (R241Q), group 3 (R241H), group 4 (R241E), and group 5 (R241K). Each group contained 10 mice. Blood samples (100 μ l) were collected from the eye one week after every second immunization. Serum was obtained by blood clotting, and centrifugation.

ELISA: Specific IgG1 levels were determined using the 25 ELISA

specific for mouse IgG1. The sera were titrated at ½ dilutions, starting from 1:160.

Specific IgE levels were determined using the ELISAs specific for mouse IgE. The sera were titrated at ½ dilutions, starting from undiluted. Optical densities were measured at 492/620 nm.

Statistical analysis: Differences between data sets were analysed by using nonparametric methods: the Kruskal-Wallis Test and the Dunn's Multiple Comparison Test.

The results are shown in figure 2. As can be seen the IgE levels of the Savinase variants are significantly reduced.

52

PAGE INTENTIONALLY LEFT BLANK

APPENDIX 1

The structure of PD498 as determined by X-ray crystallography in Brookhaven Protein Data Bank (PDB) format.

	CRYST	45.	070	67.	0.9				90.00		P212121	
	SCALE1			2219		0.00000	0.000			0.00000		
	SCALE2			0000		0.01491	0.000			0.00000		
10	SCALE3			0000		0.00000	0.0123			0.00000		
	MOTA	1	N	TRP		1	17.560			47.742	1.00 15.33	7
	ATOM	2	CA	TRP		1	18.953			47.487	1.00 15.36	6
	ATOM	3	C	TRP		1	19.164			48.002	1.00 14.46	6
	ATOM	4	0	TRP		1	18.277			47.654	1.00 17.10	8
15	ATOM	5	CB	TRP		1	19.316			46.000	1.00 21.00	6
	ATOM	6	CG	TRP		1	20.729			45.607	1.00 15.22	6
	ATOM	7	CD1		Α	1	21.877			45.845	1.00 14.54	6
	ATOM	8	CD2		Α	1	21.184			44.857	1.00 16.51	6
	ATOM	9	NE1		Α	1	22.998			45.245	1.00 18.87	7
20	ATOM	10	CE2	TRP		1	22.542			44.624	1.00 14.70	6
	ATOM	11	CE3	TRP		1	20.514			44.272	1.00 20.67	6
	ATOM	12	CZ2	TRP		1	23.347			43.931	1.00 20.48	6
	ATOM	13	CZ3	TRP		1	21.309			43.596	1.00 16.65	6
	ATOM	14	CH2	TRP		1	22.661			43.360	1.00 16.74	6
25	ATOM	15	N	SER		2	20.202			48.812	1.00 13.43	7
	ATOM	16	CA	SER		2	20.289			49.312	1.00 15.64	6
	ATOM	17	С	SER		2	21.710		.249	49.014	1.00 15.52	6
	ATOM	18	0	SER		2			.605	49.501	1.00 18.28	8
	ATOM	19	CB	SER		2	19.980		.591	50.815	1.00 25.19	6
30	ATOM	20	OG	SER		2	18.701		.130	51.119	1.00 27.27	8
	MOTA	21	И	PRO	Α	3	21.785		.317	48.032	1.00 14.76	7
	ATOM	22	CA	PRO		3	23.056		.803	47.578	1.00 14.21	б
	ATOM	23	C	PRO	Α	3	23.708		.855	48.606	1.00 14.51	6
	ATOM	24	0	PRO	Α	3	23.048		.406	49.556	1.00 14.63	8
35	ATOM	25	CB	PRO	А	3	22.743		.050	46.281	1.00 12.74	6
	ATOM	26	CG	PRO		3	21.293		.620	46.498	1.00 14.64	6
	ATOM	27	CD	PRO		3	20.663		.776	47.270	1.00 14.83	6
	ATOM	28	N	ASN		4	25.005		.718	48.445	1.00 10.92	7
	ATOM	29	CA	ASN		4	25.792		.034	49.477	1.00 13.99	6
40	ATOM	30	C	ASN		4	25.899		.526	49.311	1.00 13.94	6
	ATOM	31	0	ASN		4	26.667		.870	50.046	1.00 12.98	8
	ATOM	32	CB	ASN		4	27.215		.626	49.502	1.00 12.72	6
	ATOM	33	CG	ASN		4	28.075		.328	48.321	1.00 16.43	6
	ATOM	34		ASN		4	27.647		.473	47.509	1.00 14.80	8
45	ATOM	35		ASN		4	29.265		.911	48.155	1.00 18.33	7
	ATOM	36	N	ASP		5	25.165		.896	48.360	1.00 11.85	7
	ATOM	37	CA	ASP		5	25.401		.474	48.156	1.00 12.19	6
	ATOM	38	C	ASP		5	25.065		.624	49.348	1.00 11.69	6
	ATOM	39	0	ASP		5	23.954		.816	49.936	1.00 10.53	8
50	ATOM	40	CB	ASP		5	24.570		.988	46.920	1.00 10.10	6
	ATOM	41	CG	ASP		5	24.777		.005	45.780	1.00 9.83	б
	ATOM	42			A	5	24.199		.106	45.756	1.00 12.14	8
	ATOM	43		ASP		5	25.568		.642	44.871	1.00 12.15	8
	ATOM	44	N	PRO		6	25.900		.745	49.795	1.00 11.28	7
55	MOTA	45	CA	PRO		6	25.673		.089	51.084	1.00 11.29	6
	MOTA	46	C	PRO		6	24.481		.190	51.146	1.00 11.12	6
	ATOM	47	0	PRO		6	23.759		.196	52.180	1.00 12.14	8
	ATOM	48	CB	PRO		6	26.984		.356	51.426	1.00 12.53	6
	MOTA	49	CG	PRO		6	27.599		.217	50.014	1.00 14.20	6
60	ATOM	50	CD	PRO		6	27.226		.453	49.202	1.00 11.88	6
	MOTA	51	N	TYR		7	24.143		.465	50.046	1.00 11.91	7
	MOTA	52	CA	TYR		7	23.015		.415	50.137	1.00 12.11	6
	ATOM	53	C	TYR		7	21.733		.635	49.875	1.00 11.41	6
	ATOM	54	0	TYR		7	20.642		.099	50.172	1.00 11.81	8
65	ATOM	55	CB	TYR		7	23.237		.509	49.078	1.00 13.43	6
	ATOM	56	CG	TYR		7	24.375		.451	49.407	1.00 16.52	6
	ATOM	57	CD1	TYR	Α	7	24.897	3	.394	50.732	1.00 19.41	6

	ATOM	58	CD2	TYR A	4 7	24.9	00 4.3	10 48.518	1.00	25.90	6
	ATOM	59	CE1	TYR A				31 51.078	1.00	23.70	6
	ATOM	60	CE2	TYR A		25.9	42 5.1	52 48.885	1.00	25.53	6
	ATOM	61	CZ	TYR A		26.4	54 5.0	99 50.157	1.00	30.83	6
5	ATOM	62	OH	TYR A	A	27.4	91 5.9	83 50.400	1.00		8
	MOTA	63	N	TYR A	<i>F</i>	21.8			1.00		7
	ATOM	64	CA	TYR A	3 E				1.00		6
	MOTA	65	C	TYR A	3 E	20.2			1.00		6
	ATOM	66	0	TYR A	<i>f F</i>				1.00		8
10	MOTA	67	CB	TYR A					1.00		6
	MOTA	68	CG	TYR A					1.00	8.84	6
	MOTA	69	CD1						1.00		6
	MOTA	70	CD2	TYR A					1.00		6
	ATOM	71	CE1	TYR A					1.00		6
15	MOTA	72	CE2	TYR A					1.00		6
	ATOM	73	CZ	TYR A					1.00		6 8
	MOTA	74	ОН	TYR A					1.00		7
	ATOM	75	N	SER A					1.00		6
	ATOM	76	CA	SER A					1.00 1.00	9.76	6
20	ATOM	77	C	SER A					1.00		8
	MOTA	78 70	O	SER A					1.00		6
	ATOM	79	CB OG	SER A					1.00		8
	ATOM ATOM	80 81	N	ALA A					1.00	9.72	7
25	ATOM	82	CA	ALA A					1.00	9.30	6
25	ATOM	83	C	ALA A					1.00		6
	ATOM	84	Õ	ALA A					1.00		8
	ATOM	85	СВ	ALA A					1.00		6
	ATOM	86	N	TYR A					1.00		7
30	ATOM	87	CA	TYR A					1.00	11.21	6
50	ATOM	88	C	TYR					1.00	12.10	6
	ATOM	89	ō	TYR					1.00	11.98	8
	ATOM	90	CB	TYR Z			41 3.9	14 51.448	1.00	9.82	6
	ATOM	91	CG	TYR Z			08 4.5	87 52.293	1.00	11.77	6
35	ATOM	92	CD1	TYR Z	A 1:	19.8	15 5.3	17 53.419	1.00	15.20	6
	ATOM	93	CD2	TYR Z	A 1:	21.5	41 4.4	93 51.970	1.00	16.78	6
	ATOM	94	CE1	TYR I	A 1:	20.7	73 5.9	55 54.196	1.00	17.43	6
	MOTA	95	CE2	TYR Z	A 1:	. 22.4	94 5.1	25 52.756	1.00	19.92	6
	MOTA	96	CZ	TYR A	A 1:	22.0	84 5.8	37 53.864	1.00	18.68	6
40	ATOM	97	OH	TYR A		_ 23.0			1.00		8
	ATOM	98	N	GLN 3					1.00	9.57	7
	MOTA	99	CA	GLN A						10.23	6
	ATOM	100	C	GLN A					1.00	9.88	6
	ATOM	101	0	GLN A						10.94	8
45	ATOM	102	CB	GLN A						10.30	6
	ATOM	103	CG	GLN A					1.00	9.41	6
	MOTA	104	CD	GLN .				93 46.387			6
	ATOM	105		GLN .					1.00 1.00	9.50	8 7
	ATOM	106		GLN .					1.00	8.12	7
50	ATOM	107	N	TYR .					1.00	8.04	6
	MOTA	108 109	CA C	TYR .						11.46	6
	ATOM			TYR .						10.57	8
	ATOM ATOM	110 111	O CB	TYR .					1.00	8.33	6
	ATOM	112	CG	TYR .					1.00	8.81	6
55	ATOM	113		TYR .					1.00	8.32	6
	ATOM	114		TYR					1.00	8.79	6
	ATOM	115		TYR					1.00	9.23	6
	ATOM	116		TYR .					1.00	7.86	6
60	ATOM	117	CEZ	TYR .					1.00	9.91	6
90	ATOM	118	OH	TYR .						10.94	8
	ATOM	119	N	GLY						10.19	7
	ATOM	120	CA	GLY						10.55	6
	ATOM	121	CA	GLY						11.11	6
65	ATOM	122	0	GLY						11.34	8
9.5	ATOM	123	N	PRO					1.00	8.71	7
	ATOM	124	CA	PRO					1.00	9.03	6
	MOTA	125	C	PRO						10.83	6
			_				- · -				

	ATOM	126	0	PRO F	15	11.557	-6.333	46.772	1.00 10.41	8
	ATOM	127	CB	PRO A		14.480	-4.906	45.683	1.00 10.96	6
	ATOM	128	CG	PRO F		15.102	-3.549	45.304	1.00 9.61	6
	ATOM	129	CD	PRO F		14.229	-2.508	46.030	1.00 9.57	6
5	ATOM	130	N	GLN F		12.741	-5.038	48.222	1.00 10.84	7
	ATOM	131	CA	GLN A		12.216	-5.795	49.382	1.00 9.58	6
	ATOM	132	C	GLN A		10.677	-5.822	49.420	1.00 9.41	6
		133	0	GLN F		10.047	-6.896	49.711	1.00 12.05	8
	ATOM					12.784	-5.110	50.653	1.00 9.56	6
	ATOM	134	CB	GLN A		14.295	-5.237	50.750	1.00 10.85	6
10	ATOM	135	CG	GLN A					1.00 10.83	6
	ATOM	136	CD	GLN A		15.079	-4.045	50.301		8
	ATOM	137		GLN A		14.615	-3.357	49.328	1.00 11.39	
	ATOM	138	NE2	GLN A		16.242	-3.776	50.867	1.00 10.81	7
	ATOM	139	N	ASN A		10.073	-4.629	49.215	1.00 10.52	7
15	ATOM	140	CA	ASN A		8.627	-4.532	49.347	1.00 9.85	6
	ATOM	141	С	ASN A		7.909	-5.151	48.185	1.00 11.20	6
	ATOM	142	0	ASN A	17	6.658	-5.131	48.244	1.00 14.71	8
	ATOM	143	CB	ASN A	17	8.208	-3.046	49.509	1.00 11.59	6
	ATOM	144	CG	ASN A	17	8.432	-2.520	50.937	1.00 13.87	6
20	MOTA	145	OD1	ASN A	17	9.226	-3.101	51.658	1.00 13.47	8
	ATOM	146	ND2	ASN A	17	7.687	-1.460	51.259	1.00 12.64	7
	ATOM	147	N	THR A	18	8.566	-5.563	47.128	1.00 10.29	- 7
	ATOM	148	CA	THR A		7.890	-6.216	45.992	1.00 12.51	6
	ATOM	149	C	THR A		8.300	-7.680	45.974	1.00 12.13	6
25	ATOM	150	ō	THR A		8.100	-8.386	44.963	1.00 11.44	8
23	ATOM	151	СВ	THR A		8.244	-5.529	44.659	1.00 9.68	6
	ATOM	152	OG1	THR A		9.696	-5.431	44.525	1.00 10.42	8
	ATOM	153	CG2	THR A		7.591	-4.187	44.624	1.00 12.66	6
			N N	SER A		8.884	-8.204	47.078	1.00 10.54	7
2.0	ATOM	154				9.287	-9.606	47.140	1.00 12.19	6
30	ATOM	155	CA	SER A				46.079	1.00 12.15	6
	ATOM	156	C	SER A		10.334	-9.982			8
	ATOM	157	0	SER A		10.372	-11.143	45.609		
	ATOM	158	CB	SER A		8.113	-10.594	47.058	1.00 15.77	6
	ATOM	159	OG	SER A		7.242	-10.315	48.179	1.00 14.40	8
35	MOTA	160	N	THR A		11.176	-9.000	45.757	1.00 11.05	7
	MOTA	161	CA	THR A		12.179	-9.303	44.731	1.00 9.03	6
	MOTA	162	C	THR A	A 20	13.341	-10.159	45.212	1.00 10.84	6
	ATOM	163	0	THR A	A 20	13.841	-10.974	44.462	1.00 12.64	8
	ATOM	164	CB	THR A	A 20	12.652	-8.005	44.067	1.00 11.34	6
40	ATOM	165	OG1	THR A	A 20	11.486	-7.307	43.584	1.00 10.88	8
	ATOM	166	CG2	THR A	4 20	13.563	-8.230	42.867	1.00 13.97	6
	ATOM	167	N	PRO A		13.788	-10.140	46.474	1.00 10.13	7
	ATOM	168	CA	PRO A		14.814	-11.028	46.940	1.00 10.60	6
	ATOM	169	C	PRO Z		14.417	-12.506	46.749	1.00 11.26	6
45	ATOM	170	ō	PRO Z		15.311	-13.256	46.270	1.00 13.61	8
1,0	ATOM	171	СВ	PRO A		14.916	-10.701	48.467	1.00 10.30	6
	ATOM	172	CG	PRO A			-9.205	48.354	1.00 10.51	6
	ATOM	173	CD	PRO A		13.477	-9.064	47.464	1.00 10.93	6
	ATOM	174	N	ALA A			-12.862	46.938	1.00 12.78	7
- ^							-14.246	46.639	1.00 13.32	6
50	ATOM	175	CA	ALA A				45.123	1.00 13.52	
	ATOM	176	C	ALA A			-14.482		1.00 14.37	
	ATOM	177	0	ALA A			-15.576	44.679		
	MOTA	178	CB	ALA A			-14.454	47.282	1.00 13.94	
	ATOM	179	N	ALA A		12.273		44.396	1.00 12.81	
55	ATOM	180	CA	ALA A			-13.614	42.917	1.00 14.03	6
	ATOM	181	C	ALA A	A 23		-13.880	42.477	1.00 12.10	
	ATOM	182	0	ALA A	A 23	13.915	-14.577	41.425	1.00 12.81	
	ATOM	183	CB	ALA A	A 23	11.712	-12.341	42.261	1.00 12.05	
	MOTA	184	N	TRP I	A 24	14.752	-13.217	42.989	1.00 11.24	
60	MOTA	185	CA	TRP 2	A 24	16.128	-13.387	42.591	1.00 11.78	6
	ATOM	186	C	TRP			-14.840	42.845	1.00 13.08	
	ATOM	187	Ö	TRP		17.723	-15.104	42.305	1.00 15.03	
	ATOM	188	CB	TRP			-12.366	43.334	1.00 15.91	
	ATOM	189	CG	TRP		16.890	-10.942	42.898	1.00 12.46	
60	ATOM	190	CD1				-10.488	41.656	1.00 11.81	
65				TRP I		17.146	-9.775	43.673	1.00 12.89	_
	ATOM	191	CD2				-9.775	41.590	1.00 12.89	
	ATOM	192	NE1			16.584				
	ATOM	193	CE2	TRP .	A 24	16.965	-8.633	42.853	1.00 11.48	6

	ATOM	194	CE3 TRP A	24	17.514 -9.55	4 45.015	1.00 14.60	6
	ATOM	195	CZ2 TRP A	24	17.132 -7.30		1.00 12.39	6
			CZ2 TRP A	24	17.643 -8.26		1.00 12.43	6
	MOTA	196		24	17.501 -7.16		1.00 12.45	6
_	ATOM	197					1.00 11.43	7
5	ATOM	198	N ASP A	25				6
	MOTA	199	CA ASP A	25	16.307 -17.01		1.00 19.28	
	ATOM	200	C ASP A	25	16.013 -17.75		1.00 19.51	6
	MOTA	201	O ASP A	25	16.674 -18.76		1.00 21.06	8
	MOTA	202	CB ASP A	25	15.474 -17.59		1.00 15.40	6
10	MOTA	203	CG ASP A	25	15.889 -17.05		1.00 16.84	6
	MOTA	204	OD1 ASP A	25	14.914 -16.93	1 47.182	1.00 20.99	8
	ATOM	205	OD2 ASP A	25	17.069 -16.79	8 46.451	1.00 18.83	8
	MOTA	206	N VAL A	26	15.083 -17.23	4 41.717	1.00 16.85	7
	ATOM	207	CA VAL A	26	14.677 -17.88	3 40.450	1.00 16.29	6
15	ATOM	208	C VAL A	26	15.490 -17.30	7 39.300	1.00 14.78	6
	ATOM	209	O VAL A	26	16.049 -18.04	4 38.463	1.00 16.30	8
	ATOM	210	CB VAL A	26	13.181 -17.68		1.00 15.77	6
	ATOM	211	CG1 VAL A	26	12.727 -18.26		1.00 16.26	6
	ATOM	212	CG2 VAL A	26	12.288 -18.24		1.00 14.73	6
20	ATOM	213	N THR A	27	15.627 -15.97		1.00 13.62	7
20		214	CA THR A	27	16.434 -15.39		1.00 13.55	6
	ATOM				16.969 -13.99		1.00 13.33	6
	ATOM	215	C THR A	27			1.00 13.11	8
	ATOM	216	O THR A	27				
	ATOM	217	CB THR A	27	15.570 -15.26		1.00 16.42	6
25	MOTA	218	OG1 THR A	27	16.481 -14.65		1.00 20.55	8
	ATOM	219	CG2 THR A	27	14.260 -14.53		1.00 15.35	6
	ATOM	220	N ARG A	28	18.167 -13.71		1.00 13.95	7
	MOTA	221	CA ARG A	28	18.707 -12.37		1.00 14.11	6
	MOTA	222	C ARG A	28	18.914 -11.56		1.00 13.63	6
30	ATOM	223	O ARG A	28	19.518 -10.52	2 37.077	1.00 13.70	8
	ATOM	224	CB ARG A	28	20.007 -12.48	7 39.167	1.00 13.10	6
	MOTA	225	CG AARG A	28	19.786 -12.59	2 40.676	0.50 16.44	6
	ATOM	226	CD AARG A	28	21.015 -13.22	9 41.319	0.50 13.92	6
	ATOM	227	NE AARG A	28	21.173 -14.65	3 40.989	0.50 20.11	7
35	ATOM	228	CZ AARG A	28	22.394 -15.19		0.50 22.04	6
	ATOM	229	NH1AARG A	28	23.372 -14.37		0.50 16.08	7
	ATOM	230	NH2AARG A	28	22.629 -16.45		0.50 19.93	7
	ATOM	231	CG BARG A	28	19.609 -13.09		0.50 12.85	6
	ATOM	232	CD BARG A	28	20.809 -13.39		0.50 12.14	6
4.0				28	21.589 -14.47		0.50 12.11	7
40	ATOM	233					0.50 12.31	6
	ATOM	234	CZ BARG A	28	21.281 ~15.74			7
	ATOM	235	NH1BARG A	28	20.289 -16.18		0.50 13.92	7
	ATOM	236	NH2BARG A	28	22.032 -16.67		0.50 18.15	
	ATOM	237	N GLY A	29	18.305 -12.01		1.00 12.92	7
45	ATOM	238	CA GLY A	29	18.362 -11.29		1.00 12.43	6
	ATOM	239	C GLY A	29	19.326 -12.01		1.00 11.85	6
	MOTA	240	O GLY A	29	19.589 -13.20		1.00 16.10	8
	MOTA	241	N SER A		19.705 -11.32		1.00 11.08	7
	ATOM	242	CA SER A	330	20.543 -11.99		1.00 12.22	6
50	MOTA	243	C SER A	330	21.461 -10.94	31.078	1.00 13.35	6
	MOTA	244	O SER A	330	21.121 -9.88	39 30.574	1.00 13.86	8
	MOTA	245	CB SER A		19.712 -12.58	30.525	1.00 15.19	6
	ATOM	246	OG SER A		20.650 -12.91	7 29.463	1.00 17.47	8
	ATOM	247	N SER A		22.855 -11.29		1.00 14.23	7
55	ATOM	248	CA SER A		23.828 -10.40		1.00 13.69	6
33	ATOM	249	C SER A		23.784 -10.22		1.00 12.34	6
	ATOM	250	O SER A		24.497 -9.32		1.00 19.86	8
					25.268 -10.72		1.00 18.58	6
	ATOM	251	CB SER A					8
	ATOM	252	OG SER A		25.541 -12.03		1.00 22.11	
60	ATOM	253	N THR A		22.962 -11.06		1.00 11.83	7
	ATOM	254	CA THR A		22.892 -10.96		1.00 15.40	6
	ATOM	255	C THR A		21.538 -10.41		1.00 17.11	6
	ATOM	256	O THR A		21.235 -10.37		1.00 16.83	8
	MOTA	257	CB THR A	332	22.969 -12.36		1.00 17.26	6
65	ATOM	258	OG1 THR A		22.107 -13.30		1.00 22.90	8
	ATOM	259	CG2 THR A		24.448 -12.81		1.00 22.90	6
	ATOM	260	n GLNA	333	20.861 -9.71	L6 27.512	1.00 13.07	7
	ATOM	261	CA GLN A		19.630 -8.97	74 27.160	1.00 12.63	6

57

19.830 -7.523 27.631 1.00 13.44 20.686 -7.227 28.461 1.00 12.88 18.420 -9.526 27.862 1.00 10.82 18.173 -10.962 27.360 1.00 12.25 MOTA 262 C GLN A 333 263 O GLN A 333 264 CB GLN A 333 MOTA 6 ATOM CG GLN A 333 MOTA 265 5 ATOM ATOM ATOM 7 ATOM 7 6 MOTA 10 ATOM 6 8 ATOM 6 MOTA 8 ATOM ATOM 6 15 ATOM 7 6 ATOM ATOM 6 ATOM MOTA 20 ATOM 6 6 MOTA 7 ATOM ATOM ATOM 25 ATOM MOTA 6 7 ATOM **ATOM** 6 6 ATOM 30 ATOM 8 MOTA 6 ATOM MOTA 7 MOTA 35 ATOM 6 ATOM ATOM 6 MOTA ATOM 6 40 ATOM 6 MOTA 7 ATOM ATOM ATOM 6 45 ATOM 6 MOTA ATOM 6 ATOM 8 8 MOTA 7 50 ATOM 6 MOTA ATOM ATOM 8 ATOM 6 55 ATOM 7 ATOM ATOM 6 MOTA 6 ATOM 60 ATOM 7 ATOM 6 MOTA 6 VAL A 1.00 13.26 25.086 7.934 30.912 41 MOTA 324 0 325 VAL A 22.679 ATOM CB 41 6.202 31.427 1.00 10.61 CG1 VAL A 41 23.194 CG2 VAL A 41 21.181 N ASP A 42 24.763 CA ASP A 42 26.196 23.194 32.618 5.368 1.00 10.20 65 ATOM 6 326 ATOM 327 5.897 31.236 1.00 11.88 8.180 33.136 1.00 11.44 7 ATOM 328 8.426 33.402 1.00 13.13 MOTA 329

	ATOM	330	С	ASP	A	42	26.852	7.060	33.461	1.00	12.56	6
	ATOM	331	Ō	ASP		42	26.966	6.459	34.518	1.00	13.21	8
	ATOM	332	CB			42	26.379	9.170	34.745	1.00	13.74	6
	ATOM	333	CG	ASP		42	27.857	9.433	35.018		18.39	6
5	ATOM	334	OD1			42	28.140	10.034	36.082		21.20	8
5	ATOM	335	OD2	ASP .		42	28.672	9.005	34.208		12.32	8
						43	27.358	6.645	32.283		11.92	7
	ATOM	336	N	TYR .					32.283		12.00	6
	MOTA	337	CA	TYR .		43	27.980	5.350			13.62	6
	ATOM	338	C	TYR		43	29.429	5.271	32.714			8
10	ATOM	339	0	TYR		43	29.966	4.179	32.656		14.17	
	ATOM	340	CB	TYR		43	28.031	4.952	30.604		14.19	6
	ATOM	341	CG	TYR		43	28.532	6.090	29.719		13.96	6
	MOTA	342	CD1			43	29.876	6.376	29.758		21.10	6
	ATOM	343	CD2	TYR		43	27.649	6.817	28.949		13.89	6
15	ATOM	344	CE1	TYR		43	30.377	7.422	28.982		23.78	6
	ATOM	345	CE2	TYR	A	43	28.162	7.877	28.152	1.00	17.35	6
	ATOM	346	CZ	TYR	A	43	29.499	8.136	28.197	1.00	21.91	6
	ATOM	347	OH	TYR	A	43	30.054	9.174	27.458	1.00	25.51	8
	ATOM	348	N	ASN	A	44	29.860	6.400	33.220	1.00	14.70	7
20	MOTA	349	CA	ASN		44	31.144	6.357	33.963	1.00	15.55	6
	ATOM	350	C			44	30.923	6.074	35.433	1.00	14.58	6
	ATOM	351	ō	ASN		44	31.889	5.965	36.221		14.97	8
	ATOM	352	СВ	ASN		44	31.874	7.711	33.833		15.61	6
	ATOM	353	CG	ASN		44	32.294	7.939	32.344		13.41	6
2.5			OD1			44	32.052	9.147	32.103		22.06	8
25	MOTA	354						6.911	31.724		16.45	7
	ATOM	355	ND2	ASN		44	32.766					7
	ATOM	356	N		A	45	29.653	6.081	35.908		13.02	
	MOTA	357	CA		A	45	29.474	5.865	37.376		11.13	6
	ATOM	358	С		A	45	29.917	4.462	37.727		10.90	6
30	ATOM	359	0			45	29.653	3.499	37.064		11.84	8
	ATOM	360	CB	HIS	A	45	27.929	5.959	37.618		13.07	6
	ATOM	361	CG	HIS	A	45	27.519	6.069	39.068		11.25	6
	ATOM	362	ND1	HIS	A	45	27.779	5.071	40.007	1.00	11.49	7
	ATOM	363	CD2	HIS	Α	45	26.921	7.129	39.661	1.00	10.98	6
35	ATOM	364	CE1	HIS	A	45	27.307	5.517	41.159	1.00	12.50	6
	ATOM	365	NE2		Α	45	26.810	6.732	41.035	1.00	11.54	7
	ATOM	366	N		A	46	30.635	4.274	38.874	1.00	11.14	7
	ATOM	367	CA	PRO		46	31.062	2.985	39.335	1.00	11.47	6
	ATOM	368	C	PRO		46	29.978	1.921	39.380		10.59	6
4.0	ATOM	369	0	PRO		46	30.196	0.767	39.040		11.62	8
40					A		31.677	3.220	40.742		10.94	6
	ATOM	370	CB			46		4.671	40.742		14.48	6
	ATOM	371	CG		A	46	32.043					6
	ATOM	372	CD	PRO		46	31.085	5.353	39.688		11.69	
	ATOM	373	N		A	47	28.728	2.326	39.705		12.70	7
45	ATOM	374	CA		A	47	27.682	1.314	39.825		11.42	6
	MOTA	375	C	ASP		47	26.899	1.133	38.520		12.51	6
	MOTA	376	0	ASP		47	25.902	0.416	38.521		11.59	8
	MOTA	377	CB	ASP		47	26.702	1.688	40.990		12.16	6
	MOTA	378	CG	ASP		47	26.587	0.469	41.896	1.00	9.76	6
50	ATOM	379	OD1	ASP	Α	47	27.288	-0.541	41.945		10.00	8
	MOTA	380	OD2	ASP	Α	47	25.518	0.471	42.653	1.00	10.91	8
	ATOM	381	N	LEU	A	48	27.369	1.772	37.435	1.00	10.44	7
	ATOM	382	CA	LEU		48	26.697	1.562	36.155		11.43	6
	ATOM	383	C	LEU		48	27.672	1.221	35.027	1.00	12.97	6
55	ATOM	384	Õ	LEU		48	27.191	0.683	34.023	1.00	11.53	8
55	ATOM	385	СВ	LEU		48	25.972	2.837	35.638	1.00	11.21	6
		386	CG	LEU		48	24.787	3.235	36.572	1.00	10.61	6
	ATOM						24.767		36.324		11.90	6
	MOTA	387		LEU		48		4.643				
	ATOM	388	CD2			48	23.677	2.180	36.462		13.84	6
60	ATOM	389	N	ALA		49	28.975	1.461	35.252		12.23	7
	ATOM	390	CA	ALA		49	29.841	1.298	34.073	1.00	9.36	6
	MOTA	391	C	ALA		49	29.855	-0.091	33.513		10.78	6
	MOTA	392	0	ALA		49	30.048	-0.245	32.236		16.98	8
	MOTA	393	CB	ALA	A	49	31.268	1.712	34.531		12.23	6
65	MOTA	394	N	ARG	Α	50	29.747	-1.164	34.276	1.00	11.88	7
	ATOM	395	CA	ARG		50	29.780	-2.522	33.800		11.57	6
	ATOM	396	C	ARG		50	28.444	-2.946	33.165		12.53	6
	ATOM	397	Õ	ARG		50	28.348	-4.048	32.602		16.06	8
		55,	_			_ •		1.010				~

	ATOM	398	CB	ARG A	A 50	30.103	-3.524	34.930	1.00 15.4	7 6
	ATOM	399	CG	ARG A		31.531	-3.240	35.482	1.00 11.8	
	ATOM	400	CD	ARG A	50	32.055	-4.513	36.187	1.00 15.4	5 6
	ATOM	401	NE	ARG A	50	31.187	-4.897	37.307	1.00 16.2	
5	ATOM	402	CZ	ARG A	50	31.384	-5.965	38.064	1.00 19.9	
	ATOM	403	NH1	ARG A	A 50	32.429	-6.782	37.837	1.00 22.2	
	ATOM	404	NH2	ARG A	¥ 50	30.526	-6.230	39.057	1.00 18.5	
	ATOM	405	N	LYS A	A 51	27.436	-2.075	33.346	1.00 11.5	
	ATOM	406	CA	LYS A	¥ 51	26.104	-2.471	32.907	1.00 11.6	
10	ATOM	407	C	LYS A		25.570	-1.744	31.675	1.00 12.7	
	MOTA	408	0	LYS A		24.582	-2.212	31.104	1.00 13.7	
	MOTA	409	CB	LYS A		25.152	-2.127	34.077	1.00 12.6	
	MOTA	410	CG	LYS A	¥ 51	25.387	-2.922	35.380	1.00 13.2	
	ATOM	411	CD	LYS A	4 51	25.538	-4.413	35.201	1.00 14.7	
15	MOTA	412	CE	LYS A		24.312	-5.051	34.628	1.00 13.0	
	MOTA	413	NZ	LYS A		23.056	-4.815	35.491	1.00 12.1	
	MOTA	414	N	VAL A	A 52	26.124	-0.623	31.345	1.00 11.7	
	ATOM	415	CA	VAL A	A 52	25.551	0.247	30.312	1.00 10.5	
	ATOM	416	C	VAL A	A 52	26.166	0.046	28.941	1.00 14.7	
20	MOTA	417	0	VAL A	4 52	27.383	0.061	28.778	1.00 16.0	
	MOTA	418	CB	VAL A		25.711	1.692	30.750	1.00 10.8	
	MOTA	419	CG1			25.233	2.601	29.613	1.00 15.7	
	MOTA	420	CG2	VAL A	A 52	24.874	1.987	32.005	1.00 11.4	
	MOTA	421	N	ILE A		25.247	-0.130	27.987	1.00 11.3	
25	MOTA	422	CA	ILE A		25.609	-0.098	26.552	1.00 11.7	
	ATOM	423	С	ILE A		25.210	1.272	26.028	1.00 14.4	
	MOTA	424	0	ILE A		24.071	1.711	26.289	1.00 13.7	
	MOTA	425	CB	ILE A		24.877	-1.179	25.791	1.00 12.4	
	ATOM	426	CG1	ILE A		25.331	-2.530	26.296	1.00 14.6	
30	MOTA	427	CG2	ILE A		25.229	-1.050	24.291	1.00 11.2	
	MOTA	428	CD1	ILE A		24.535	-3.702	25.780	1.00 20.9	
	ATOM	429	N	LYS A		26.112	1.975	25.367	1.00 14.2	
	MOTA	430	CA	LYS A		25.812	3.317	24.896	1.00 12.8	
	MOTA	431	C	LYS A		24.994	3.315	23.618	1.00 12.9	
35	ATOM	432	0	LYS A		25.458	2.835	22.572	1.00 17.6	
	MOTA	433	CB	LYS A		27.109	4.126	24.613	1.00 13.3	
	ATOM	434	CG	LYS A		27.905	4.467	25.886	1.00 13.7	
	ATOM	435	CD	LYS A		29.303	4.949	25.440	1.00 23.5	
	ATOM	436	CE	LYS A		30.311	4.482	26.488	1.00 25.4	
40	ATOM	437	NZ	LYS A		30.879	3.152	26.128	1.00 39.2	
	ATOM	438	N	GLY Z		23.737	3.675	23.690	1.00 12.1	
	ATOM	439	CA	GLY A		22.853	3.848	22.554	1.00 12.9	
	ATOM	440	C	GLY A		22.968	5.304	22.070	1.00 12.9	
	ATOM	441	0	GLY A		23.771	6.146	22.479	1.00 13.2	
45	ATOM	442	N	TYR A		22.084	5.613	21.090	1.00 13.5	
	ATOM	443	CA	TYR		22.092	6.918	20.449	1.00 12.8	
	ATOM	444	C	TYR I		21.594	8.052		1.00 14.9 1.00 14.7	
	ATOM	445	0	TYR I		20.699	7.845	22.158 19.085	1.00 14.7	
	ATOM	446	CB	TYR		21.369	6.789 7.944		1.00 12.2	
50	ATOM	447	CG	TYR		21.659		18.131 17.542	1.00 12.4	
	ATOM	448		TYR		22.915	7.978		1.00 13.3	
	ATOM	449		TYR		20.766	8.959	17.915	1.00 15.0	
	MOTA	450		TYR .		23.255	9.010	16.664 17.016	1.00 15.1	
	ATOM	451	CE2			21.106	10.017			
55	ATOM	452	CZ	TYR .		22.347	10.002	16.421	1.00 16.7	
	ATOM	453	ОН	TYR .		22.603	11.097	15.574	1.00 20.7	
	ATOM	454	N	ASP .		22.042	9.257	21.061	1.00 12.5	
	MOTA	455	CA	ASP .		21.604	10.456	21.735	1.00 11.2	
	ATOM	456	C	ASP .		20.882	11.313	20.683	1.00 14.1	
60	ATOM	457	0_	ASP .		21.559	11.878	19.812	1.00 14.4	
	ATOM	458	CB	ASP		22.814	11.201	22.293	1.00 15.0	
	MOTA	459	CG	ASP .			12.521	22.943	1.00 13.7	
	ATOM	460		ASP .		21.400	13.019	22.765	1.00 13.3	
	ATOM	461		ASP .			13.058	23.622	1.00 17.3	
65		462	N	PHE .			11.263	20.737	1.00 11.1	
	ATOM	463	CA	PHE .			12.002	19.764	1.00 13.0	
	ATOM	464	C	PHE .			13.475	20.055	1.00 16.3	
	MOTA	465	0	PHE	A 58	18.071	14.222	19.282	1.00 17.7	1 8

	ATOM	466	СВ	PHE A	58	1	7.292	11.407	19.790	1.00 14.04	6
	ATOM	467		PHE A			7.284	10.018	19.247	1.00 11.93	6
	ATOM	468	CD1	PHE A	58	1	7.055	9.878	17.861	1.00 12.43	6
	ATOM	469	CD2	PHE A	. 58		7.546	8.841	19.950	1.00 11.15	6 6
5	MOTA	470		PHE A			.7.078	8.627	17.325	1.00 13.41 1.00 13.98	6
	MOTA	471	CE2	PHE A		-	7.564	7.606	19.383		6
	MOTA	472	CZ	PHE A			7.345	7.456	17.990	_	7
	ATOM	473	N	ILE A			9.092	13.940	21.251	1.00 13.50 1.00 15.65	6
	MOTA	474	CA	ILE A			9.180	15.354	21.596 20.964	1.00 13.03	6
10	MOTA	475	C	ILE A			20.410	15.974	20.364	1.00 23.97	8
	MOTA	476	0	ILE A			20.220	17.014 15.477	23.146	1.00 25.57	6
	MOTA	477	CB	ILE A			19.241		23.140	1.00 19.46	6
	ATOM	478					17.951	15.100 16.921	23.536	1.00 22.80	6
	MOTA	479	CG2	ILE A			L9.590	15.695	23.499	1.00 21.33	6
15	MOTA	480		ILE A			L6.626 21.568	15.421	21.177	1.00 19.52	7
	ATOM	481	N	ASP A			22.810	15.974	20.563	1.00 20.37	6
	ATOM	482	CA	ASP A			23.051	15.391	19.176	1.00 23.56	6
	ATOM	483	C	ASP A			24.039	15.842	18.532	1.00 21.66	8
	MOTA	484	O	ASP A			24.011	15.638	21.423	1.00 24.04	6
20	MOTA	485	CB	ASP F			24.163	16.251	22.799	1.00 29.23	6
	MOTA	486	CG	ASP A			23.498	17.279	23.093	1.00 27.86	8
	MOTA	487		ASP A			24.968	15.676	23.597	1.00 22.41	8
	ATOM	488	N	ARG A			22.353	14.341	18.772	1.00 18.93	7
	ATOM	489 490	CA	ARG A			22.668	13.639	17.519	1.00 18.74	6
25	MOTA	491	CA	ARG A			24.106	13.184	17.487	1.00 22.32	6
	ATOM	492	Ö	ARG A			25.042	13.415	16.667	1.00 20.82	8
	ATOM ATOM	493	CB	ARG A			22.241	14.566	16.363	1.00 20.03	6
	MOTA	494	CG	ARG A			20.743	14.751	16.239	1.00 27.06	6
30	ATOM	495	CD	ARG A			20.210	15.689	15.210	0.00 20.00	6
30	ATOM	496	NE	ARG Z			19.042	16.306	15.859	0.00 20.00	7
	ATOM	497	CZ	ARG A			18.388	17.288	15.185	0.00 20.00	6
	ATOM	498		ARG 2			18.805	17.666	13.981	0.00 20.00	7
	ATOM	499		ARG Z			17.318	17.872	15.746	0.00 20.00	7
35	ATOM	500	N	ASP 2			24.436	12.342	18.480	1.00 18.53	7
	ATOM	501	CA	ASP 2	A 62		25.742	11.759	18.713	1.00 19.28	6
	ATOM	502	C	ASP 2	A 62		25.598	10.378	19.351	1.00 17.15	6
	ATOM	503	0	ASP .	A 62		24.462	9.943	19.708	1.00 17.25	8
	ATOM	504	CB	ASP .	A 62		26.663	12.711	19.495	1.00 19.71	6
40	ATOM	505	CG	ASP .	A 62		26.330	12.887	20.966	1.00 25.11	6 8
	MOTA	506	OD1	ASP .			25.880	11.940	21.630	1.00 17.54	8
	MOTA	507	OD2				26.480	13.999	21.532	1.00 26.53 1.00 16.07	7
	MOTA	508	N	ASN .			26.690	9.644	19.555	1.00 16.07 1.00 18.08	6
	MOTA	509	CA	ASN			26.714	8.291	20.046 21.540	1.00 14.21	6
45	MOTA	510	C	ASN			27.071	8.238	22.004	1.00 19.73	8
	ATOM	511	0	ASN			27.589	7.220	19.289	1.00 22.90	6
	MOTA	512	CB	ASN			27.775	7.473 7.776	19.315	0.00 20.00	6
	MOTA	513	CG	ASN			29.335	6.934	19.572	0.00 20.00	8
	ATOM	514		ASN			30.201 29.600	9.079	19.152	0.00 20.00	7
50		515		ASN			26.975	9.391	22.182	1.00 15.25	7
	MOTA	516	N	ASN			27.400	9.532	23.602	1.00 16.89	6
	MOTA	517	CA	ASN			26.266		24.433	1.00 14.33	6
	ATOM	518	C	ASN			25.999		24.588	1.00 14.56	8
	ATOM	519	0	ASN			28.546		23.613	1.00 16.40	6
55		520	CB	ASN ASN			29.073		25.019	1.00 20.17	6
	ATOM	521	CG	L ASN			28.566		25.964	1.00 24.63	8
	ATOM	522					30.049		25.183	1.00 24.89	7
	ATOM	523		2 ASN			25.502		24.989	1.00 11.21	7
. ب	ATOM	524 525	N CA	PRO PRO			24.242		25.665	1.00 13.27	6
60		525 526	CA	PRO			24.437		27.151	1.00 13.67	6
	ATOM	526 527		PRO			23.672			1.00 12.46	8
	MOTA	527 528		PRO			23.409				6
	ATOM	528 529		PRO			24.468				6
. ــ	ATOM	530		PRO			25.668			1.00 11.45	6
6		530		MET			25.496			1.00 12.49	7
	MOTA MOTA	531					25.738			1.00 10.69	6
	ATOM	532 533		MET			24.601				6
	WION	223	_	2-117- T	0	-					

	ATOM	534	0	MET A	A 66	23.929	12.691	28.560	1.00	12.73	8
	ATOM	535	CB		A 66	27.055	11.880	28.760	1.00	14.19	6
	ATOM	536	CG	MET A	A 66	27.469	12.471	30.079	1.00	13.14	6
	MOTA	537	SD	MET A	A 66	27.514	11.384	31.542	1.00	14.24	16
5	ATOM	538	CE	MET A	A 66	28.725	10.247	30.960	1.00	16.73	6
	MOTA	539	N	ASP A	A 67	24.280	11.753	30.541	1.00	12.39	7
	ATOM	540	CA	ASP A	A 67	23.223	12.441	31.250		13.65	6
	MOTA	541	C	ASP 2	A 67	23.622	13.848	31.714	1.00	13.30	6
	ATOM	542	0	ASP A		24.628	13.878	32.457		14.71	8
10	ATOM	543	CB	ASP A		22.881	11.608	32.498		12.61	6
	ATOM	544	CG	ASP A		21.584	12.025	33.128		10.52	6
	MOTA	545		ASP A		20.838	12.937	32.766		10.71	8
	MOTA	546	OD2	ASP A		21.311	11.380	34.194			8
	MOTA	547	N	LEU A		22.901	14.887	31.398		12.91	7
15	MOTA	548	CA	LEU Z		23.230	16.219	31.935		11.29	6
	ATOM	549	C	LEU		22.184	16.689	32.938			6
	MOTA	550	0	LEU A		21.977	17.877	33.191		18.88	8
	ATOM	551	CB	LEU A		23.273	17.220	30.784		13.93	6
	MOTA	552	CG	LEU /		24.425	16.942	29.829		18.76	6
20	ATOM	553		LEU		24.437	18.059	28.780		20.21	6
	ATOM	554	CD2	LEU		25.787	16.856	30.516		23.79	6 7
	ATOM	555	N	ASN A		21.312	15.750	33.311			6
	ATOM	556	CA	ASN A		20.183 20.208	16.121 15.373	34.185 35.507		13.25 15.28	6
٥.	ATOM	557	C	ASN A		20.208		36.595		13.89	8
25	ATOM ATOM	558 550	O	ASN A			15.947 15.820	33.493		13.49	6
		559 560	CB CG	ASN A			16.122	34.412		13.28	6
	ATOM ATOM	561		ASN A			15.258	35.220		15.35	8
	ATOM	562		ASN			17.347	34.413		12.65	7
30	ATOM	563	N N	GLY I		20.371	14.062	35.389		11.32	7
30	ATOM	564	CA	GLY .		20.428	13.126	36.501		12.47	6
	ATOM	565	C	GLY .		19.248	12.180	36.565		12.10	6
	ATOM	566	Õ	GLY .		19.392	11.092	37.153		11.37	8
	ATOM	567	Ň	HIS .			12.548	36.033		10.92	7
35	ATOM	568	CA	HIS			11.677	36.064			6
55	ATOM	569	C	HIS			10.320	35.425		10.47	6
	ATOM	570	ŏ	HIS .			9.246	36.005		10.18	8
	ATOM	571	CB	HIS			12.443	35.303		12.10	6
	ATOM	572	CG		A 71		11.898	35.281		10.59	6
40	ATOM	573			A 71		11.083	34.222	1.00	9.81	7
	ATOM	574		HIS .			12.059	36.137	1.00	11.36	6
	ATOM	575	CE1	HIS .	A 71	12.804	10.755	34.481	1.00	9.45	6
	ATOM	576	NE2	HIS .	A 71	12.394	11.339	35.617	1.00	11.67	7
	ATOM	577	N	GLY .	A 72	17.747	10.309	34.214	1.00	9.91	7
45	ATOM	578	CA	GLY .	A 72	17.985	9.019	33.539	1.00	8.20	6
	ATOM	579	С	GLY .	A 72		8.130	34.294		10.22	6
	ATOM	580	0	GLY .	A 72		6.914		1.00		8
	MOTA	581	N	THR .			8.710	34.949		9.41	7
	ATOM	582	CA	THR			7.870	35.678		10.00	6
50	ATOM	583	C	THR .			7.190	36.904	1.00	9.47	6
	MOTA	584	0	THR			6.058	37.215		10.68	8
	MOTA	585	CB	THR			8.789	36.140		12.41	6
	MOTA	586	OG1				9.288	34.942		11.16	8
	ATOM	587	CG2				8.096	36.950		11.66	6
55	ATOM	588	N	HIS			7.989	37.489	1.00	9.10	7
	ATOM	589	CA	HIS			7.468	38.683		10.08	6
	MOTA	590	С	HIS			6.317	38.222	1.00	8.45	6
	MOTA	591	0	HIS			5.193	38.797	1.00	9.63	8
	ATOM	592	CB	HIS			8.629	39.336		11.77	6
60	MOTA	593	CG	HIS			8.281	40.697		10.65	6
	MOTA	594		HIS			7.546	40.892		10.09	7
	MOTA	595		\mathtt{HIS}			8.640	41.909		10.65	6
	MOTA	596		HIS			7.418	42.194		10.71	6
	MOTA	597		HIS			8.091	42.847		11.39	7
65	MOTA	598	N	VAL			6.560	37.128	1.00	8.72	7
	MOTA	599	CA	VAL			5.516	36.601	1.00	9.96	6
	MOTA	600	C	VAL			4.281	36.196	1.00	9.80	6
	MOTA	601	0	VAL	A 75	16.493	3.159	36.569	1.00	9.73	8

	ATOM	602	СВ	VAL	Δ	75	15.368	6.143	35.397	1.00 8.91	6
	ATOM	603			A	75	14.632	5.037	34.614	1.00 11.90	6
			CG2	VAL		75 75	14.373	7.207	35.906	1.00 12.26	6
	MOTA	604								1.00 12.20	7
_	ATOM	605	N	ALA		76	18.045	4.463	35.550		
5	ATOM	606	CA	ALA		76	18.828	3.299	35.109	1.00 10.80	6
	ATOM	607	C	ALA		76	19.311	2.512	36.325	1.00 8.05	6
	MOTA	608	0	ALA		76	19.350	1.268	36.257	1.00 9.57	8
	MOTA	609	СВ	ALA	Α	76	20.067	3.817	34.296	1.00 11.31	6
	ATOM	610	N	GLY	Α	77	19.719	3.244	37.394	1.00 8.67	7
10	MOTA	611	CA	GLY	Α	77	20.240	2.442	38.509	1.00 10.66	6
	ATOM	612	C	GLY		77	19.100	1.609	39.154	1.00 8.38	6
		613	Õ	GLY		77	19.432	0.501	39.628	1.00 9.24	8
	ATOM										7
	ATOM	614	N	THR		78	17.898	2.146	39.196		
	ATOM	615	CA	THR		78	16.820	1.294	39.724	1.00 9.31	6
15	ATOM	616	C	THR		78	16.604	0.018	38.930	1.00 7.59	6
	MOTA	617	0	THR	Α	78	16.379	-1.093	39.396	1.00 10.79	8
	MOTA	618	CB	THR	A	78	15.550	2.127	39.833	1.00 9.05	6
	ATOM	619	OG1	THR	Α	78	15.760	3.175	40.796	1.00 10.11	8
	ATOM	620	CG2	THR		78	14.375	1.266	40.327	1.00 10.42	6
20	ATOM	621	N	VAL		79	16.642	0.189	37.555	1.00 9.12	7
20	ATOM	622	CA	VAL		79	16.411	-0.985	36.685	1.00 8.17	6
											6
	ATOM	623	C	VAL		79	17.466	-2.025	36.875	1.00 8.18	
	MOTA	624	0	VAL		79	17.192	-3.196	36.970	1.00 10.26	8
	MOTA	625	CB	VAL	Α	79	16.354	-0.577	35.186	1.00 13.01	6
25	MOTA	626	CG1	VAL	Α	79	16.039	-1.862	34.342	1.00 16.27	6
	ATOM	627	CG2	VAL	Α	79	15.250	0.388	34.873	1.00 16.24	6
	ATOM	628	N	ALA	Α	80	18.753	-1.594	36.861	1.00 9.76	7
	ATOM	629	CA	ALA	Ά	80	19.799	-2.612	36.679	1.00 9.95	6
	ATOM	630	C	ALA		80	21.149	-2.084	37.067	1.00 11.86	6
20	ATOM	631	Ö	ALA		80	22.196	-2.334	36.405	1.00 10.30	8
30											6
	MOTA	632	CB	ALA		80	19.814	-3.107	35.195	1.00 10.99	
	ATOM	633	N	ALA		81	21.287	-1.333	38.172	1.00 10.11	7
	MOTA	634	CA	ALA	Α	81	22.606	-1.043	38.738	1.00 8.94	6
	ATOM	635	C	ALA	Α	81	23.431	-2.334	38.881	1.00 10.93	6
35	ATOM	636	0	ALA	Α	81	22.877	-3.375	39.066	1.00 10.46	8
	MOTA	637	CB	ALA		81	22.577	-0.382	40.119	1.00 8.60	6
	ATOM	638	N	ASP		82	24.767	-2.153	38.897	1.00 9.68	7
	ATOM	639	CA	ASP		82	25.667	-3.283	39.195	1.00 13.33	6
											6
	ATOM	640	C	ASP		82	25.333	-3.770	40.643	1.00 9.64	
40	ATOM	641	0	ASP		82	25.341	-2.891	41.492	1.00 10.48	8
	MOTA	642	CB	ASP	Α	82	27.068	-2.744	39.036	1.00 11.80	6
	ATOM	643	CG	ASP	A	82	28.160	-3.765	38.888	1.00 13.40	6
	ATOM	644	OD1	ASP	Α	82	29.241	-3.350	38.394	1.00 12.00	8
	ATOM	645	OD2	ASP	Α	82	27.952	-4.901	39.318	1.00 12.74	8
45	ATOM	646	N	THR		83	25.143	-5.049	40.755	1.00 9.60	7
	ATOM	647	CA	THR		83	24.598	-5.567	42.041	1.00 10.59	6
	ATOM	648	C	THR		83	25.509	-6.677		1.00 11.19	6
							26.203	-7.421	41.875	1.00 13.87	8
	ATOM	649	O	THR		83		-6.205		1.00 13.87	
	ATOM	650	CB	THR		83	23.240		41.715		6
50	MOTA	651		THR		83	22.452	-5.144	41.178	1.00 11.10	8
	MOTA	652	CG2	THR	Α	83	22.502	-6.829	42.913	1.00 11.07	6
	MOTA	653	N	ASN	Α	84	25.558	-6.640	43.926	1.00 11.01	7
	MOTA	654	CA	ASN	Α	84	26.421	-7.579	44.672	1.00 12.42	6
	ATOM	655	C	ASN		84	27.916	-7.260	44.404	1.00 12.70	6
55	ATOM	656	ō	ASN		84	28.717	-8.171	44.505	1.00 14.84	8
55		657	СВ	ASN			26.083	-9.024	44.364	1.00 14.55	6
	ATOM					84					
	ATOM	658	CG	ASN		84	26.516	-9.910	45.538	1.00 17.95	6
	MOTA	659		ASN		84	26.308	-9.587	46.712	1.00 16.26	8
	ATOM	660	ND2	ASN	Α	84	27.136	-11.035	45.221	1.00 19.28	7
60	MOTA	661	N	ASN	Α	85	28.181	-5.973	44.137	1.00 11.37	7
	ATOM	662	CA	ASN		85	29.540	-5.534	43.883	1.00 11.85	6
	ATOM	663	C	ASN		85	30.208	-4.745	44.988	1.00 11.88	6
	ATOM	664	Õ	ASN		85	31.195	-4.054	44.863	1.00 14.14	8
								-4.736	42.574	1.00 12.33	
	ATOM	665	CB	ASN		85	29.614				6
65	ATOM	666	CG	ASN		85	28.901	-3.418	42.600	1.00 12.64	6
	ATOM	667		ASN		85	27.959	-3.237	43.365	1.00 11.43	8
	MOTA	668	ND2	ASN		85	29.298	-2.439	41.789	1.00 11.56	7
	ATOM	669	N	GLY	Α	86	29.539	-4.755	46.163	1.00 12.16	7

	ATOM	670	CA	GLY	7.	86	29.982	-4.130	47.358	1 00	12.38	6
	ATOM	671	C	GLY		86	30.003	-2.614	47.377	1.00		6
			0			86	30.591	-1.914	48.220	1.00		8
	ATOM	672		GLY					46.388	1.00		7
_	ATOM	673	N	ILE		87	29.329	-2.004				6
5	ATOM	674	CA	ILE		87	29.278	-0.603	46.104		11.71	
	ATOM	675	С	ILE		87	27.805	-0.195	45.920	1.00		6
	MOTA	676	0	ILE	Α	87	27.039	-0.898	45.250	1.00		8
	MOTA	677	CB	ILE	Α	87	30.001	-0.268	44.734	1.00	13.16	6
	ATOM	678	CG1	ILE	A	87	31.488	-0.601	44.998	1.00	15.49	6
10	MOTA	679	CG2	ILE	Α	87	29.743	1.152	44.317	1.00	17.65	6
	ATOM	680	CD1	ILE		87	32.209	-0.655	43.631	1.00	17.42	6
	ATOM	681	N	GLY		88	27.452	0.954	46.442		12.42	7
		682	CA	GLY		88	26.194	1.569	45.989	1.00		6
	ATOM								46.250	1.00	9.96	6
	ATOM	683	C	GLY		88	24.950	0.749				
15	MOTA	684	0	GLY		88	24.668	0.199	47.288		11.18	8
	ATOM	685	N	VAL		89	24.106	0.667	45.193	1.00	10.48	7
	ATOM	686	CA	VAL	A	89	22.741	0.149	45.260	1.00	8.53	6
	ATOM	687	C	VAL	Α	89	22.639	-1.190	44.549	1.00	11.23	6
	ATOM	688	0	VAL	Α	89	23.666	-1.596	43.948	1.00	10.26	8
20	ATOM	689	CB	VAL	Α	89	21.727	1.175	44.689	1.00	10.06	6
	ATOM	690	CG1			89	21.615	2.398	45.639	1.00	11.70	6
	ATOM	691	CG2	VAL		89	22.081	1.654	43.263	1.00		6
								-1.829	44.640	1.00	7.95	7
	MOTA	692	N	ALA		90	21.477					
	ATOM	693	CA	ALA		90	21.184	-3.046	43.869	1.00	8.13	6
25	MOTA	694	C	ALA		90	20.078	-2.755	42.876	1.00	8.97	6
	MOTA	695	0	ALA	Α	90	19.085	-2.156	43.204		10.80	8
	ATOM	696	CB	ALA	A	90	20.696	-4.124	44.835	1.00	11.49	6
	ATOM	697	N	GLY	Α	91	20.356	-3.266	41.655	1.00	9.50	7
	ATOM	698	CA	GLY	Α	91	19.313	-3.059	40.624	1.00	10.29	6
30	ATOM	699	C	GLY		91	18.278	-4.178	40.615	1.00	10.12	6
50	ATOM	700	Ö	GLY		91	18.457	-5.295	41.120	1.00	9.70	8
			N		A	92	17.069	-3.849	40.120		10.51	7
	ATOM	701									10.40	6
	ATOM	702	CA		A	92	15.995	-4.836	40.046			
	ATOM	703	C		Α	92	16.312	-6.044	39.169	1.00	8.63	6
35	MOTA	704	0		Α	92	15.853	-7.173	39.474		10.07	8
	ATOM	705	CB	MET	Α	92	14.700	-4.133	39.525	1.00	10.66	6
	ATOM	706	CG	MET	Α	92	14.024	-3.346	40.670	1.00	10.45	6
	ATOM	707	SD	MET	A	92	13.253	-4.371	41.946	1.00	11.55	16
	ATOM	708	CE		Α	92	11.912	-5.093	41.007	1.00	12.16	6
40	ATOM	709	N	ALA		93	17.126	-5.840	38.098	1.00	8.87	7
40		710	CA	ALA		93	17.598	-6.935	37.268		10.60	6
	ATOM						19.126	-6.945	37.275		12.63	6
	ATOM	711	C	ALA		93						8
	ATOM	712	0_	ALA		93	19.803	-6.326	36.467		11.07	
	ATOM	713	CB	ALA		93	17.041	-6.652	35.841	1.00	11.23	6
45	MOTA	714	N	PRO		94	19.692	-7.579	38.287	1.00	10.81	7
	MOTA	715	CA	PRO		94	21.127	-7.515	38.517		12.42	6
	MOTA	716	C	PRO	Α	94	21.963	-7.765	37.291		12.53	6
	ATOM	717	0	PRO	A	94	22.990	-7.094	37.087	1.00	14.34	8
	ATOM	718	CB	PRO		94	21.350	-8.634	39.578	1.00	11.90	6
50	MOTA	719	CG	PRO		94	20.077	-8.538	40.360	1.00	12.96	6
50	ATOM	720	CD	PRO		94	18.941	-8.272	39.338		12.20	6
		721		ASP		95	21.647	-8.786	36.456		11.92	7
	ATOM		N								11.78	6
	ATOM	722	CA	ASP		95	22.593	-9.148	35.399	1.00		
	MOTA	723	С	ASP		95	22.215	-8.578	34.037	1.00	12.73	6
55	ATOM	724	0	ASP	Α	95	23.039	-8.643	33.127	1.00	14.73	8
	ATOM	725	CB	ASP	Α	95	22.661	-10.672	35.300	1.00	12.28	6
	ATOM	726	CG	ASP	A	95	23.335	-11.242	36.572	1.00	18.00	6
	ATOM	727		ASP		95		-10.496	37.098	1.00	20.06	8
	ATOM	728	OD2			95	22.929	-12.386	36.860		27.51	8
<i>c</i> 0		729	N	THR		96	21.016	-7.956	33.957		12.12	7
60	ATOM											
	MOTA	730	CA	THR		96	20.613	-7.407	32.635		12.08	6
	MOTA	731	C	THR		96	21.336	-6.110	32.325		11.03	6
	MOTA	732	0	THR		96	21.555	-5.271	33.207		12.04	8
	MOTA	733	CB	THR	Α	96	19.095	-7.274	32.590		10.42	6
65	ATOM	734	OG1	THR	Α	96	18.501	-8.585	32.725		12.83	8
	MOTA	735	CG2	THR		96	18.523	-6.733	31.241		11.86	6
	ATOM	736	N	LYS		97	21.685	-5.929	31.026		10.74	7
	ATOM	737	CA	LYS		97	22.392	-4.675	30.685		11.13	6
	LT OLI		-27		A-7	- .		1.0/0				~

	ATOM	738	C LYS	. Δ	97	21.400	-3.550	30.376	1.00 12.38	6
	ATOM	739	O LYS		97	20.182	-3.832	30.148	1.00 11.36	8
		740	CB ALYS		97	23.198	-4.880	29.382	0.50 12.99	6
	ATOM					24.181	-6.046	29.425	0.50 17.25	6
_	ATOM	741	CG ALYS		97				0.50 17.23	6
5	ATOM	742	CD ALYS		97	25.152	-5.891	30.584		
	ATOM	743	CE ALYS		97	26.500	-6.533	30.211	0.50 12.42	6
	MOTA	744	NZ ALYS		97	27.416	-6.547	31.382	0.50 18.98	7
	ATOM	745	CB BLYS	3 A	97	23.436	-4.843	29.571	0.50 14.58	6
	ATOM	746	CG BLYS	S A	97	24.588	-5.769	29.995	0.50 15.40	6
10	ATOM	747	CD BLYS	S A	97	25.597	-5.958	28.888	0.50 16.62	6
	ATOM	748	CE BLYS		97	26.770	-6.845	29.293	0.50 22.87	6
	ATOM	749	NZ BLYS		97	27.610	-6.168	30.320	0.50 27.60	7
					98	21.861	-2.310	30.465	1.00 10.38	7
	ATOM	750		ΞΑ						6
	ATOM	751	CA ILE		98	21.048	-1.145	30.182		
15	ATOM	752		ΕΑ	98	21.459	-0.617	28.815	1.00 10.92	6
	ATOM	753	O ILE	ΞΑ	98	22.618	-0.354	28.624	1.00 12.98	8
	ATOM	754	CB ILE	ΞΑ	98	21.342	-0.073	31.253	1.00 10.78	6
	ATOM	755	CG1 ILE	ΞΑ	98	20.779	-0.412	32.644	1.00 11.69	6
	MOTA	756	CG2 ILE	ΞΑ	98	20.758	1.269	30.847	1.00 11.52	6
20	MOTA	757	CD1 ILE		98	21.604	0.253	33.746	1.00 14.34	6
	ATOM	758		JA	99	20.522	-0.415	27.892	1.00 9.93	7
	ATOM	759		JA	99	20.815	0.298	26.649	1.00 10.06	6
							1.743	26.901	1.00 10.50	6
	ATOM	760		JA	99	20.432				
	ATOM	761	O LEU		99	19.225	2.085	27.071	1.00 9.69	8
25	MOTA	762		JΑ	99	19.984	-0.359	25.506	1.00 11.55	6
	ATOM	763	CG LEU	JΑ	99	20.103	0.469	24.236	1.00 11.50	6
	MOTA	764	CD1 LEU	JA	99	21.553	0.416	23.750	1.00 12.90	6
	MOTA	765	CD2 LEU	JA	99	19.138	-0.039	23.204	1.00 10.92	6
	ATOM	766			100	21.356	2.645	27.040	1.00 10.31	7
30	ATOM	767			100	21.060	4.046	27.338	1.00 9.78	6
50		768			100	20.713	4.770	26.039	1.00 9.48	6
	ATOM						4.833	25.119	1.00 11.85	8
	ATOM	769			100	21.557				
	ATOM	770			100	22.296	4.739	27.974	1.00 11.54	6
	MOTA	771			101	19.480	5.268	26.012	1.00 9.16	7
35	MOTA	772	CA VAI	À	101	19.062	6.013	24.795	1.00 10.09	6
	ATOM	773	C VAI	À	101	18.654	7.409	25.253	1.00 10.39	6
	ATOM	774	O VAI	· A	101	17.733	7.523	26.060	1.00 9.86	8
	ATOM	775			101	17.937	5.305	24.085	1.00 10.01	6
	ATOM	776			101	17.556	6.021	22.742	1.00 11.37	6
40	ATOM	777			101	18.227	3.846	23.765	1.00 12.69	6
40					102	19.294	8.449	24.771	1.00 10.96	7
	MOTA	778								
	MOTA	779			102	19.041	9.797	25.252	1.00 10.28	6
	ATOM	780			102	18.003	10.499	24.396	1.00 13.39	6
	ATOM	781			102	18.193	10.765	23.188	1.00 14.69	8
45	MOTA	782	CB ARG	ЗΑ	102	20.353	10.595	25.469	1.00 11.23	6
	ATOM	783	CG ARC	3 A	102	19.993	12.026	25.927	1.00 11.92	6
	ATOM	784	CD ARC	3 A	102	21.318	12.674	26.332	1.00 11.26	6
	ATOM	785			102	21.088	13.998	26.872	1.00 13.14	7
	ATOM	786			102	21.537	15.160	26.462	1.00 17.86	6
50	ATOM	787	NH1 ARC			22.286	15.196	25.353	1.00 17.29	7
50						21.231	16.264	27.119	1.00 17.25	7
	ATOM	788			102					
	MOTA	789			103	16.871	10.780	24.968	1.00 11.62	7
	MOTA	790			103	15.757	11.445	24.301	1.00 11.54	6
	MOTA	791	C VA	LΑ	103	15.264	12.696	25.053	1.00 12.58	6
55	ATOM	792	O VAI	LΑ	103	14.272	13.343	24.613	1.00 15.25	8
	ATOM	793	CB VAI	LΑ	103	14.520	10.520	24.049	1.00 12.23	6
	ATOM	794	CG1 VA			14.893	9.393	23.047	1.00 15.01	6
	MOTA	795	CG2 VA			13.912	9.972	25.323	1.00 14.01	6
									1.00 14.01	7
	ATOM	796			104	15.806	13.018	26.201		
60	ATOM	797			104	15.505	14.207	26.989	1.00 13.95	6
	ATOM	798			104	16.824	14.933	27.248	1.00 11.06	6
	MOTA	799			104	17.900	14.395	27.389	1.00 12.49	8
	ATOM	800	CB LE	υA	104	14.908	13.887	28.361	1.00 16.60	6
	ATOM	801			104	13.683	12.967	28.283	1.00 12.90	6
65	ATOM	802	CD1 LE			13.236	12.655	29.717	1.00 15.91	6
	ATOM	803			104	12.590	13.532	27.433	1.00 17.02	6
	ATOM	804			105	16.640	16.297	27.188	1.00 14.57	7
								27.108	1.00 14.37	6
	MOTA	805	CA AS	r A	105	17.795	17.210	27.308	1.00 11./3	0

	3 TTO M	200	~	ASP	70	105	18.165	17.499	28.737	1 00	14.97	6
	ATOM	806	C						29.654		13.31	8
	ATOM	807	0	ASP			17.755	16.820				
	ATOM	808	CB	ASP	Α	105	17.447	18.495	26.529		15.08	6
	ATOM	809	CG	ASP	Α	105	16.415	19.378	27.163		21.30	6
5	MOTA	810	OD1	ASP	Α	1.05	16.024	19.199	28.320	1.00	16.65	8
_	ATOM	811		ASP			15.940	20.341	26.470	1.00	22.26	8
								18.442	28.926		15.23	7
	ATOM	812	N	ALA			19.112					
	MOTA	813	CA	ALA	A	106	19.549	18.691	30.304		13.88	6
	ATOM	814	С	ALA	Α	106	18.448	19.148	31.242	1.00	14.07	6
10	ATOM	815	0	ALA	Δ	106	18.632	18.970	32.464	1.00	15.73	8
10				ALA			20.623	19.791	30.277		16.83	6
	MOTA	816	CB									
	MOTA	817	N	ASN	Α	107	17.337	19.694	30.787		15.93	7
	ATOM	818	CA	ASN	Α	107	16.227	20.076	31.629	1.00	18.54	6
	MOTA	819	C	ASN	Α	107	15.139	19.031	31.736	1.00	17.24	6
15	ATOM	820	Ö	ASN			14.093	19.274	32.355	1.00	19.75	8
15											23.46	6
	MOTA	821	CB	ASN			15.587	21.347	31.038			
	ATOM	822	CG	ASN	А	107	16.601	22.481	31.051	1.00	26.78	6
	MOTA	823	OD1	ASN	Α	107	17.162	22.753	32.113	1.00	25.51	8
	MOTA	824	ND2	ASN	Α	107	16.820	23.099	29.904	1.00	26.59	7
20	ATOM	825	N	GLY			15.389	17.863	31.134		16.72	7
20									31.185		19.02	6
	MOTA	826	CA	GLY			14.401	16.793				
	MOTA	827	C	\mathtt{GLY}	Α	108	13.346	16.911	30.090		19.28	6
	MOTA	828	0	GLY	Α	108	12.324	16.199	30.201	1.00	23.96	8
	MOTA	829	N	SER	Δ	109	13.569	17.695	29.071	1.00	18.97	7
25	ATOM	830	CA	SER			12.556	17.941	28.046		19.93	6
25											19.26	
	MOTA	831	C	SER			12.936	17.281	26.738			6
	ATOM	832	0	SER	Α	109	14.111	17.132	26.434	1.00	16.92	8
	ATOM	833	CB	SER	Α	109	12.425	19.456	27.829	1.00	27.39	6
	ATOM	834	OG	SER			12.017	20.008	29.076	1.00	36.14	8
2.0									25.927		19.72	7
30	ATOM	835	N	GLY			11.937	16.950				
	ATOM	836	CA	GLY			12.225	16.262	24.673		20.18	6
	ATOM	837	С	GLY	Α	110	11.058	16.418	23.718	1.00	21.15	6
	ATOM	838	0	GLY	Δ	110	9.991	16.848	24.138	1.00	27.11	8
	ATOM	839	N	SER			11.377	16.282	22.422		16.93	7
35	ATOM	840	CA	SER			10.303	16.416	21.451		18.93	6
	ATOM	841	C	SER	Α	111	9.655	15.052	21.244	1.00	17.00	6
	MOTA	842	0	SER	Α	111	10.258	14.004	21.422	1.00	17.14	8
	ATOM	843	CB	SER			10.853	16.982	20.148	1.00	21.62	6
							11.640	16.039	19.448	1.00		8
	MOTA	844	OG	SER								
40	MOTA	845	N	LEU	A	112	8.354	15.122	20.969	1.00	16.14	7
	ATOM	846	CA	LEU	Α	112	7.698	13.807	20.756	1.00	15.65	6
	MOTA	847	C	LEU	Α	112	8.360	13.083	19.577	1.00	14.33	6
	ATOM	848	0	LEU			8.393	11.832	19.644	1.00	17.13	8
				LEU			6.187	13.940	20.629	1.00		6
	MOTA	849	CB									
45	ATOM	850	CG	LEU			5.437	14.470	21.857		22.13	6
	ATOM	851	CD1	LEU	Α	112	3.926	14.464	21.622	1.00	28.11	6
	ATOM	852	CD2	LEU	Α	112	5.685	13.699	23.153	1.00	25.27	6
	ATOM	853	N	ASP			8.726	13.761	18.498	1 00	17.80	7
							9.300	12.973	17.388		18.50	6
	ATOM	854	CA	ASP								
50	ATOM	855	C	ASP	А	113	10.622	12.343	17.758		19.37	6
	ATOM	856	0	ASP	Α	113	10.820	11.187	17.316	1.00	18.50	8
	ATOM	857	CB	ASP			9.322	13.894	16.160	1.00	20.24	6
	MOTA	858	CG	ASP			8.011	14.173	15.519		19.59	6
	ATOM	859		ASP			7.995	15.140	14.672		29.00	8
55	ATOM	860	OD2	ASP	Α	113	6.943	13.587	15.713	1.00	24.47	8
	MOTA	861	N	SER	Α	114	11.438	12.963	18.569	1.00	17.25	7
	ATOM	862	CA	SER			12.699	12.385	19.032		20.51	6
	ATOM	863	C	SER			12.440	11.230	19.998		17.38	6
	ATOM	864	0	SER	Α	114	13.134	10.212	19.896		16.74	8
60	ATOM	865	CB	SER	A	114	13.525	13.459	19.733	1.00	25.71	6
-	ATOM	866	OG			114	14.016	14.313	18.706		28.28	8
								11.380	20.891		13.42	7
	MOTA	867	N	ILE			11.470					
	MOTA	868	CA			115	11.184	10.283	21.816		11.54	6
	ATOM	869	C	ILE	Α	115	10.687	9.106	21.001	1.00	11.78	6
65	ATOM	870	0	ILE	A	115	11.072	7.934	21.265	1.00	12.76	8
-	ATOM	871	ČВ			115	10.132	10.720	22.855		12.31	6
											15.30	
	MOTA	872	CG1		A	TTP	10.815	11.775	23.737			6
	ATOM	873	CG2	ILE	A	115	9.621	9.579	23.726	T.00	14.78	6

	ATOM	874	CD1	ILE A	115	9.771	12.522	24.544	1.00 16.55	6
	ATOM	875	N	ALA A		9.807	9.353	20.024	1.00 12.41	7
	ATOM	876	CA	ALA A		9.318	8.291	19.178	1.00 11.46	6
	ATOM	877	C	ALA A	116	10.435	7.610	18.400	1.00 10.70	6
5	ATOM	878	0	ALA A		10.537	6.377	18.397	1.00 11.22	8
	MOTA	879	CB	ALA A	116	8.292	8.902	18.184	1.00 14.75	6
	ATOM	880	N	SER A		11.370	8.395	17.848	1.00 12.15	7
	ATOM	881	CA	SER A	117	12.490	7.738	17.150	1.00 12.96	6
	ATOM	882	C	SER A	117	13.387	6.913	18.093	1.00 10.71	6
10	ATOM	883	0		117	13.805	5.814	17.704	1.00 13.52	8
	MOTA	884	CB	SER A	117	13.345	8.825	16.510	1.00 15.02	6
	ATOM	885	OG		117	12.600	9.369	15.405	1.00 17.64	8
	ATOM	886	N	GLY A		13.537	7.392	19.343	1.00 11.17	7
	ATOM	887	CA	GLY A		14.357	6.612	20.301	1.00 11.65	6
15	MOTA	888	C	GLY A		13.617	5.336	20.707	1.00 12.79	6
	MOTA	889	0	GLY A		14.241	4.305	20.887	1.00 11.77	8
	ATOM	890	N		1119	12.284	5.358	20.869	1.00 10.37	7
	ATOM	891	CA		1119	11.517	4.140	21.164	1.00 9.25	6
	ATOM	892	C	ILE Z		11.754	3.131	20.016	1.00 9.88	6
20	ATOM	893	0_	ILE A		11.966	1.949	20.317	1.00 9.88	8
	ATOM	894	CB		1119	10.045	4.484	21.337	1.00 8.90	6
	ATOM	895		ILE A		9.871	5.274	22.714	1.00 10.96	6
	ATOM	896	CG2	ILE A		9.131	3.264	21.306	1.00 10.98	6
	ATOM	897		ILE A		8.439	5.822	22.768	1.00 11.18	6 7
25	ATOM	898	N		120	11.557	3.597	18.756	1.00 9.24	6
	ATOM	899	CA	ARG A		11.799	2.616	17.683 17.652	1.00 10.97 1.00 9.58	6
	ATOM	900	C	ARG A		13.239	2.125		1.00 9.58	8
	ATOM	901	O	ARG A		13.447 11.497	0.905 3.354	17.482 16.336	1.00 11.11	6
20	ATOM	902	CB CG	ARG A		10.021	3.739	16.215	1.00 10.43	6
30	ATOM	903	CD	ARG A		9.770	4.717	14.988	1.00 12.73	6
	ATOM ATOM	904 905	NE		120	9.824	3.724	13.911	1.00 12.77	7
	ATOM	906	CZ	ARG A		8.753	3.068	13.511	1.00 13.20	6
	ATOM	907		ARG A		7.523	3.292	13.896	1.00 12.69	7
35	ATOM	908		ARG A		8.965	2.095	12.638	1.00 11.60	7
33	ATOM	909	N	TYR Z		14.187	3.005	17.934	1.00 10.24	7
	MOTA	910	CA		1 121	15.594	2.588	17.988	1.00 12.90	6
	ATOM	911	C		121	15.860	1.471	18.969	1.00 9.83	6
	ATOM	912	Ö		1 121	16.522	0.447	18.788	1.00 11.54	8
40	ATOM	913	ČВ		A 121	16.416	3.837	18.292	1.00 12.06	6
10	ATOM	914	CG		A 121	17.853	3.571	18.596	1.00 11.82	6
	ATOM	915	CD1		A 121	18.818	3.475	17.604	1.00 13.12	6
	ATOM	916	CD2		A 121	18.273	3.395	19.896	1.00 11.97	6
	ATOM	917	CE1		A 121	20.157	3.225	17.930	1.00 13.85	6
45	ATOM	918	CE2		A 121	19.575	3.177	20.250	1.00 11.79	6
	ATOM	919	CZ		A 121	20.518	3.073	19.252	1.00 15.08	6
	ATOM	920	OH		A 121	21.856	2.849	19.585	1.00 17.95	8
	ATOM	921	N		A 122	15.231	1.676	20.166	1.00 9.11	7
	ATOM	922	CA		A 122	15.446	0.670	21.197	1.00 9.16	6
50	ATOM	923	С		A 122	14.894	-0.675	20.774	1.00 10.24	6
	ATOM	924	0		A 122	15.500	-1.733	21.045	1.00 12.08	8
	MOTA	925	CB	ALA	A 122	14.726	1.101	22.481	1.00 10.97	6
	ATOM	926	N		A 123	13.672	-0.746	20.160	1.00 10.00	7
	MOTA	927	CA	ALA .	A 123	13.177	-2.032	19.660	1.00 9.79	6
55	MOTA	928	C	ALA .	A 123	14.082	-2.548	18.522	1.00 10.77	6
	ATOM	929	0	ALA .	A 123	14.298	-3.791	18.464	1.00 12.07	8
	ATOM	930	CB		A 123	11.747	-1.789	19.135	1.00 12.17	6
	MOTA	931	N	ASP .	A 124	14.513	-1.608	17.684	1.00 10.69	7
	ATOM	932	CA		A 124	15.338	-2.079	16.548	1.00 11.25	6
60	ATOM	933	C	ASP .	A 124	16.699	-2.611	17.014	1.00 11.36	6
	ATOM	934	0		A 124	17.263	-3.536	16.372	1.00 12.55	8
	ATOM	935	СВ		A 124	15.528	-0.967	15.527	1.00 10.62	6
	ATOM	936	CG		A 124	14.197	-0.704	14.727	1.00 11.72	6
	ATOM	937		ASP		13.461	-1.679	14.609	1.00 13.58	8
65	ATOM	938		ASP		14.060	0.480	14.352	1.00 13.00	8
	ATOM	939	N		A 125	17.178	-2.140	18.152	1.00 10.69	7
	ATOM	940	CA		A 125	18.385	-2.681	18.772	1.00 11.00	6
	ATOM	941	C		A 125	18.156	-3.958	19.527	1.00 10.13	6

	MOTA	942	0	GLN	Α	125	19.112	-4.519	20.114	1.00 1	4.93	8
	ATOM	943	CB	GLN	A	125	19.045	-1.632	19.690	1.00 1	.3.56	6
	ATOM	944	CG	GLN			19.636	-0.472	18.900	1.00 1	5.15	6
	MOTA	945	CD	GLN	Α	125	20.953	-0.735	18.192	1.00 2	1.96	6
5	ATOM	946	OE1	GLN	Α	125	21.571	-1.784	18.291	1.00 2	8.15	8
_	ATOM	947	NE2	GLN			21.464	0.234	17.433	1.00 2	9.01	7
	ATOM	948	N	GLY			16.930	-4.457	19.666	1.00	9.97	7
	ATOM	949	CA	GLY			16.710	-5.768	20.279	1.00 1	1.91	6
	ATOM	950	C	GLY			16.402	-5.656	21.789	1.00	9.69	6
10	ATOM	951	Ö	GLY			16.461	-6.756	22.347	1.00 1	1.42	8
	ATOM	952	N	ALA			16.191	-4.473	22.311	1.00 1	0.80	7
	ATOM	953	CA	ALA			15.916	-4.514	23.775	1.00 1		6
	ATOM	954	C	ALA			14.656	-5.298	24.094	1.00 1		6
	ATOM	955	0	ALA			13.625	-5.169	23.382	1.00 1		8
15	ATOM	956	СВ	ALA			15.812	-3.046	24.241	1.00 1		6
13		957	N	LYS			14.714	-6.115	25.193	1.00 1		7
	ATOM		CA	LYS			13.507	-6.851	25.520	1.00 1		6
	ATOM	958		LYS			12.450	-6.045	26.274	1.00	8.78	6
	MOTA	959	C				11.270	-6.377	26.274	1.00 1		8
	ATOM	960	O	LYS						1.00 1		6
20	ATOM	961	CB	LYS			13.834	-8.046	26.442	1.00 1		
	ATOM	962	CG	LYS			14.845	-9.003	25.841			6 6
	ATOM	963	CD	LYS			14.181	-9.713	24.663	1.00 1		
	MOTA	964	CE	LYS				-10.781	24.174	1.00 2		6
	MOTA	965	NZ	LYS				-11.333	22.835	1.00 2		7
25	MOTA	966	N	VAL			12.912	-4.970	26.905	1.00	9.09	7
	MOTA	967	CA	VAL			12.007	-4.094	27.687	1.00	8.78	6
	MOTA	968	С	VAL			12.468	-2.678	27.406	1.00	8.25	6
	ATOM	969	0	VAL			13.664	-2.390	27.317	1.00 1		8
	ATOM	970	CB	VAL			12.239	-4.362	29.188	1.00 1		6
30	ATOM	971	CG1	VAL			11.286	-3.527	30.071	1.00 1		6
	ATOM	972	CG2	VAL	Α	129	11.977	-5.856	29.468	1.00 1		6
	ATOM	973	N	LEU	Α	130	11.489	-1.779	27.289	1.00	8.25	7
	ATOM	974	CA	LEU	Α	130	11.736	-0.350	27.185	1.00	8.42	6
	ATOM	975	C	LEU	Α	130	11.104	0.353	28.411	1.00	8.00	6
35	ATOM	976	0	LEU	Α	130	9.952	0.083	28.784	1.00	9.41	8
	MOTA	977	CB	LEU	Α	130	11.008	0.264	25.940	1.00 1	.1.97	6
	ATOM	978	CG	LEU	А	130	11.719	0.108	24.579	1.00 1	0.92	6
	MOTA	979	CD1	LEU	Α	130	11.814	-1.346	24.191	1.00 1	.3.24	6
	MOTA	980	CD2	LEU	Α	130	10.890	0.862	23.514	1.00 1	0.28	6
40	ATOM	981	N	ASN	Α	131	11.941	1.213	29.065	1.00	7.78	7
	ATOM	982	CA	ASN			11.363	1.989	30.168	1.00	8.96	6
	ATOM	983	C	ASN			11.240	3.469	29.713	1.00	9.31	6
	MOTA	984	0	ASN	Α	131	12.244	4.033	29.259	1.00 1	1.04	8
	MOTA	985	CB	ASN	Α	131	12.331	1.939	31.372	1.00	9.40	б
45	ATOM	986	CG	ASN	Α	131	11.721	2.692	32.537	1.00	9.88	6
	ATOM	987	OD1	ASN	A	131	10.903	2.118	33.269	1.00 1	0.13	8
	ATOM	988		ASN			12.055	3.968	32.661	1.00	9.63	7
	ATOM	989	N	LEU			9.984	3.975	29.880	1.00	8.49	7
	ATOM	990	CA	LEU			9.726	5.379	29.557	1.00	9.46	6
50	ATOM	991	C	LEU			9.192	6.133	30.788	1.00	9.52	6
	ATOM	992	ō	LEU			8.007	6.230	31.045	1.00	9.42	8
	ATOM	993	CB	LEU			8.612	5.453	28.466	1.00	9.79	6
	ATOM	994	CG	LEU			9.154	4.944	27.085		1.13	6
	ATOM	995		LEU			8.014	4.418	26.261		2.43	6
55	ATOM	996	CD2				9.822	6.117	26.408	1.00 1		6
33	ATOM	997	N	SER			10.203	6.676	31.523	1.00	9.31	7
	ATOM	998	CA	SER			9.908	7.485	32.708	1.00	8.09	6
				SER			9.697	8.938	32.700	1.00	9.51	6
	MOTA	999	C					9.828		1.00		8
~~	MOTA	1000	O	SER			10.434	7.383	32.570	1.00		6
60	ATOM	1001	CB	SER			11.008		33.752			
	ATOM	1002	OG	SER			10.943	6.119	34.401	1.00	9.84	8
	ATOM	1003	N	LEU			8.623	9.104	31.429	1.00	9.63	7
	ATOM	1004	CA	LEU			8.400	10.415	30.762	1.00	9.62	6
	MOTA	1005	C	LEU			6.942	10.351	30.296	1.00 1		6
65	MOTA	1006	0_	LEU			6.298	9.299	30.147	1.00 1		8
	MOTA	1007	CB	LEU			9.378	10.676	29.612	1.00 1		6
	MOTA	1008	CG	LEU			9.390	9.650	28.500	1.00 1		6
	MOTA	1009	CD1	LEU	Α	134	8.275	9.976	27.482	1.00 1	13.93	6

	ATOM	1010	CD2	LEU A	134	10.722	9.590	27.782	1.00 16.32	6
	MOTA	1011	N	GLY A		6.429	11.549	29.949	1.00 12.94	7
	ATOM	1012	CA	GLY A		5.066	11.531	29.372	1.00 16.25	6
		1012	C	GLY A		4.494	12.937	29.388	1.00 20.76	6
_	ATOM					5.104	13.911	29.837	1.00 19.61	8
5	ATOM	1014	0	GLY F				28.855		7
	MOTA	1015	N	CYS F		3.264	12.934		1.00 16.71	6
	MOTA	1016	CA	CYS F		2.541	14.220	28.850	1.00 20.54	
	ATOM	1017	С	CYS F		1.077	13.966	28.524	1.00 16.55	6
	MOTA	1018	0	CYS A		0.649	12.886	28.170	1.00 14.70	8
10	ATOM	1019	CB	CYS A		3.085	15.195	27.836	1.00 22.72	6
	ATOM	1020	SG	CYS A	136	3.714	14.546	26.303	1.00 26.03	16
	MOTA	1021	N	GLU A	137	0.333	15.093	28.682	1.00 18.30	7
	ATOM	1022	CA	GLU A	137	-1.056	15.040	28.175	1.00 17.88	6
	MOTA	1023	C	GLU A		-1.003	15.557	26.748	1.00 22.52	6 -
15	ATOM	1024	Ö	GLU F		-1.289	16.704	26.391	1.00 21.83	8
13	ATOM	1025	ČВ	GLU F		-2.021	15.837	29.031	1.00 20.26	6
		1025	CG	GLU F		-2.281	15.296	30.439	1.00 22.38	6
	ATOM					-3.418	16.130	31.064	1.00 26.72	6
	ATOM	1027	CD	GLU A					1.00 25.72	8
	MOTA	1028		GLU A		-3.051	17.088	31.746		8
20	MOTA	1029	OE2			-4.576	15.757	30.819	1.00 21.07	
	MOTA	1030	N	CYS A		-0.616	14.673	25.866	1.00 21.75	7
	MOTA	1031	CA	CYS A		-0.209	14.969	24.515	1.00 27.45	6
	MOTA	1032	C	CYS A		-0.666	13.873	23.581	1.00 31.92	6
	MOTA	1033	0	CYS A	138	-0.656	12.705	23.982	1.00 30.57	8
25	ATOM	1034	CB	CYS A	138	1.332	15.100	24.522	1.00 29.63	6
	ATOM	1035	SG	CYS A	138	2.180	13.664	25.316	1.00 26.98	16
	ATOM	1036	N	ASN A	139	-1.166	14.258	22.421	1.00 30.94	7
	ATOM	1037	CA	ASN A		-1.597	13.300	21.407	1.00 30.40	6
	ATOM	1038	C	ASN A		-0.544	13.308	20.306	1.00 27.83	6
30	ATOM	1039	ŏ	ASN A		-0.056	14.362	19.882	1.00 27.73	8
30	ATOM	1040	CB	ASN A		-2.957	13.676	20.845	1.00 34.15	6
				ASN A		-4.122	12.993	21.530	1.00 44.83	6
	ATOM	1041	CG					22.756	1.00 44.83	8
	ATOM	1042		ASN A		-4.207	13.025			7
	MOTA	1043				-4.999	12.389	20.735	1.00 50.90	
35	MOTA	1044	N	SER A		-0.166	12.120	19.829	1.00 18.15	7
	ATOM	1045	CA	SER A	140	0.870	12.081	18.795	1.00 18.59	6
	ATOM	1046	С	SER A	140	0.759	10.738	18.087	1.00 16.05	6
	MOTA	1047	0	SER A	140	0.941	9.697	18.736	1.00 16.64	8
	MOTA	1048	CB	SER A	140	2.267	12.165	19.402	1.00 20.72	6
40	ATOM	1049	OG	SER A	140	3.309	11.908	18.514	1.00 23.30	8
	ATOM	1050	N	THR A		0.370	10.712	16.804	1.00 18.63	7
	MOTA	1051	CA	THR A		0.271	9.420	16.137	1.00 18.09	6
	ATOM	1052	C	THR A		1.670	8.843	15.884	1.00 15.35	6
	ATOM	1053	ō		141	1.750	7.578	15.886	1.00 15.18	8
45	ATOM	1054	CB		141	-0.540	9.429	14.838	1.00 20.90	6
45	ATOM	1055	OG1			0.118	10.358	13.966	1.00 23.57	8
	ATOM	1056	CG2			-1.990	9.800	15.085	1.00 17.57	6
		1057		THR A		2.720	9.626	15.861	1.00 16.63	7
	MOTA		N						1.00 10.03	
e -	ATOM	1058	CA	THR A		4.094	9.149	15.775 17.053	1.00 14.88	6 6
50	ATOM	1059	C	THR A		4.529	8.429			
	ATOM	1060	0_	THR A		5.094	7.345	16.979	1.00 14.05	8
	MOTA	1061	СВ	THR A		4.997	10.341	15.457	1.00 24.16	6
	MOTA	1062	OG1			4.523	10.835	14.153	1.00 28.29	8
	MOTA	1063	CG2	THR A	142	6.432	9.970	15.210	1.00 26.14	6
55	MOTA	1064	N	LEU A	143	4.124	8.997	18.199	1.00 13.69	7
	MOTA	1065	CA	LEU A	143	4.512	8.335	19.463	1.00 13.71	6
	MOTA	1066	C	LEU A	143	3.729	7.043	19.617	1.00 12.67	6
	ATOM	1067	0	LEU A		4.267	6.012	20.055	1.00 11.28	8
	ATOM	1068	CB	LEU A		4.184	9.316	20.618	1.00 12.30	6
60	ATOM	1069	CG	LEU A		4.738	8.845	21.995	1.00 15.95	6
00	ATOM	1070		LEU A		6.227	8.878	22.029	1.00 15.41	6
								22.948	1.00 15.72	6
	ATOM	1071		LEU		4.099	9.884		1.00 15.72	7
	ATOM	1072	N		A 144	2.400	7.101	19.314		
	ATOM	1073	CA	LYS A		1.651	5.858	19.420	1.00 11.23	6
65	ATOM	1074	C	LYS A		2.211	4.764	18.517	1.00 10.18	6
	MOTA	1075	0		A 144	2.312	3.600	18.899	1.00 10.89	8
	MOTA	1076	CB		A 144	0.159	6.178	19.140	1.00 15.25	6
	MOTA	1077	CG	LYS	A 144	-0.627	4.905	19.387	1.00 18.48	6

	ATOM	1078	CD	LYS	2	144	-2.062	4.950	19.844	1.00 24.85	6
	MOTA	1079	CE	LYS			-2.564	3.597	20.366	1.00 15.78	6
	ATOM	1080	NZ	LYS			-2.599	2.616	19.228	1.00 14.78	7
	ATOM	1081	N	SER			2.539	5.151	17.273	1.00 11.46	7
5	ATOM	1082	CA	SER			3.097	4.182	16.357	1.00 10.88	6
,	MOTA	1083	C	SER			4.407	3.579	16.834	1.00 10.64	6
	ATOM	1084	0	SER			4.628	2.364	16.771	1.00 11.55	8
	ATOM	1085	CB	SER			3.372	4.933	15.034	1.00 11.53	6
	MOTA	1086	OG	SER			4.095	4.059	14.159	1.00 12.02	8
10	MOTA	1087	N	ALA			5.223	4.406	17.500	1.00 11.16	7
10	ATOM	1088	CA	ALA			6.521	3.907	17.961	1.00 10.64	6
	ATOM	1089	C	ALA			6.280	2.864	19.071	1.00 8.68	6
	ATOM	1090	0	ALA			6.945	1.842	19.103	1.00 10.24	8
	ATOM	1091	CB	ALA			7.363	5.053	18.531	1.00 13.58	6
15	ATOM	1092	N	VAL			5.345	3.181	19.973	1.00 9.25	7
13	ATOM	1093	CA	VAL			5.063	2.216	21.057	1.00 10.47	6
	ATOM	1094	C	VAL			4.479	0.936	20.530	1.00 9.13	6
	ATOM	1095	0	VAL			4.842	-0.172	20.914	1.00 11.53	8
	MOTA	1096	CB	VAL			4.051	2.840	22.072	1.00 9.11	6
20	ATOM	1097		VAL			3.468	1.828	23.057	1.00 10.14	6
20	ATOM	1098	CG2				4.741	3.918	22.848	1.00 11.38	6
	ATOM	1099	N	ASP			3.531	1.044	19.538	1.00 10.88	7
	ATOM	1100	CA	ASP			2.945	-0.158	18.998	1.00 9.20	6
	ATOM	1101	C	ASP			3.904	-0.986	18.148	1.00 10.40	6
25	ATOM	1102	Ö	ASP			3.989	-2.216	18.235	1.00 12.08	8
23	ATOM	1103	ČВ	ASP			1.722	0.191	18.150	1.00 9.51	6
	ATOM	1104	CG	ASP			0.523	0.649	18.916	1.00 12.65	6
	ATOM	1105	OD1				-0.363	1.347	18.361	1.00 13.89	8
	ATOM	1106	OD2				0.454	0.337	20.139	1.00 12.46	8
30	ATOM	1107	N	TYR			4.776	-0.203	17.443	1.00 10.28	7
50	ATOM	1108	CA	TYR			5.839	-0.920	16.701	1.00 11.03	6
	ATOM	1109	C	TYR			6.725	-1.735	17.654	1.00 11.91	6
	ATOM	1110	Ö	TYR			7.097	-2.870	17.371	1.00 11.38	8
	ATOM	1111	СB	TYR			6.606	0.125	15.893	1.00 9.52	6
35	ATOM	1112	CG	TYR			7.854	-0.425	15.218	1.00 9.13	6
	ATOM	1113	CD1	TYR			7.714	-1.156	14.034	1.00 13.04	6
	ATOM	1114	CD2	TYR			9.133	-0.220	15.669	1.00 9.76	6
	ATOM	1115	CE1				8.844	-1.655	13.380	1.00 11.71	6
	ATOM	1116	CE2	TYR			10.277	-0.692	15.036	1.00 10.97	6
40	ATOM	1117	CZ	TYR			10.099	-1.415	13.843	1.00 13.29	6
	ATOM	1118	OH	TYR			11.230	-1.879	13.246	1.00 12.70	8
	ATOM	1119	N	ALA			7.149	-1.061	18.759	1.00 10.29	7
	MOTA	1120	CA	ALA			8.086	-1.801	19.644	1.00 10.75	6
	ATOM	1121	C	ALA			7.409	-3.014	20.263	1.00 12.48	6
45	MOTA	1122	0	ALA	Α	150	7.986	-4.102	20.400	1.00 11.16	8
	ATOM	1123	CB	ALA			8.414	-0.867	20.792	1.00 11.39	6
	ATOM	1124	N	TRP	Α	151	6.140	-2.882	20.642	1.00 9.91	7
	MOTA	1125	CA	TRP	Α	151	5.362	-4.015	21.124	1.00 10.13	6
	ATOM	1126	C	TRP	Α	151	5.261	-5.146	20.085	1.00 9.48	6
50	ATOM	1127	0	TRP	Α	151	5.539	-6.305	20.358	1.00 10.95	8
	MOTA	1128	CB	TRP	Α	151	3.927	-3.582	21.579	1.00 10.48	6
	MOTA	1129	CG	TRP	Α	151	3.161	-4.785	21.971	1.00 11.85	6
	MOTA	1130	CD1	TRP	Α	151	2.277	-5.511	21.197	1.00 13.81	6
	ATOM	1131	CD2	TRP	Α	151	3.146	-5.490	23.235	1.00 9.96	6
55	MOTA	1132	NE1	TRP	A	151	1.771	-6.612	21.846	1.00 15.34	7
	ATOM	1133	CE2	TRP	Α	151	2.285	-6.592	23.111	1.00 11.52	6
	MOTA	1134	CE3	TRP	Α	151	3.799	-5.270	24.452	1.00 12.17	6
	MOTA	1135	CZ2	TRP	Α	151	2.055	-7.487	24.161	1.00 11.76	6
	MOTA	1136	CZ3	TRP	Α	151	3.603	-6.161	25.520	1.00 14.83	6
60	MOTA	1137	CH2	TRP	Α	151	2.747	-7.235	25.354	1.00 11.91	6
	MOTA	1138	N	ASN	Α	152	4.921	-4.758	18.850	1.00 10.31	7
	MOTA	1139	CA	ASN			4.758	-5.805	17.805	1.00 10.90	6
	MOTA	1140	C	ASN	А	152	6.078	-6.365	17.381	1.00 12.51	6
	MOTA	1141	0	ASN	Α	152	6.094	-7.498	16.850	1.00 18.29	8
65	MOTA	1142	CB	ASN			4.057	-5.138	16.614	1.00 12.21	6
	MOTA	1143	CG	ASN	А	152	2.596	-4.898	16.919	1.00 15.60	6
	MOTA	1144		ASN			1.888	-5.697	17.581	1.00 16.16	8
	ATOM	1145	ND2	ASN	Α	152	2.084	-3.807	16.394	1.00 16.47	7

	ATOM	1146	N	LYS .	A 153	7.214	-5.769	17.698	1.00	12.60	7
	ATOM	1147	CA	LYS .	A 15:	8.552	-6.282	17.497	1.00	12.34	6
	ATOM	1148	C	LYS .	A 15:		-7.341	18.558	1.00	11.63	6
	ATOM	1149	0	LYS .	A 153	9.908	-8.014	18.454	1.00	16.70	8
5	ATOM	1150	CB	LYS .	A 15:	9.587	-5.158	17.537	1.00	14.85	6
•	ATOM	1151	CG	LYS			-4.265	16.316	1.00 2	21.79	6
	ATOM	1152	CD	LYS .	A 15:	10.522	-4.776	15.210	1.00 2	20.60	6
	ATOM	1153	CE	LYS .	A 15	12.016	-4.864	15.642	1.00	14.64	6
	ATOM	1154	NZ	LYS .			-5.708	14.521	1.00 2	23.18	7
10	ATOM	1155	N	GLY .			-7.351	19.658	1.00	11.47	7
	ATOM	1156	CA	GLY .			-8.288	20.722	1.00	10.77	6
	ATOM	1157	C	GLY .	A 154	8.817	-7.664	22.030	1.00	10.93	6
	ATOM	1158	0	GLY .			-8.468	22.922	1.00	12.36	8
	ATOM	1159	N	ALA .			-6.356	22.134	1.00	10.32	7
15	ATOM	1160	CA	ALA .			-5.744	23.380	1.00	9.51	6
	ATOM	1161	C	ALA			-5.469	24.340	1.00	10.33	6
	ATOM	1162	ō	ALA			-5.268	23.959	1.00	10.45	8
	ATOM	1163	СВ	ALA			-4.418	22.994	1.00	10.15	6
	ATOM	1164	N	VAL			-5.419	25.626	1.00	10.20	7
20	ATOM	1165	CA	VAL .			-4.930	26.644	1.00	9.64	6
	ATOM	1166	C	VAL			-3.424	26.826	1.00	11.32	6
	ATOM	1167	ō	VAL			-3.071	26.918	1.00	11.90	8
	ATOM	1168	CB	VAL			-5.665	27.974	1.00	8.78	6
	ATOM	1169		VAL			-5.108	29.060	1.00	8.99	6
25	ATOM	1170	CG2	VAL			-7.139	27.784	1.00	10.63	6
	ATOM	1171	N	VAL			-2.653	26.805	1.00	8.38	7
	ATOM	1172	CA	VAL			-1.208	27.010	1.00	7.61	6
	ATOM	1173	C	VAL			-0.872	28.402	1.00	7.95	6
	ATOM	1174	ō	VAL			-1.202	28.638	1.00	9.65	8
30	ATOM	1175	СВ	VAL			-0.421	25.888	1.00	9.67	6
-	ATOM	1176		VAL			1.064	26.099	1.00	11.64	6
	MOTA	1177		VAL			-0.831	24.528	1.00	11.35	6
	ATOM	1178	N	VAL			-0.189	29.203	1.00	8.45	7
	ATOM	1179	CA	VAL			0.190	30.574	1.00	9.13	6
35	ATOM	1180	C	VAL			1.706	30.663	1.00	9.56	6
-	ATOM	1181	Ō	VAL			2.222	30.248	1.00	9.44	8
	ATOM	1182	CB	VAL			-0.489	31.598	1.00	8.39	6
	ATOM	1183		VAL			-0.079	33.007	1.00	9.17	6
	ATOM	1184	CG2				-2.003	31.414	1.00	9.94	6
40	ATOM	1185	N	ALA			2.385	31.165	1.00	8.36	7
	ATOM	1186	CA	ALA			3.865	31.227	1.00	8.80	6
	ATOM	1187	C	ALA			4.389	32.506	1.00	9.68	6
	ATOM	1188	0	ALA			3.858	33.049	1.00	9.19	8
	ATOM	1189	CB	ALA			4.442	30.023	1.00	11.81	6
45	ATOM	1190	N	ALA			5.486	32.979	1.00	10.16	7
	ATOM	1191	CA	ALA	A 16	5.305	6.213	34.150	1.00	8.09	6
	ATOM	1192	C	ALA	A 16	3.970	6.867	33.890	1.00	10.59	6
	ATOM	1193	0	ALA	A 16	3.740	7.477	32.843	1.00	12.25	8
	ATOM	1194	CB	ALA			7.244	34.509	1.00	10.91	6
50	ATOM	1195	N		A 16		6.756	34.901	1.00	10.18	7
	ATOM	1196	CA	ALA	A 16	1.740	7.326	34.667	1.00	9.20	6
	MOTA	1197	C	ALA	A 16	1.681	8.838	34.846	1.00	9.69	6
	ATOM	1198	0	ALA	A 16	0.615	9.381	34.494	1.00	11.99	8
	MOTA	1199	CB	ALA	A 16	0.757	6.678	35.666	1.00	11.17	6
55	ATOM	1200	N	GLY	A 16	2.697	9.461	35.379	1.00	10.16	7
	MOTA	1201	CA	GLY	A 16	2.728	10.929	35.525	1.00	11.47	6
	MOTA	1202	C	GLY	A 16	2.542	11.334	36.997	1.00	11.99	6
	MOTA	1203	0	GLY	A 16	2.058	10.534	37.818	1.00	11.61	8
	ATOM	1204	N	ASN	A 16	2.830	12.646	37.210	1.00	13.68	7
60	MOTA	1205	CA	ASN	A 16	3.016	13.100	38.616	1.00	14.00	6
	MOTA	1206	C	ASN	A 16	2.233	14.384	38.911	1.00	14.39	6
	MOTA	1207	0	ASN	A 16		15.174	39.760	1.00	18.79	8
	ATOM	1208	CB	ASN			13.375	38.878	1.00	17.01	6
	MOTA	1209	CG		A 16		12.263	38.552	1.00		6
65	MOTA	1210		ASN			11.120	38.907	1.00	22.23	8
	MOTA	1211		ASN			12.569	37.843	1.00		7
	MOTA	1212	N	ASP	A 16		14.444	38.394	1.00		7
	ATOM	1213	CA	ASP	A 16	0.248	15.664	38.640	1.00	15.43	6

	A TOM	1214	C ASP A	161	-0.891	15.376	39.610	1.00 16.52	6
	ATOM	1214							
	ATOM	1215	O ASP A	164	-1.808	16.205	39.791	1.00 16.92	8
	ATOM	1216	CB ASP A	164	-0.340	16.092	37.304	1.00 18.79	6
	ATOM	1217	CG ASP A		0.611	16.817	36.382	1.00 31.26	6
5	ATOM	1218	OD1 ASP A	164	0.099	17.435	35.437	1.00 32.77	8
	MOTA	1219	OD2 ASP A	164	1.843	16.799	36.578	1.00 32.99	8
									7
	MOTA	1220	n asna		-0.956	14.222	40.228	1.00 13.48	
	ATOM	1221	CA ASN A	165	-2.032	13.774	41.047	1.00 13.19	6
	MOTA	1222	C ASN A	165	-3.417	13.950	40.424	1.00 12.14	6
10	ATOM	1223	O ASN A	165	-4.334	14.510	41.036	1.00 15.12	8
	MOTA	1224	CB ASN A	165	-2.028	14.587	42.369	1.00 12.06	6
	ATOM	1225	CG ASN A	165	-2.933	13.893	43.348	1.00 10.24	6
	ATOM	1226	OD1 ASN A	165	-3.244	12.729	43.479	1.00 12.45	8
	ATOM	1227	ND2 ASN A	165	-3.428	14.777	44.297	1.00 11.65	7
1 =		1228	N VAL A		-3.533	13.571	39.169	1.00 12.64	7
15	MOTA								
	ATOM	1229	CA VAL A	166	-4.803	13.600	38.442	1.00 13.30	6
	MOTA	1230	C VAL A	166	-5.190	12.205	37.908	1.00 13.31	6
						11.280	37.855		8
	MOTA	1231	O VAL A		-4.366				
	ATOM	1232	CB VAL A	166	-4.852	14.651	37.330	1.00 15.75	6
20	MOTA	1233	CG1 VAL A	166	-4.413	16.035	37.817	1.00 19.38	6
20									
	MOTA	1234	CG2 VAL A		-3.879	14.327	36.205	1.00 15.73	6
	MOTA	1235	N SER A	167	-6.430	12.097	37.425	1.00 15.05	7
	MOTA	1236	CA SER A	167	-6.858	10.862	36.753	1.00 14.74	6
	MOTA	1237	C SER A		-7.051	10.847	35.266	1.00 11.97	6
25	MOTA	1238	O SER A	167	-7.439	9.759	34.833	1.00 14.98	8
	ATOM	1239	CB SER A		-8.159	10.374	37.453	1.00 21.93	6
	MOTA	1240	OG SER A	167	-9.169	11.371	37.231	1.00 21.70	8
	MOTA	1241	N ARG A	168	-6.733	12.019	34.760	1.00 14.80	7
	ATOM	1242	CA ARG A		-6.628	12.185	33.336	1.00 14.30	6
30	MOTA	1243	C ARG A	168	-5.557	11.225	32.761	1.00 14.04	6
	ATOM	1244	O ARG A	168	-4.583	11.016	33.472	1.00 16.56	8
	ATOM	1245	CB ARG A		-6.450	13.600	32.868	1.00 14.72	6
	MOTA	1246	CG ARG A	168	-7.590	14.492	33.412	1.00 17.52	6
	MOTA	1247	CD ARG A	168	-7.488	15.866	32.744	1.00 19.22	6
2 =	ATOM	1248	NE ARG A		-6.152	16.434	32.854	1.00 19.87	7
35									
	MOTA	1249	CZ ARG A		-5.777	17.137	33.946	1.00 18.90	6
	MOTA	1250	NH1 ARG A	168	-6.683	17.234	34.915	1.00 22.35	7
	MOTA	1251	NH2 ARG A	168	-4.590	17.669	34.037	1.00 27.26	7
									7
	ATOM	1252	N THR A		-5.775	10.681	31.545	1.00 13.30	
40	ATOM	1253	CA THR A	169	-4.663	9.851	31.036	1.00 14.18	6
	ATOM	1254	C THR A	169	-3.476	10.689	30.653	1.00 14.82	6
	ATOM	1255	O THR A		-3.422	11.859	30.220	1.00 16.21	8
	ATOM	1256	CB THR A	169	-5.168	9.131	29.752	1.00 14.96	6
	ATOM	1257	OG1 THR A	169	-5.576	10.096	28.754	1.00 15.86	8
45	ATOM	1258	CG2 THR A		-6.305	8.184	30.046	1.00 17.51	6
45									
	ATOM	1259	N PHE A	170	-2.290	10.036	30.708	1.00 12.69	7
	MOTA	1260	CA PHE A	170	-0.978	10.559	30.350	1.00 10.15	6
				170	-0.366	9.550		1.00 10.51	6
	ATOM	1261					29.382		
	MOTA	1262	O PHE A	170	-0.516	8.340	29.517	1.00 13.04	8
50	MOTA	1263	CB APHE A	170	0.010	10.860	31.486	0.50 9.69	6
	ATOM	1264	CG APHE A		-0.086	12.208	32.151	0.50 12.91	6
	ATOM	1265	CD1APHE A	170	1.046	12.996	32.247	0.50 15.42	6
	MOTA	1266	CD2APHE A	170	-1.271	12.657	32.723	0.50 15.96	6
	ATOM	1267	CE1APHE A		0.999	14.230	32.893	0.50 17.60	6
									0
55	ATOM	1268	CE2APHE A	170	-1.322	13.894	33.359	0.50 14.69	6
	MOTA	1269	CZ APHE A	170	-0.193	14.664	33.434	0.50 18.78	6
			CB BPHE A		-0.239	10.454	31.713	0.50 11.27	6
	MOTA	1270							6
	MOTA	1271	CG BPHE A		1.070	11.133	31.830	0.50 10.40	6
	ATOM	1272	CD1BPHE A	170	2.277	10.418	31.853	0.50 10.22	6
60		1273	CD2BPHE A		1.133	12.520		0.50 13.93	6
60	ATOM						31.939		0
	ATOM	1274	CE1BPHE A	170	3.482	11.075	31.968	0.50 12.32	6
	MOTA	1275	CE2BPHE A	170	2.348	13.165	32.052	0.50 13.83	6
	ATOM	1276	CZ BPHE A		3.544	12.456	32.077	0.50 15.52	6
									0
	ATOM	1277	N GLN A		0.238	10.113	28.331	1.00 11.14	7
65	ATOM	1278	CA GLN A	171	0.856	9.335	27.255	1.00 10.59	6
	ATOM	1279	C GLN A		2.348	9.422	27.239	1.00 10.58	6
	ATOM	1280	O GLN A		2.822	10.459	27.645	1.00 13.39	8
	MOTA	1281	CB GLN A	171	0.297	9.849	25.865	1.00 11.19	6

	ATOM	1282	CG	GLN	A 17	-1.200	9.613	25.647	1.00 11.83	6
	ATOM	1283	CD	GLN			10.468	26.524	1.00 13.12	6
	ATOM	1284		GLN			9.928	27.305	1.00 15.76	8
	ATOM	1285	NE2	GLN	A 17	-2.011	11.790	26.391	1.00 14.42	7
5	ATOM	1286	N	PRO	A 17	3.043	8.320	26.919	1.00 11.03	7
	ATOM	1287	CA	PRO	A 17	2.572	7.108	26.347	1.00 11.46	6
	ATOM	1288	C	PRO			6.025	27.235	1.00 11.03	6
	ATOM	1289	0	PRO	A 17		5.023	26.809	1.00 11.22	8
	MOTA	1290	CB	PRO	A 17	3.819	6.511	25.610	1.00 11.89	6
10	ATOM	1291	CG	PRO			6.978	26.569	1.00 11.81	6
	ATOM	1292	CD	PRO	A 17	4.490	8.404	26.935	1.00 12.12	6
	ATOM	1293	N	ALA	A 17	2.069	6.254	28.594	1.00 9.12	7
	ATOM	1294	CA	ALA	A 17		5.194	29.473	1.00 9.14	6
	ATOM	1295	C	ALA	A 17	0.120	4.778	29.127	1.00 10.86	6
15	ATOM	1296	0	ALA			3.582	29.296	1.00 11.28	8
	ATOM	1297	CB	ALA			5.713	30.931	1.00 11.79	6
	ATOM	1298	N	SER			5.696	28.751	1.00 9.25	7
	ATOM	1299	CA	SER			5.257	28.562	1.00 10.77	6
	ATOM	1300	C	SER			4.456	27.262	1.00 11.85	6
20	ATOM	1301	0	SER			3.938	27.120	1.00 12.90	8
	ATOM	1302	CB	SER			6.504	28.585	1.00 12.82	6
	ATOM	1303	OG	SER	A 17	-2.887	7.251	27.376	1.00 13.72	8
	ATOM	1304	N	TYR	A 17	-1.417	4.375	26.405	1.00 11.48	7
	ATOM	1305	CA	TYR	A 17	-1.695	3.533	25.228	1.00 12.72	6
25	ATOM	1306	С	TYR	A 17	-1.927	2.094	25.655	1.00 10.63	6
	MOTA	1307	0	TYR			1.611	26.603	1.00 11.10	8
	ATOM	1308	CB	TYR	A 17	-0.435	3.567	24.316	1.00 11.23	6
	ATOM	1309	CG	TYR	A 17	-0.129	4.914	23.750	1.00 10.17	6
	ATOM	1310	CD1	TYR	A 17	-1.068	5.887	23.517	1.00 13.17	6
30	ATOM	1311	CD2	TYR	A 17	1.198	5.229	23.425	1.00 9.64	6
	ATOM	1312	CE1	TYR	A 17		7.116	22.977	1.00 11.74	6
	ATOM	1313	CE2	TYR	A 17	1.529	6.450	22.873	1.00 11.86	6
	ATOM	1314	CZ	TYR			7.397	22.648	1.00 15.00	6
	ATOM	1315	OH	TYR	A 17	0.880	8.636	22.122	1.00 16.46	8
35	MOTA	1316	N	PRO .	A 17	-2.776	1.327	25.028	1.00 11.70	7
	ATOM	1317	CA	PRO .	A 17	-2.959	-0.092	25.360	1.00 11.01	6
	ATOM	1318	C	PRO .	A 17	-1.660	-0.878	25.468	1.00 10.13	6
	ATOM	1319	0	PRO .	A 17	-1.615	-1.766	26.289	1.00 11.27	8
	ATOM	1320	CB	PRO	A 17	-3.990	-0.665	24.357	1.00 12.68	6
40	ATOM	1321	CG	PRO	A 17	-4.746	0.637	24.093	1.00 11.38	6
	ATOM	1322	CD	PRO .	A 17	-3.780	1.833	24.052	1.00 13.11	6
	ATOM	1323	N	ASN	A 17	-0.723	-0.656	24.506	1.00 11.05	7
	ATOM	1324	CA	ASN .	A 17	0.441	-1.544	24.522	1.00 12.20	6
	ATOM	1325	C	ASN .	A 17	1.551	-1.045	25.410	1.00 11.24	6
45	ATOM	1326	0	ASN .	A 17	2.629	-1.720	25.402	1.00 11.19	8
	ATOM	1327	CB	ASN	A 17	0.857	-1.640	23.046	1.00 10.48	6
	ATOM	1328	CG	ASN .	A 17	0.051	-2.684	22.321	1.00 12.91	6
	ATOM	1329	OD1	ASN .	A 17		-3.689	22.832	1.00 14.78	8
	ATOM	1330	ND2	ASN .	A 17		-2.441	20.970	1.00 15.54	7
50	ATOM	1331	N	ALA			-0.058	26.278	1.00 10.52	7
	ATOM	1332	CA	ALA .	A 17		0.293	27.312	1.00 9.20	6
	ATOM	1333	С	ALA			-0.191	28.662	1.00 11.35	6
	ATOM	1334	0	ALA .			0.004	28.907	1.00 10.58	8
	ATOM	1335	CB	ALA			1.825	27.370	1.00 11.60	6
55	ATOM	1336	N	ILE .			-0.779	29.554	1.00 9.76	7
	ATOM	1337	CA	ILE .	A 17		-0.944	30.966	1.00 8.57	6
	ATOM	1338	C	ILE .			0.427	31.641	1.00 9.10	6
	ATOM	1339	0	ILE .			0.926	31.750	1.00 10.06	8
	ATOM	1340	CB	ILE .			-1.961	31.637	1.00 8.69	6
60	ATOM	1341		ILE			-3.292	30.879	1.00 11.26	6
	ATOM	1342		ILE .			-2.226	33.097	1.00 10.57	6
	ATOM	1343		ILE .			-4.323	31.403	1.00 13.43	6
	ATOM	1344	N	ALA .			0.950	32.181	1.00 8.93	7
	ATOM	1345	CA	ALA			2.243	32.870	1.00 8.88	6
65	ATOM	1346	C	ALA			1.988	34.378	1.00 9.81	6
	ATOM	1347	0	ALA .			1.134	34.956	1.00 10.08	8
	ATOM	1348	CB	ALA .			2.936	32.657	1.00 10.99	6
	ATOM	1349	N	VAL.	A 18	2.333	2.692	34.886	1.00 8.81	7

	ATOM	1350	CA	VAL A	181	2.750	2.473	36.298	1.00 7.21	6
	ATOM	1351	C	VAL A		2.625	3.698	37.175	1.00 10.43	6
		1351	0	VAL A		3.187	4.746	36.896	1.00 9.18	8
	ATOM							36.222	1.00 7.41	6
_	MOTA	1353	CB	VAL A		4.252	2.124			6
5	MOTA	1354		VAL A		4.729	1.806	37.634		
	ATOM	1355		VAL A		4.527	0.886	35.362	1.00 8.70	6
	ATOM	1356	N	GLY A	182	1.839	3.465	38.248	1.00 10.46	7
	ATOM	1357	CA	GLY A	182	1.639	4.475	39.285	1.00 9.36	6
	ATOM	1358	C	GLY A	182	2.682	4.200	40.403	1.00 10.52	6
10	ATOM	1359	0	GLY A	182	3.453	3.263	40.320	1.00 10.35	8
	ATOM	1360	N	ALA A		2.714	5.147	41.349	1.00 9.62	7
	ATOM	1361	CA	ALA A		3.677	4.975	42.430	1.00 8.49	6
	ATOM	1362	C	ALA A		2.990	4.939	43.792	1.00 10.18	6
				ALA A		2.028	5.635	44.041	1.00 10.96	8
	ATOM	1363	O				6.262		1.00 10.30	6
15	ATOM	1364	CB	ALA A		4.536		42.471		
	MOTA	1365	N	ILE A		3.671	4.126	44.619	1.00 8.08	7
	ATOM	1366	CA	ILE A		3.277	4.029	46.044	1.00 9.34	6
	ATOM	1367	C	ILE A		4.522	4.315	46.889	1.00 10.84	6
	ATOM	1368	0	ILE A	184	5.660	4.279	46.425	1.00 10.59	8
20	MOTA	1369	CB	ILE A	184	2.765	2.623	46.440	1.00 9.26	6
	ATOM	1370	CG1	ILE A	184	3.623	1.537	45.777	1.00 9.29	6
	ATOM	1371	CG2	ILE A	184	1.298	2.458	46.049	1.00 10.38	6
	ATOM	1372	CD1	ILE A	184	3.337	0.145	46.343	1.00 9.89	6
	ATOM	1373	N	ASP A		4.246	4.604	48.177	1.00 9.31	7
25	ATOM	1374	CA	ASP A		5.388	4.755	49.122	1.00 11.76	6
25		1375	C	ASP A		5.646	3.419	49.776	1.00 9.50	6
	ATOM							49.400	1.00 11.06	8
	MOTA	1376	0	ASP A		5.128	2.363			
	ATOM	1377	CB	ASP A		4.996	5.878	50.077	1.00 12.42	6
	MOTA	1378	CG	ASP A		3.878	5.520	51.008	1.00 16.62	6
30	MOTA	1379		ASP A		3.498	4.359	51.188	1.00 19.16	8
	ATOM	1380	OD2	ASP A	185	3.331	6.525	51.584	1.00 21.71	8
	ATOM	1381	N	SER A	186	6.557	3.525	50.791	1.00 10.02	7
	ATOM	1382	CA	SER A	186	6.943	2.275	51.483	1.00 11.07	6
	MOTA	1383	C	SER A	186	5.904	1.628	52.388	1.00 11.68	6
35	ATOM	1384	Ō	SER A		6.089	0.458	52.791	1.00 12.40	8
	ATOM	1385	CB	SER A		8.278	2.475	52.195	1.00 12.70	6
	ATOM	1386	OG	SER A		8.020	3.342	53.353	1.00 13.04	8
						4.805	2.372	52.571	1.00 13.01	7
	ATOM	1387	N	ASN A						6
	ATOM	1388	CA	ASN A		3.674	1.829	53.284	1.00 11.75	
40	ATOM	1389	C	ASN A		2.521	1.414	52.403	1.00 14.42	6
	MOTA	1390	0	ASN Z		1.387	1.286	52.844	1.00 14.41	8
	ATOM	1391	CB	ASN A		3.208	2.885	54.299	1.00 13.43	6
	MOTA	1392	CG	ASN A	187	2.435	2.266	55.455	1.00 24.32	6
	MOTA	1393	OD1	ASN A	187	2.664	1.109	55.787	1.00 28.21	8
45	ATOM	1394	ND2	ASN A	187	1.561	3.083	56.015	1.00 24.99	7
	ATOM	1395	\mathbf{N}	ASP A	188	2.816	1.287	51.095	1.00 12.93	7
	ATOM	1396	CA	ASP Z	188	1.790	0.919	50.135	1.00 12.49	6
	MOTA	1397	C	ASP A	188	0.681	1.950	49.920	1.00 12.89	6
	ATOM	1398	Ō	ASP A		-0.362	1.549	49.382	1.00 16.50	8
50	ATOM	1399	CB	ASP Z		1.210	-0.478	50.410	1.00 14.69	6
50	ATOM	1400	CG	ASP A		2.107	-1.661	50.168	1.00 14.67	6
								49.644	1.00 14.07	8
	ATOM	1401		ASP A		3.257	-1.503			0
	MOTA	1402	OD2			1.754	-2.821	50.535	1.00 17.10	8
	MOTA	1403	N	ARG Z		0.944	3.168	50.317	1.00 11.91	7
55	MOTA	1404	CA	ARG A	189	-0.057	4.193	50.068	1.00 11.81	6
	MOTA	1405	C	ARG Z	189	0.318	4.940	48.809	1.00 10.44	6
	ATOM	1406	0	ARG 2	189	1.490	5.032	48.450	1.00 11.22	8
	MOTA	1407	CB	ARG 2	A 189	-0.070	5.188	51.257	1.00 12.95	6
	ATOM	1408	CG		189	-0.635	4.385	52.458	1.00 19.11	6
60	ATOM	1409	CD		A 189	-0.942	5.273	53.602	0.00 20.00	6
50	MOTA	1410	NE		A 189	-1.563	4.465	54.658	0.00 20.00	7
	ATOM	1411	CZ		189	-2.073	5.120	55.718	0.00 20.00	6
										7
	ATOM	1412		ARG		-2.009	6.439	55.778	0.00 20.00	7
	MOTA	1413	NH2			-2.641	4.429	56.712	0.00 20.00	
65	ATOM	1414	N		A 190	-0.725	5.371	48.044	1.00 12.65	7
	ATOM	1415	CA		A 190	-0.437	6.168	46.830	1.00 13.29	6
	MOTA	1416	С		A 190	0.475	7.292	47.111	1.00 12.33	6
	MOTA	1417	0	LYS .	A 190	0.366	8.054	48.112	1.00 12.55	8

	ATOM	1418	CB	LYS	Α	190	-1.739	6.688	46.193	1.00	14.04	6
	ATOM	1419	CG	LYS	Α	190	-1.575	7.374	44.863	1.00	13.43	6
	MOTA	1420	CD	LYS	А	190	-2.892	8.042	44.365	1.00	14.23	6
	ATOM	1421	CE	LYS	Α	190	-2.848	9.547	44.467	1.00	11.74	6
5	ATOM	1422	NZ	LYS	Α	190	-1.794	10.509	44.344	1.00	14.74	7
	MOTA	1423	N	ALA	A	191	1.539	7.488	46.284	1.00	9.54	7
	MOTA	1424	CA	ALA			2.402	8.643	46.397	1.00	10.14	6
	MOTA	1425	C	ALA	Α	191	1.569	9.962	46.232	1.00	12.32	6
	ATOM	1426	0	ALA			0.650	9.922	45.406	1.00	12.53	8
10	MOTA	1427	CB	ALA			3.479	8.638	45.324	1.00	12.15	6
	ATOM	1428	N	SER			1.965	10.976	46.997	1.00	13.24	7
	ATOM	1429	CA	SER			1.044	12.139	46.993	1.00	15.23	6
	ATOM	1430	C	SER			0.868	12.637	45.580	1.00	11.65	6
	ATOM	1431	ō	SER			-0.259	13.044	45.208	1.00	11.90	8
1.5	ATOM	1432	CB	SER			1.586	13.158	48.008	1.00	19.44	6
1.0	ATOM	1433	OG	SER			2.765	13.652	47.508	1.00	23.70	8
	ATOM	1434	N	PHE			1.863	12.658	44.721		12.20	7
	ATOM	1435	CA	PHE			1.810	13.199	43.381	1.00	14.48	6
	ATOM	1436	C	PHE			1.385	12.209	42.289		13.11	6
20	ATOM	1437	Ö	PHE			1.238	12.595	41.135		11.70	8
20	ATOM	1438	ČВ	PHE			3.310	13.582	43.106		17.86	6
	ATOM	1439	CG	PHE			4.249	12.384	43.353		20.29	6
	ATOM	1440		PHE			4.287	11.322	42.438		22.95	6
	ATOM	1441		PHE			5.040	12.214	44.448	1.00	8.24	6
25	ATOM	1442		PHE			5.098	10.236	42.710		19.68	6
25	ATOM	1443		PHE			5.864	11.222	44.781		21.76	6
	ATOM	1444	CZ	PHE			5.910	10.164	43.860		19.49	6
	ATOM	1445	N	SER			1.240	10.942	42.667		10.08	7
	ATOM	1446	CA	SER			1.056	10.001	41.524	1.00	9.55	6
30	ATOM	1447	C			194	-0.269	10.206	40.817		10.73	6
30	MOTA	1448	Ö			194	-1.304	10.320	41.445		11.77	8
	ATOM	1449	CB			194	1.096	8.580	42.077		10.02	6
	ATOM	1450	OG			194	0.951	7.609	41.021		11.46	8
	ATOM	1451	N	ASN			-0.250	10.146	39.487	1.00	9.56	7
2 E	ATOM	1452	CA	ASN			-1.500	10.042	38.765	1.00	9.33	6
35	ATOM	1452	CA	ASN			-2.095	8.658	39.068		12.48	6
	ATOM	1454	0	ASN			-1.471	7.723	39.599		11.95	8
	ATOM	1455	CB	ASN			-1.288	10.176	37.252	1.00	9.08	6
	ATOM	1456	CG			195	-0.941	11.572	36.865		11.88	6
4.0		1457		ASN			-1.104	12.515	37.608		12.04	8
40	ATOM ATOM	1458		ASN			-0.437	11.729	35.635		12.30	7
	ATOM	1459	N N			196	-3.396	8.535	38.769		11.14	7
	ATOM	1460	CA			196	-4.117	7.344	39.186	1.00	9.82	6
	ATOM	1461	C			196	-5.386	7.196	38.350		13.03	6
4 =	ATOM	1462	O.			196	-5.716	8.132	37.629		14.68	8
43	ATOM	1463	CB			196	-4.544	7.490	40.681		11.85	6
	ATOM	1464	CG			196	-5.414	8.701	40.933		12.37	6
	MOTA	1465		TYR			-4.871	9.945	41.165		12.29	6
	ATOM	1466	CD2			196	-6.802	8.592	40.906		11.59	6
50	ATOM	1467		TYR			-5.612	11.084	41.371		13.98	6
50	MOTA	1468		TYR			-7.586	9.704	41.112		15.81	6
	MOTA	1469	CZ			196	-7.009	10.918	41.336		15.20	6
	MOTA	1470	OH			196	-7.817	12.040	41.542		19.65	8
	MOTA	1471	N			197	-5.882	5.993	38.403		11.13	7
55	ATOM	1472	CA.			197	-7.170	5.755	37.680		11.68	6
55	ATOM	1473	C			197	-7.164	4.338	37.161		12.24	6
	ATOM	1474	Ö			197	-6.200	3.578	37.267		13.15	8
	ATOM	1475	N			198	-8.311	3.905	36.542		12.40	7
	ATOM	1476	CA			198	-8.425	2.531	36.111		11.46	6
CO		1477	CA			198	-7.578	2.248	34.855		12.92	6
60							-7.329	1.063	34.613		14.81	8
	MOTA	1478	O			198 198	-9.918	2.151	35.818	1.00		6
	ATOM	1479	CB OC1	THR			-10.361	2.131	34.785		20.98	8
	ATOM	1480					-10.785	2.300	37.056		17.57	6
~ -	MOTA	1481		THR		198	-7.107	3.325	34.195		12.12	7
65	ATOM	1482	N CA			199	-6.192	3.157	33.081		12.12	6
	ATOM	1483	CA			199	-6.192 -4.774	2.869	33.525		11.15	6
	ATOM	1484					-3.896	2.557	32.737		13.41	8
	MOTA	1485	0	TKP	A	199	-3.036	4.33/	22.121	1.00	T3.4T	O

	ATOM	1486	CB	TRP A	199	-6.194	4.421	32.173	1.00 11.96	6
	ATOM	1487	CG	TRP A		-5.744	5.662	32.884	1.00 11.22	6
	ATOM	1488	CD1	TRP A	199	-6.470	6.564	33.633	1.00 16.14	6
	MOTA	1489	CD2	TRP A		-4.419	6.188	32.931	1.00 10.56	6
5	MOTA	1490	NE1	TRP A		-5.702	7.565	34.144	1.00 16.05	7
	MOTA	1491	CE2	TRP A		-4.397	7.379	33.705	1.00 14.41	6
	MOTA	1492	CE3	TRP A		-3.218	5.745	32.325	1.00 12.64	6
	MOTA	1493	CZ2	TRP A		-3.239	8.128	33.914	1.00 17.36	6
	MOTA	1494	CZ3	TRP A		-2.092	6.505	32.566	1.00 15.03	6
10	MOTA	1495	CH2	TRP A		-2.081	7.654	33.347	1.00 14.87	6 7
	MOTA	1496	N	VAL A		-4.468	3.143	34.811	1.00 10.34 1.00 12.70	6
	ATOM	1497	CA	VAL A		-3.115	2.805	35.303		6
	MOTA	1498	C	VAL A		-3.087	1.330	35.623	1.00 11.86	8
	MOTA	1499	0_	VAL A		-4.069	0.763	36.157 36.568	1.00 14.02 1.00 10.90	6
15	MOTA	1500	CB	VAL A		-2.815	3.607		1.00 10.30	6
	MOTA	1501		VAL A		-1.476	3.218	37.118 36.300	1.00 10.81	6
	MOTA	1502		VAL A		-2.907	5.097	35.152	1.00 10.81	7
	MOTA	1503	N	ASP A		-2.127	0.525 -0.917	35.152	1.00 10.79	6
	MOTA	1504	CA	ASP A		-2.205	-0.917	36.611	1.00 10.73	6
20	ATOM	1505	C	ASP A		-1.714	-2.193	37.259	1.00 11.73	8
	ATOM	1506	0	ASP A		-2.428 -1.361	-2.193	34.104	1.00 10.74	6
	MOTA	1507	CB	ASP F		-2.014	-1.237	32.785	1.00 14.68	6
	MOTA	1508	CG	ASP F		-3.197	-1.603	32.591	1.00 12.39	8
2.5	MOTA	1509 1510		ASP A		-1.329	-0.642	31.929	1.00 11.24	8
25	MOTA	1511	N	VAL A		-0.478	-1.016	36.955	1.00 10.17	7
	ATOM	1511	CA	VAL A		0.069	-1.498	38.207	1.00 10.76	6
	ATOM ATOM	1512	C	VAL A		0.716	-0.337	38.925	1.00 9.89	6
	ATOM	1514	Ö	VAL A		0.872	0.733	38.352	1.00 9.72	8
30	ATOM	1515	CB	VAL A		1.128	-2.591	38.016	1.00 9.97	6
30	ATOM	1516		VAL A		0.504	-3.847	37.440	1.00 12.13	6
	ATOM	1517	CG2	VAL A		2.283	-2.104	37.130	1.00 14.06	6
	ATOM	1518	N	THR A		1.041	-0.552	40.192	1.00 9.69	7
	MOTA	1519	CA	THR A		1.817	0.426	40.984	1.00 8.33	6
35	ATOM	1520	C	THR A		3.076	-0.208	41.542	1.00 8.20	6
,,	ATOM	1521	Õ	THR A		3.152	-1.455	41.659	1.00 8.89	8
	MOTA	1522	СB	THR A		0.899	1.018	42.077	1.00 10.11	6
	MOTA	1523	OG1			1.528	2.183	42.573	1.00 9.97	8
	ATOM	1524	CG2	THR A		0.604	0.003	43.200	1.00 10.55	6
40	MOTA	1525	N	ALA A		4.060	0.625	41.900	1.00 8.43	7
	MOTA	1526	CA	ALA A		5.322	0.114	42.440	1.00 7.80	6
	ATOM	1527	С	ALA A		5.934	1.201	43.307	1.00 7.92	6
	ATOM	1528	0	ALA A	204	5.639	2.403	43.176	1.00 8.87	8
	MOTA	1529	CB	ALA A	204	6.215	-0.218	41.206	1.00 9.02	6
45	ATOM	1530	N	PRO A	205	6.889	0.857	44.167	1.00 9.20	7
	MOTA	1531	CA	PRO A	205	7.626	1.788	44.988	1.00 10.66	6
	ATOM	1532	C		205	8.167		44.122	1.00 10.80	6
	MOTA	1533	0		205	8.865	2.755	43.103	1.00 10.53	8
	MOTA	1534	CB	PRO A	1 205	8.810	0.934	45.486	1.00 11.87	6
50	MOTA	1535	CG		1 205	8.066	-0.386	45.743	1.00 9.61	6
	MOTA	1536	CD		205	7.222	-0.568	44.424	1.00 10.97	6
	MOTA	1537	N		1 206	7.855	4.139	44.552	1.00 9.51	7
	MOTA	1538	CA		A 206	8.265	5.328	43.848	1.00 8.77	6
	MOTA	1539	С		A 206	8.571	6.543	44.702	1.00 9.82	6
55		1540	0		A 206	8.762	7.640	44.198	1.00 12.47	8
	ATOM	1541	N		A 207	8.608	6.363	46.053	1.00 9.75	7
	ATOM	1542	CA		A 207	8.789	7.498	46.954	1.00 11.01	6
	MOTA	1543	С		A 207	10.120	7.353	47.646	1.00 10.23	6
	ATOM	1544	0		A 207	10.366	6.348	48.257	1.00 11.51	8
60	MOTA	1545	CB		A 207	7.679	7.624	48.011	1.00 9.92	6
	MOTA	1546		VAL .		7.938	8.802	48.933	1.00 10.74	6
	MOTA	1547		VAL .		6.369	7.832	47.256	1.00 12.64	6
	MOTA	1548	N		A 208	10.960	8.360	47.573	1.00 9.70	7
	ATOM	1549	CA		A 208	12.257	8.317	48.278	1.00 9.99	6
65		1550	C		A 208	13.030	7.058	47.981	1.00 9.86	6
	ATOM	1551	0		A 208	13.447	6.265	48.772	1.00 10.57	8
	MOTA	1552	CB		A 208	12.033	8.481	49.791	1.00 12.47	6
	MOTA	1553	CG	ASN	A 208	11.614	9.893	50.142	1.00 16.00	6

	ATOM	1554	OD1	ASN	A 208	11.947	10.841	49.487	1.00 1	7.81	8
	ATOM	1555			A 208	10.820	9.952	51.225	1.00 2	3.41	7
	ATOM	1556	N		A 209	13.185	6.904	46.648	1.00 1	1.72	7
	ATOM	1557	CA		A 209	13.934	5.767	46.091	1.00 1	1.01	6
5	ATOM	1558	C		A 209	15.425	6.097	45.962	1.00 1		6
5		1559	0		A 209	15.707	7.084	45.253		0.52	8
	ATOM					13.406	5.365	44.711		9.48	6
	ATOM	1560	CB		A 209			44.806		9.44	6
	ATOM	1561			A 209	11.918	4.982		1.00 1		6
	ATOM	1562	CG2		A 209	14.242	4.273	44.034			
10	MOTA	1563			A 209	11.642	3.820	45.762		9.01	6
	MOTA	1564	N		A 210	16.292	5.399	46.705		8.36	7
	MOTA	1565	CA		A 210	17.741	5.665	46.491		9.20	6
	ATOM	1566	C	ALA	A 210	18.266	5.060	45.191	1.00 1		6
	MOTA	1567	0	ALA	A 210	18.035	3.879	45.016	1.00 1	1.02	8
15	ATOM	1568	CB	ALA	A 210	18.464	5.038	47.678	1.00 1	0.57	6
	ATOM	1569	N	SER	A 211	19.037	5.807	44.408	1.00 1	0.47	7
	ATOM	1570	CA		A 211	19.647	5.229	43.209	1.00	9.26	6
	ATOM	1571	C		A 211	20.849	6.075	42.839	1.00 1		6
	ATOM	1572	Ö		A 211	21.241	7.011	43.573	1.00 1		8
20	ATOM	1573	CB		A 211	18.572	5.218	42.076		1.65	6
20					A 211	19.186	4.429	41.031		9.57	8
	ATOM	1574	OG							9.45	7
	ATOM	1575	N		A 212	21.521	5.684	41.776			6
	MOTA	1576	CA		A 212	22.650	6.435	41.237		9.57	
	MOTA	1577	C		A 212	22.316	7.786	40.601		0.33	6
25	MOTA	1578	0		A 212	21.312	7.897	39.943	1.00 1		8
	MOTA	1579	CB	\mathtt{THR}	A 212	23.230	5.539	40.123	1.00 1		6
	MOTA	1580	OG1	THR	A 212	22.197	5.032	39.255	1.00 1		8
	MOTA	1581	CG2	THR	A 212	23.860	4.247	40.683	1.00 1	1.54	6
	ATOM	1582	N	VAL	A 213	23.202	8.751	40.854	1.00 1	1.50	7
30	ATOM	1583	CA	VAL	A 213	23.084	10.032	40.112	1.00 1	0.64	6
50	ATOM	1584	C		A 213	24.479	10.365	39.618	1.00 1	2.70	6
	ATOM	1585	ō		A 213	25.449	9.733	40.023	1.00 1	4.01	8
	ATOM	1586	CB		A 213	22.430	11.117	40.929	1.00 1		6
		1587			A 213	20.952	10.866	41.236	1.00 1		6
٥.	ATOM					23.176	11.444	42.212	1.00 1		6
35	ATOM	1588			A 213				1.00 1		7
	MOTA	1589	N		A 214	24.599	11.271	38.634			6
	MOTA	1590	CA		A 214	25.893	11.455	38.032	1.00 1		
	MOTA	1591	С		A 214	27.016	11.909	38.959	1.00 1		6
	MOTA	1592	0		A 214	26.744	12.410	40.052	1.00 1		8
40	ATOM	1593	CB	PRO	A 214	25.641	12.502	36.919	1.00 1		6
	MOTA	1594	CG	PRO	A 214	24.175	12.119	36.585	1.00 1	1.84	6
	MOTA	1595	CD	PRO	A 214	23.489	11.956	37.969	1.00 1	4.36	6
	ATOM	1596	N	ASN	A 215	28.217	11.674	38.451	1.00 1	7.19	7
	ATOM	1597	CA	ASN	A 215	29.421	12.081	39.228	1.00 1	9.26	6
45	ATOM	1598	C	ASN	A 215	29.493	11.275	40.514	1.00 1	8.85	6
	ATOM	1599	0		A 215	29.781	11.814	41.595	1.00 2	1.66	8
	ATOM	1600	CB		A 215	29.417	13.592	39.493	1.00 1		6
	ATOM	1601	CG		A 215	29.256	14.419	38.223	1.00 3		6
	MOTA	1602			A 215	29.976	14.179	37.251	1.00 2		8
50	MOTA	1603			A 215	28.346	15.396	38.116	1.00 3		7
50	ATOM	1604	N		A 216	29.395	9.955	40.364	1.00 1		7
							9.014	41.466	1.00 1		6
	ATOM	1605	CA		A 216	29.543					6
	MOTA	1606	C		A 216	28.733	9.469	42.678	1.00 1		
	MOTA	1607	0		A 216	29.202	9.375	43.865	1.00 1		8
55	MOTA	1608	CB		A 216	31.049	8.938	41.893	1.00 1		6
	ATOM	1609	CG	ASN	A 216	31.212	7.736	42.799	1.00 1		6
	MOTA	1610	OD1	ASN	A 216	30.528	6.722	42.724	1.00 1	5.44	8
	ATOM	1611	ND2	ASN	A 216	32.178	7.841	43.735	1.00 2	2.33	7
	ATOM	1612	N	GLY	A 217	27.452	9.740	42.450	1.00 1	5.37	7
60	ATOM	1613	CA	GLY	A 217	26.528	10.146	43.484	1.00 1	5.63	6
	ATOM	1614	C		A 217	25.397	9.108	43.658	1.00 1	2.67	6
	ATOM	1615	Ö		A 217	25.274	8.223	42.830		3.61	8
	ATOM	1616	N		A 218	24.763	9.167	44.820		4.53	7
							8.474	45.147	1.00 1		6
~-	ATOM	1617	CA		A 218	23.540		45.748	1.00 1		6
65	ATOM	1618	C		A 218	22.573	9.467				
	MOTA	1619	0		A 218	23.042	10.313	46.555	1.00 1		8
	ATOM	1620	CB		A 218	23.781	7.308	46.161	1.00 1		6
	MOTA	1621	CG	TYR	A 218	24.809	6.356	45.591	1.00 1	2.20	6

	ATOM	1622	CD1	TYR	A	218	26.208	6.488	45.773	1.00	13.37	6
	ATOM	1623	CD2	TYR	Α	218	24.426	5.277	44.820		12.84	6
	ATOM	1624	CE1	TYR	Α	218	27.084	5.638	45.230		13.51	6
	ATOM	1625	CE2	TYR			25.300	4.451	44.233		11.27	6
5	ATOM	1626	cz	TYR			26.691	4.566	44.425		11.33	6
	ATOM	1627	OH	TYR			27.563	3.704	43.856		14.19	8
	ATOM	1628	N	SER			21.302	9.383	45.406		13.70	7
	ATOM	1629	CA	SER			20.345	10.292	45.991		12.43	6
	ATOM	1630	C	SER			18.946	9.690	45.979		12.57	6
10	MOTA	1631	0_	SER			18.687	8.690	45.259		11.67	8
	ATOM	1632	СВ	SER			20.380	11.571	45.175		16.94	6
	MOTA	1633	OG	SER			19.543	11.401	44.030		27.04	8
	ATOM	1634	N	TYR			18.080	10.236	46.794		11.86	7
	ATOM	1635	CA	TYR			16.690	9.896	46.724		11.51	6
15	ATOM	1636	C	TYR			16.047	10.722	45.635		12.74	6
	ATOM	1637	O	TYR			16.188	11.953	45.508		13.70	8 6
	MOTA	1638	CB	TYR			16.005	10.337 9.479	48.053 49.223		11.07 15.23	6
	ATOM	1639	CG	TYR			16.356 16.096	8.130	49.223		12.19	6
20	MOTA	1640	CD1	TYR TYR			16.970	10.065	50.348		20.94	6
20	ATOM	1641	CD2 CE1	TYR			16.418	7.319	50.348		17.15	6
	ATOM ATOM	1642 1643	CE2	TYR			17.282	9.257	51.432		20.63	6
	ATOM	1644	CZ	TYR			17.013	7.927	51.455		20.24	6
	ATOM	1645	OH	TYR			17.330	7.134	52.548		22.60	8
25	ATOM	1646	N	MET			15.085	10.098	44.923		12.98	7
25	ATOM	1647	CA	MET			14.179	10.786	43.985		10.83	6
	ATOM	1648	C	MET			12.794	10.191	44.197		10.00	6
	ATOM	1649	Ö	MET			12.691	9.016	44.620		11.94	8
	ATOM	1650	CB	MET			14.581	10.675	42.492		12.31	6
30	ATOM	1651	CG	MET			15.728	11.611	42.190		13.70	6
-	ATOM	1652	SD	MET			15.997	11.530	40.390		15.78	16
	ATOM	1653	CE	MET			17.585	12.292	40.256	1.00	23.46	6
	ATOM	1654	N	SER			11.723	10.901	43.905	1.00	10.92	7
	ATOM	1655	CA	SER			10.357	10.422	44.042	1.00	9.76	6
35	MOTA	1656	C	SER	Α	222	9.586	10.751	42.758	1.00	12.04	6
	MOTA	1657	0	SER	Α	222	9.755	11.827	42.185	1.00	15.35	8
	MOTA	1658	CB	SER	Α	222	9.609	11.100	45.197	1.00	14.86	6
	MOTA	1659	OG	SER	Α	222	10.216	10.861	46.463	1.00	13.78	8
	MOTA	1660	N	GLY	Α	223	8.779	9.812	42.394	1.00	12.72	7
40	MOTA	1661	CA	GLY	A	223	7.819	10.014	41.264		15.17	6
	MOTA	1662	C	GLY	Α	223	7.505	8.657	40.630	1.00	10.31	6
	ATOM	1663	0	GLY	A	223	8.041	7.604	40.919	1.00	11.61	8
	MOTA	1664	N	THR	Α	224	6.499	8.863	39.717	1.00	10.35	7
	MOTA	1665	CA	THR			6.175	7.685	38.909	1.00	8.89	6
45	MOTA	1666	С	THR			7.383	7.335	38.027	1.00	9.98	6
	MOTA	1667	0	THR			7.487	6.168	37.607	1.00	9.81	8
	MOTA	1668	CB			224	4.920			1.00		6
	MOTA	1669		THR			5.026	8.958	37.216		11.03	8
	MOTA	1670	CG2	THR			3.671	7.909	38.950	1.00	9.27	6
50	ATOM	1671	N	SER			8.317	8.243	37.735		10.17	7
	ATOM	1672	CA	SER			9.552	7.955	37.067		11.35	6
	MOTA	1673	C	SER			10.427	6.946	37.830	1.00	8.09	6
	MOTA	1674	0	SER			11.258	6.285	37.163	1.00	8.80	8
	ATOM	1675	CB	SER			10.482	9.186	36.881		12.32	6
55	ATOM	1676	OG	SER			9.832	10.043	35.881		13.46	8
	MOTA	1677	N	MET			10.191	6.844	39.146	1.00	8.91	7
	ATOM	1678	CA	MET			10.978	5.898	39.914	1.00	9.87	6
	MOTA	1679	C	MET			10.277	4.558	40.071	1.00	8.01	6
	ATOM	1680	0_	MET			10.852	3.512	40.318		10.42	8
60	MOTA	1681	CB	MET			11.246	6.476	41.336		10.18	6
	MOTA	1682	CG	MET			12.310	7.569	41.381	1.00	9.98	6
	MOTA	1683	SD	MET			11.911	9.112	40.574		11.41	16
	ATOM	1684	CE	MET			13.090	8.930	39.205			6
	ATOM	1685	N	ALA			8.939	4.581	39.923	1.00	9.49	7
65	ATOM	1686	CA	ALA			8.136	3.349	40.019	1.00	9.59	6
	ATOM	1687	C	ALA			8.327	2.524	38.724	1.00	8.92	6
	MOTA	1688	0_	ALA			8.449	1.279	38.759	1.00	9.60	8
	MOTA	1689	CB	ALA	A	227	6.684	3.754	40.239	1.00	12.00	6

	ATOM	1690	N	SER	A 228	8.258	3.251	37.598	1.00	8.46	7
	MOTA	1691	CA		A 228	8.366	2.564	36.293	1.00	9.33	6
	ATOM	1692	C		A 228	9.597	1.685	36.177	1.00	9.11	6
	ATOM	1693	0		A 228	9.393	0.525	35.768	1.00	8.88	8
5	MOTA	1694	CB	SER	A 228	8.311	3.644	35.222	1.00	8.72	6
	ATOM	1695	OG	SER	A 228	8.326	3.035	33.893	1.00	8.59	8
	ATOM	1696	N		A 229	10.790	2.071	36.569	1.00	9.43	7
	ATOM	1697	CA	PRO	A 229	11.941	1.221	36.420	1.00	9.18	6
	ATOM	1698	C		A 229	11.901	-0.018	37.312	1.00	9.20	6
10	ATOM	1699	0	PRO	A 229	12.519	-1.041	37.077	1.00	10.50	8
	MOTA	1700	CB		A 229	13.198	2.065	36.744	1.00	10.68	6
	ATOM	1701	CG		A 229	12.614	3.303	37.459	1.00	10.44	6
	ATOM	1702	CD		A 229	11.196	3.448	36.832		10.93	6
	ATOM	1703	N		A 230	11.144	0.079	38.459	1.00	8.14	7
15	ATOM	1704	CA		A 230	10.984	-1.193	39.194	1.00	8.04	6
10	ATOM	1705	C		A 230	10.199	-2.229	38.398	1.00	8.61	6
	ATOM	1706	ō		A 230	10.502	-3.422	38.383		11.42	8
	ATOM	1707	CB		A 230	10.245	-0.952	40.567	1.00	8.82	6
	ATOM	1708	CG		A 230	11.092	-0.269	41.632	1.00	7.05	6
20	ATOM	1709			A 230	11.161	1.109	41.777	1.00	7.95	7
20	ATOM	1710			A 230	11.925	-0.847	42.579		10.46	6
	MOTA	1711			A 230	12.001	1.359	42.791		11.65	6
	ATOM	1712			A 230	12.464	0.188	43.283		10.70	7
	ATOM	1713	N		A 231	9.136	-1.757	37.702	1.00	9.27	7
25	ATOM	1714	CA		A 231	8.379	-2.623	36.808	1.00	9.26	6
25	ATOM	1715	C		A 231	9.199	-3.052	35.601	1.00	8.69	6
	ATOM	1716	0		A 231	9.159	-4.237	35.255	1.00	9.29	8
	ATOM	1717	CB		A 231	7.078	-1.927	36.389	1.00	8.06	6
	ATOM	1718			A 231	6.310	-2.873	35.444		12.86	6
2.0		1710			A 231 A 231	6.254	-1.603	37.646	1.00	9.44	6
30	ATOM	1719			A 231	9.967	-2.118	35.010	1.00	8.72	7
	ATOM		N					33.900	1.00	9.54	6
	ATOM	1721	CA		A 232	10.810	-2.548	34.291	1.00	9.30	6
	MOTA	1722	C		A 232	11.885	-3.530	33.567	1.00	9.44	8
2.5	ATOM	1723	0		A 232	12.173	-4.505	33.299		10.48	6
35	MOTA	1724	CB		A 232	11.466	-1.262				7
	MOTA	1725	N		A 233	12.382	-3.408	35.553	1.00	9.18	6
	ATOM	1726	CA		A 233	13.367	-4.396	36.019	1.00	9.95	
	MOTA	1727	C		A 233	12.770	-5.794	36.214	1.00	8.05	6 8
	ATOM	1728	0		A 233	13.315	-6.802	35.870	1.00	9.80	7
40	ATOM	1729	N		A 234	11.543	-5.846	36.799	1.00	8.56	
	ATOM	1730	CA		A 234	10.797	-7.116	36.861	1.00	9.22	6
	MOTA	1731	C		A 234	10.564	-7.685	35.452	1.00	8.93	6
	ATOM	1732	O		A 234	10.703	-8.869	35.257		11.08	8
	ATOM	1733	CB		A 234	9.502	-6.924	37.673		10.61	6
45	ATOM	1734	CG		A 234	8.527	-8.118	37.675		10.54	6
	ATOM	1735			A 234	9.338	-9.334	38.172		10.76	6
	ATOM	1736			A 234	7.332	-7.778	38.516		11.53	6
	MOTA	1737	N		A 235	10.192	-6.794	34.514	1.00		7
	ATOM	1738	CA		A 235	9.995	-7.321	33.159	1.00	9.02	6
50	ATOM	1739	C		A 235	11.282	-7.907	32.638	1.00	9.50	6
	ATOM	1740	0		A 235	11.236	-8.925	31.905	1.00	9.26	8
	ATOM	1741	CB		A 235	9.452	-6.193	32.283	1.00	8.43	6
	ATOM	1742	N		A 236	12.423	-7.302	32.983	1.00	9.58	7
	ATOM	1743	CA		A 236	13.686	-7.893	32.481		10.25	6
55	ATOM	1744	C		A 236	13.951	-9.229	33.200	1.00	9.83	6
	MOTA	1745	0		A 236	14.536	-10.134	32.561		11.26	8
	ATOM	1746	CB		A 236	14.866	-6.960	32.777		11.37	6
	ATOM	1747	N		A 237	13.560	-9.388	34.455		10.12	7
	ATOM	1748	CA		A 237	13.759	-10.691	35.102		11.28	6
60	ATOM	1749	С		A 237		-11.749	34.387		11.62	6
	MOTA	1750	0		A 237		-12.838	34.062		11.77	8
	MOTA	1751	CB		A 237		-10.615	36.577	1.00	9.89	6
	ATOM	1752	CG		A 237	14.114	-9.812	37.528		10.68	6
	MOTA	1753			A 237	13.489	-9.905	38.936		10.83	6
65	MOTA	1754	CD2	LEU	A 237	15.587	-10.206	37.543		12.79	6
	ATOM	1755	N		A 238	11.724	-11.386	34.007		10.46	7
	MOTA	1756	CA		A 238		-12.313	33.258	1.00	10.34	6
	MOTA	1757	C	LEU	A 238	11.442	-12.561	31.856	1.00	11.39	6

	ATOM	1758	0	LEU	A	238	11.368	-13.727	31.401	1.00	11.82	8
	ATOM	1759	CB	LEU	A	238	9.446	-11.747	33.253	1.00	11.04	6
	ATOM	1760	CG	LEU	Α	238	8.748	-11.652	34.596	1.00	9.18	6
	ATOM	1761	CD1	LEU	A	238	7.624	-10.610	34.653		13.12	6
5	ATOM	1762	CD2	LEU				-13.037	34.992		14.13	6
	ATOM	1763	N	ALA	Α	239		-11.570	31.187		11.41	7
	ATOM	1764	CA	ALA	A	239		-11.834	29.836		11.12	6
	ATOM	1765	C	ALA				-12.810	29.917		13.22	6
	MOTA	1766	0	ALA				-13.584	28.964		14.69	8
10	ATOM	1767	CB	ALA				-10.507	29.271		11.43	6
	MOTA	1768	N	SER				-12.833	31.034		10.04	7
	MOTA	1769	CA	SER				-13.706	31.190		11.57	6
	MOTA	1770	C	SER				-15.158	31.346		11.74	6
	MOTA	1771	0	SER				-16.007	31.212		17.10	8
15	ATOM	1772	CB	SER				-13.253	32.339		15.20	6 8
	MOTA	1773	OG	SER				-13.487	33.636		15.38	7
	ATOM	1774	N	GLN				-15.390	31.539		12.24	
	MOTA	1775	CA	GLN				-16.765	31.686		13.26	6
	ATOM	1776	C	GLN				-17.298	30.311		16.69	6
20	ATOM	1777	0	GLN				-18.381	30.257		17.39	8
	ATOM	1778	CB	GLN				-16.794	32.671		12.49	6
	ATOM	1779	CG	GLN				-16.408	34.116		14.22	6
	ATOM	1780	CD	GLN				-16.351	34.927		14.64	6
	ATOM	1781	OE1	GLN				-15.569	34.925		15.36	8
25	ATOM	1782	NE2	GLN				-17.409	35.756		14.32	7 7
	ATOM	1783	N	GLY				-16.404	29.347		16.05	
	ATOM	1784	CA	GLY				-16.812	27.982		17.81	6
	MOTA	1785	C	GLY				-16.549	27.658		18.23	6
	ATOM	1786	0	GLY				-17.054	26.710		19.39	8
30	ATOM	1787	N	LYS				-15.778	28.476		15.28	7
	ATOM	1788	CA	LYS				-15.458	28.344		12.91	6
	ATOM	1789	C	LYS				-14.336	27.290		13.52	6
	MOTA	1790	0	LYS				-13.408	27.296		16.08	8
	ATOM	1791	CB	LYS				-14.995	29.664		15.99	6
35	ATOM	1792	CG	LYS				-16.185	30.633		16.79	6
	ATOM	1793	$^{\rm CD}$	LYS				-15.687	32.070		21.08	6
	MOTA	1794	CE	LYS				-17.016	32.871		25.90	6
	MOTA	1795	NZ	LYS				-16.829	34.309		25.09	7
	MOTA	1796	N	ASN				-14.396	26.458		12.59	7
40	ATOM	1797	CA	ASN				-13.360	25.428		12.14	6
	ATOM	1798	С	ASN				-12.172	26.019		12.86	6
	MOTA	1799	0	ASN				-12.195	27.204		12.30	8
	ATOM	1800	CB	ASN				-13.969	24.225		11.92	6
	ATOM	1801	CG	ASN				-14.363	24.487		14.11	6
45	ATOM	1802		ASN				-13.891	25.246		14.17	8 7
	MOTA	1803		ASN				-15.450	23.740		25.93	7
	ATOM			ASN				-11.158	25.223		11.75 12.32	6
	MOTA	1805	CA	ASN			6.231		25.803			
	MOTA	1806	C	ASN			4.838		26.373		11.73	6
50	MOTA	1807	0	ASN			4.488	-9.607	27.389		11.85	8
	MOTA	1808	CB	ASN			6.266	-8.706	24.917	1.00	9.82	6
	ATOM	1809	CG	ASN			5.639	-8.895	23.503		11.05	6 8
	ATOM	1810		ASN			5.182	-9.975	23.141		12.49	7
	MOTA	1811		ASN			5.668	-7.759	22.832		11.22	
55	MOTA	1812	N	VAL				-10.938	25.608		12.28	7
	MOTA	1813	CA	VAL				-11.231	26.102		11.50	6
	MOTA	1814	C	VAL				-11.932	27.464		12.02	6
	MOTA	1815	0	VAL				-11.541	28.399		13.42	8
	MOTA	1816	CB	VAL				-12.088	25.084		13.60	6
60	MOTA	1817		VAL				-12.527	25.579		17.63	6
	MOTA	1818		VAL				-11.266	23.802		15.00	6
	MOTA	1819	N	GLN				-12.913	27.577		13.17	7
	MOTA	1820	CA	GLN				-13.682	28.797		12.37	6
	MOTA	1821	С			247		-12.767	29.958		13.38	6
65	MOTA	1822	0	GLN				-12.922	31.081		13.69	8
	MOTA	1823	CB			247		-14.778	28.529		14.20	6
	MOTA	1824	CG			247		-15.911	27.719		16.06	6
	ATOM	1825	CD	GLN	A	247	5.269	-16.941	27.390	1.00	19.34	6

	ATOM	1826	OF1	GLN A	247	6 402	-16.706	27.042	1.00 1	6.30	8
	ATOM	1827	NE2	GLN A			-18.224	27.535	1.00 3		7
	ATOM	1828	NEZ	ILE A			-11.937	29.616	1.00 1		7
		1829	CA	ILE A			-10.997	30.646		9.94	6
E	ATOM ATOM	1830	C	ILE A			-10.099	31.209	1.00 1		6
5		1831		ILE A		4.620	-9.931	32.436	1.00 1		8
	ATOM		O			6.992	-10.169	30.002		9.93	6
	ATOM	1832	CB	ILE A					1.00 1		6
	ATOM	1833		ILE A			-11.067	29.687			6
	ATOM	1834	CG2	ILE A		7.433	-9.060	30.990	1.00 1		
10	ATOM	1835		ILE A		9.257		28.894	1.00 1		6
	ATOM	1836	N	ARG A		4.049	-9.408	30.310	1.00 1		7
	ATOM	1837	$^{\rm CA}$	ARG A		3.025	-8.484	30.767	1.00 1		6
	MOTA	1838	C	ARG A		1.907	-9.207	31.499	1.00 1		6
	ATOM	1839	0	ARG A	249	1.515	-8.692	32.585	1.00 1		8
15	MOTA	1840	CB	ARG A	249	2.523	-7.745	29.486	1.00 1		6
	ATOM	1841	CG	ARG A	249	1.422	-6.790	30.009	1.00 1	4.83	6
	MOTA	1842	$^{\rm CD}$	ARG A	249	0.941	-5.857	28.893	1.00 1	1.70	6
	ATOM	1843	NE	ARG A	249	0.026	-4.852	29.485	1.00 13	2.16	7
	ATOM	1844	CZ	ARG A	249	-0.233	-3.681	28.909	1.00 1	7.32	6
20	MOTA	1845	NH1	ARG A	249	0.242	-3.351	27.697	1.00 1	2.81	7
	ATOM	1846	NH2	ARG A	249	-1.008	-2.825	29.582	1.00 1	7.64	7
	ATOM	1847	N	GLN A	250	1.444	-10.388	31.087	1.00 13	2.08	7
	ATOM	1848	CA	GLN A			-11.146	31.801	1.00 1	2.15	6
	ATOM	1849	C	GLN A			-11.527	33.183	1.00 1		6
25	ATOM	1850	Ö	GLN A			-11.410	34.154	1.00 1		8
23	ATOM	1851	СВ	GLN A			-12.401	30.982	1.00 1		6
	ATOM	1852	CG	GLN A			-13.177	31.520	1.00 2		6
	ATOM	1853	CD	GLN A			-14.042	30.351	1.00 3		6
	ATOM	1854		GLN A			-14.231	29.379	1.00 4		8
30	ATOM	1855	NE2	GLN A			-14.525	30.453	1.00 4		7
30				ALA A			-11.906	33.278	1.00 1		7
	ATOM	1856	N								6
	ATOM	1857	CA	ALA A			-12.323	34.620	1.00 1		
	MOTA	1858	C	ALA A			-11.135	35.535	1.00 1		6
	ATOM	1859	0	ALA A			-11.212	36.717	1.00 1		8
35	MOTA	1860	CB	ALA A		4.077		34.470	1.00 1		6
	ATOM	1861	N	ILE A		3.171		35.045	1.00 1		7
	ATOM	1862	CA	ILE A		3.233	-8.795	35.947	1.00 1		6
	MOTA	1863	C	ILE A		1.845	-8.365	36.406	1.00 1		6
	MOTA	1864	0	ILE A	1 252	1.633	-8.028	37.616	1.00 1		8
40	ATOM	1865	CB	ILE A	A 252	3.878	-7.669	35.112	1.00 1	2.15	6
	MOTA	1866	CG1	ILE A	252	5.396	-7.885	34.981	1.00 1	1.82	6
	MOTA	1867	CG2	ILE A	252	3.648	-6.337	35.843	1.00 1	3.44	6
	MOTA	1868	CD1	ILE A	252	6.044	-6.969	33.949	1.00 1	3.14	6
	MOTA	1869	N	GLU A	4 253	0.879	-8.376	35.492	1.00 1	2.32	7
45	MOTA	1870	CA	GLU A	253	-0.446	-7.831	35.833	1.00 1	3.24	6
	ATOM	1871	C	GLU A	253	-1.237	-8.841	36.640	1.00 1	2.78	6
	ATOM	1872	0	GLU A	253	-1.895	-8.507	37.621	1.00 1	5.59	8
	ATOM	1873	CB	GLU Z		-1.189		34.507	1.00 1	1.47	6
	ATOM	1874	CG	GLU Z		-0.638		33.908	1.00 1		6
50	ATOM	1875	CD	GLU Z		-1.256		32.527	1.00 1		6
50	ATOM	1876		GLU A		-1.899		31.926	1.00 1		8
	ATOM	1877		GLU Z		-1.005		32.206	1.00 1		8
	ATOM	1878	N		A 254		-10.134	36.212	1.00 1		7
	ATOM	1879	CA		A 254		-11.122	36.842	1.00 1		6
~ ~							-11.501	38.222	1.00 1		6
55	MOTA	1880	C		A 254						0
	ATOM	1881	0		A 254		-11.966	39.024	1.00 1		8
	ATOM	1882	CB		A 254		-12.364	35.966	1.00 1		6
	ATOM	1883	CG		A 254		-12.159	34.651	1.00 1		6
	ATOM	1884	CD		A 254		-11.906	34.885	1.00 1		6
60	ATOM	1885		GLN Z			-12.665	35.520	1.00 1		8
	ATOM	1886	NE2	GLN A	A 254	-4.734	-10.738	34.346	1.00 1	9.67	7
	ATOM	1887	N	THR I	A 255	-0.340	-11.323	38.570	1.00 1	2.59	7
	ATOM	1888	CA	THR I	A 255	0.078	-11.666	39.938	1.00 1		6
	MOTA	1889	C	THR I	A 255	0.218	-10.480	40.876	1.00 1	1.92	6
65	ATOM	1890	0	THR I	A 255	0.652	-10.698	41.999	1.00 1	3.55	8
	ATOM	1891	CB		A 255		-12.367	39.919	1.00 1	1.55	6
	ATOM	1892		THR			-11.507	39.357	1.00 1		8
	ATOM	1893		THR			-13.635	39.054	1.00 1		6
								_	-		

	T TOM	1004	3.7	7 T 7	N 256	0 211	0 200	40.417	1.00 12.4	42 7
	ATOM	1894			A 256	-0.211	-9.309			
	ATOM	1895			A 256	0.004	-8.131	41.307	1.00 11.	
	ATOM	1896	C .	ALA A	A 256	-0.832	-8.313	42.563	1.00 13.3	
	MOTA	1897			A 256	-1.957	-8.835	42.505	1.00 15.4	40 8
5	ATOM	1898			A 256	-0.438	-6.931	40.502	1.00 13.0	
5										
	MOTA	1899			A 257	-0.266	-7.824	43.683	1.00 10.8	
	ATOM	1900	CA .	ASP .	A 257	-1.023	-7.893	44.954	1.00 11.3	
	MOTA	1901	С.	ASP .	A 257	-2.151	-6.879	44.921	1.00 12.0	69 6
	ATOM	1902			A 257	-1.949	-5.658	44.672	1.00 12.3	
						-0.048	-7.519	46.064	1.00 12.0	
10	MOTA	1903			A 257					
	MOTA	1904	CG .	ASP A	A 257	0.966	-8.615	46.339	1.00 14.3	
	ATOM	1905	OD1 .	ASP .	A 257	0.623	-9.774	46.083	1.00 17.	70 8
	ATOM	1906	OD2	ASP	A 257	2.038	-8.290	46.893	1.00 18.3	13 8
		1907			A 258	-3.323	-7.323	45.341	1.00 12.	
	ATOM									
15	MOTA	1908			A 258	-4.489	-6.445	45.358	1.00 13.	
	MOTA	1909	C	LYS .	A 258	-4.583	-5.594	46.592	1.00 14.4	
	ATOM	1910	0	LYS .	A 258	-5.543	-5.711	47.389	1.00 16.2	26 8
	ATOM	1911			A 258	-5.790	-7.213	45.052	1.00 17.8	
	MOTA	1912			A 258	-5.563	-7.937	43.706	1.00 22.	
20	MOTA	1913	CD	LYS .	A 258	-6.836	-8.271	42.954	1.00 27.	
	ATOM	1914	CE	LYS .	A 258	-6.527	-9.082	41.707	1.00 24.	57 6
	MOTA	1915			A 258	-5.879	-8.283	40.605	1.00 25.3	
	ATOM	1916			A 259	-3.678	-4.648	46.756	1.00 15.	
	MOTA	1917			A 259	-3.576	-3.775	47.898	1.00 13.	
25	MOTA	1918	C	ILE .	A 259	-4.677	-2.717	47.867	1.00 13.0	04 6
	ATOM	1919		TIE	A 259	-5.360	-2.579	46.845	1.00 12.0	63 8
					A 259	-2.175	-3.096	47.981	1.00 14.	
	ATOM	1920								
	MOTA	1921	CG1	ILE .	A 259	-1.974	-2.187	46.764	1.00 14.	
	ATOM	1922	CG2	ILE .	A 259	-1.086	-4.132	48.153	1.00 13.	52 6
30	ATOM	1923	CD1	TLE	A 259	-0.796	-1.246	46.901	1.00 14.3	29 6
50						-4.840	-1.987	48.985	1.00 13.0	
	ATOM	1924			A 260					
	ATOM	1925			A 260	-5.820	-0.905	48.928	1.00 13.	
	ATOM	1926	C	SER .	A 260	-5.545	0.022	47.760	1.00 14.8	
	ATOM	1927			A 260	-4.392	0.338	47.415	1.00 15.3	35 8
2.5						-5.652	-0.158	50.271	1.00 23.4	
35	MOTA	1928			A 260					
	ATOM	1929	OG	SER .	A 260	-6.523	0.961	50.264	1.00 32.	
	ATOM	1930	N	GLY .	A 261	-6.615	0.415	47.065	1.00 14.	79 7
	ATOM	1931	CA	GLY	A 261	-6.451	1.204	45.853	1.00 15.	91 6
	ATOM	1932			A 261	-6.756	0.360	44.617	1.00 12.	
40	ATOM	1933			A 261	-6.863	0.965	43.534	1.00 12.	
	ATOM	1934	N	THR .	A 262	-6.655	-0.924	44.705	1.00 12.4	44 7
	ATOM	1935	CA	THR	A 262	-6.915	-1.796	43.537	1.00 10.	57 6
	ATOM	1936			A 262	-8.331	-1.542	43.030	1.00 13.	90 6
								43.819	1.00 15.	
	ATOM	1937			A 262	-9.301	-1.632			
45	MOTA	1938			A 262	-6.699	-3.286	43.840	1.00 13.	
	ATOM	1939	OG1	THR	A 262	-5.331	-3.420	44.229	1.00 14.	15 8
	MOTA	1940	CG2	THR	A 262	-6.959	-4.137	42.617	1.00 16.	51 6
	ATOM	1941			A 263	-8.396	-1.179	41.747	1.00 11.	
									1.00 12.	
	MOTA	1942			A 263	-9.735	-0.902	41.152		
50	ATOM	1943	С	GLY	A 263	-10.071	0.568	41.158	1.00 11.	46 6
	MOTA	1944	0	GLY	A 263	-10.990	1.093	40.464	1.00 14.	08 8
	ATOM	1945			A 264	-9.309	1.422	41.872	1.00 10.	76 7
	MOTA	1946			A 264	-9.488	2.859	41.933	1.00 10.	
	ATOM	1947	C	THR	A 264	-8.266	3.602	41.401	1.00 11.	
55	ATOM	1948	0	THR	A 264	-8.356	4.471	40.518	1.00 13.	25 8
	ATOM	1949			A 264	-9.810	3.214	43.400	0.50 13.	
									0.50 13.	
	ATOM	1950			A 264	-10.941	2.511	43.897		
	MOTA	1951	CG2A	THR	A 264	-9.919	4.711	43.436	0.50 8.	
	ATOM	1952	CB B	THR	A 264	-9.844	3.467	43.308	0.50 11.	69 6
60	ATOM	1953			A 264	-8.956	2.998	44.344	0.50 11.	
00								43.724	0.50 10.	
	MOTA	1954			A 264	-11.253	3.162			
	MOTA	1955			A 265	-7.080	3.363	42.000	1.00 10.	
	MOTA	1956	CA	ASN	A 265	-5.841	4.057	41.612	1.00 10.	
	ATOM	1957			A 265	-5.059	3.298	40.573	1.00 11.	
6=	ATOM	1958			A 265	-4.186	3.892	39.906	1.00 11.	
65										
	MOTA	1959			A 265	-4.983	4.241	42.859	1.00 11.	
	MOTA	1960	ÇG	ASN	A 265	-5.590	5.258	43.826	1.00 12.	28 6
	MOTA	1961	OD1	ASN	A 265	-6.418	6.059	43.416	1.00 15.	68 8
						- · - -				

	7 MOM	1060	MIDO	A CAT	7.	265	-5.153	E 175	45.083	1 00	16.82	7
	ATOM	1962		ASN				5.175				
	ATOM	1963	N	PHE			-5.368	2.029	40.370		12.07	7
	ATOM	1964	ca	$_{ m PHE}$	Α	266	-4.728	1.230	39.337	1.00	13.47	6
	MOTA	1965	C	PHE	Α	266	-5.576	-0.003	39.144	1.00	11.98	6
5	ATOM	1966	Ō	PHE			-6.414	-0.342	40.025	1.00	13.68	8
5												
	ATOM	1967	CB	PHE			-3.273	0.833	39.743	1.00	11.51	6
	MOTA	1968	CG	$_{ m PHE}$	A	266	-3.191	0.624	41.228	1.00	10.99	6
	MOTA	1969	CD1	PHE	Α	266	-2.709	1.603	42.034	1.00	12.36	6
	ATOM	1970	CD2	PHE			-3.617	-0.589	41.768	1.00	12.87	6
10										1.00	15.18	6
10	MOTA	1971	CE1	PHE			-2.646	1.489	43.437			
	MOTA	1972	CE2	PHE	A	266	-3.548	-0.720	43.157	1.00	13.50	6
	MOTA	1973	CZ	$_{ m PHE}$	A	266	-3.086	0.299	43.954	1.00	13.91	6
	MOTA	1974	N	LYS	Δ	267	-5.481	-0.713	38.018	1.00	10.86	7
			CA	LYS			-6.372	-1.827	37.757	1.00		6
	ATOM	1975										
15	MOTA	1976	C	LYS			-5.996	-3.143	38.415	1.00	11.29	6
	ATOM	1977	0	LYS	Α	267	-6.827	-3.835	39.018	1.00	14.13	8
	MOTA	1978	CB	LYS	Α	267	-6.427	-2.056	36.234	1.00	10.21	6
	ATOM	1979	CG	LYS			-7.269	-3.230	35.800	1.00	10.69	6
	MOTA	1980	CD	LYS			-7.434	-3.314	34.277	1.00	17.41	6
20	ATOM	1981	$^{ m CE}$	LYS	A	267	-8.125	-4.645	33.961	1.00	20.47	6
	MOTA	1982	NZ	LYS	Α	267	-9.590	-4.515	34.312	1.00	28.85	7
	ATOM	1983	N	TYR			-4.703	-3.507	38.377	1.00	10.94	7
												6
	MOTA	1984	CA	TYR			-4.306	-4.845	38.774	1.00		
	MOTA	1985	C	TYR	A	268	-3.780	-4.934	40.185	1.00	12.48	6
25	ATOM	1986	0	TYR	Α	268	-4.004	-5.966	40.828	1.00	14.47	8
	MOTA	1987	CB	TYR	Δ	268	-3.247	-5.379	37.737	1.00	11.99	6
	ATOM	1988	CG	TYR			-3.869	-5.582	36.354	1.00	12.59	6
	MOTA	1989	CD1	TYR			-4.729	-6.636	36.098	1.00		6
	ATOM	1990	CD2	TYR	Α	268	-3.567	-4.713	35.315	1.00	11.77	6
30	MOTA	1991	CE1	TYR	Α	268	-5.286	-6.819	34.836	1.00	16.83	6
	ATOM	1992	CE2	TYR			-4.127	-4.878	34.044	1.00	14.50	6
	MOTA	1993	CZ	TYR			-4.975	-5.940	33.842	1.00		6
	MOTA	1994	OH	TYR	Α	268	-5.578	-6.179	32.594	1.00	16.50	8
	MOTA	1995	N	GLY	A	269	-2.951	-3.959	40.589	1.00	11.21	7
35	MOTA	1996	CA	GLY			-2.363	-4.068	41.950	1.00	11.42	6
33										1.00		6
	MOTA	1997	C	GLY			-0.884	-3.640	41.935			
	MOTA	1998	0	\mathtt{GLY}	Α	269	-0.410	-2.979	40.981	1.00	12.33	8
	ATOM	1999	N	LYS	Α	270	-0.250	-3.975	43.039	1.00	10.84	7
	MOTA	2000	CA	LYS	Δ	270	1.158	-3.689	43.298	1.00	10.02	6
4.0	ATOM		C	LYS			1.989	-4.849	42.786	1.00	10.57	6
40		2001										
	ATOM	2002	0	LYS			1.759	-6.030	43.116	1.00	10.24	8
	ATOM	2003	CB	LYS	Α	270	1.355	-3.550	44.835	1.00	9.80	6
	ATOM	2004	CG	LYS	Α	270	2.838	-3.440	45.234	1.00	10.47	6
	ATOM	2005	CD	LYS			2.766	-3.574	46.792	1.00	13.93	6
45	MOTA	2006	CE	LYS			4.141	-3.882	47.323	1.00	13.15	6
	MOTA	2007	NZ	LYS	Α	270	4.141	-4.146	48.814	1.00	12.38	7
	ATOM	2008	N	ILE	Α	271	3.068	-4.553	41.981	1.00	9.21	7
	ATOM	2009	CA	ILE	Δ	271	3.827	-5.684	41.486	1.00	10.54	6
	ATOM	2010	C				4.345	-6.567	42.615	1.00		6
				ILE								
50	MOTA	2011	0	ILE	Α	271	4.722	-6.097	43.676	1.00	10.76	8
	MOTA	2012	CB	ILE	A	271	5.015	-5.309	40.579	1.00	9.40	6
	MOTA	2013	CG1	ILE	А	271	5.942	-4.342	41.302	1.00	10.70	6
	ATOM	2014	CG2	ILE			4.462	-4.651	39.299		12.37	6
												-
	ATOM	2015	CD1				7.353	-4.230	40.661	1.00	11.12	6
55	ATOM	2016	N	ASN	Α	272	4.358	-7.864	42.304	1.00	11.32	7
	MOTA	2017	CA	ASN	Α	272	4.927	-8.895	43.187	1.00	11.90	6
	ATOM	2018	C	ASN			5.887	-9.781	42.379	1.00		6
	MOTA	2019	0	ASN			5.512	-10.582	41.534	1.00		8
	ATOM	2020	CB	ASN			3.791	-9.719	43.774	1.00	10.81	6
60	MOTA	2021	CG	ASN	Α	272	4.423	-10.703	44.785	1.00	13.73	6
	ATOM	2022		ASN				-11.324	44.563	1.00		8
			255	7 (7)7	7	272		-10.772	45.915		15.82	7
	ATOM	2023		ASN								
	MOTA	2024	N	SER			7.192	-9.406	42.462	1.00	11.18	7
	ATOM	2025	ca	SER	A	273	8.176	-10.054	41.573	1.00	9.11	6
65	ATOM	2026	C	SER			8.243	-11.575	41.796	1.00	10.89	6
	ATOM	2027	Ö	SER			8.463	-12.256	40.830	1.00	11.77	8
	MOTA	2028	CB	SER			9.575	-9.501	41.899		12.03	6
	MOTA	2029	OG	SER	A	273	9.574	-8.068	41.685	1.00	11.29	8

	ATOM	2030	N	ASN	Δ	274	8 098	-11.968	43.092	1.00	11.68	7
	ATOM	2031	CA	ASN				-13.417	43.328	1.00		6
	ATOM	2032	C	ASN			7.075	-14.195	42.716		11.54	6
							7.388	-15.228	42.085		14.09	8
_	ATOM	2033	O	ASN							13.98	6
5	ATOM	2034	CB	ASN			8.376		44.846			
	MOTA	2035	CG	ASN				-15.149	45.061	1.00		6
	ATOM	2036		ASN			9.757	-15.640	44.474	1.00		8
	MOTA	2037	ND2	ASN	Α	274	8.018	-15.690	45.988	1.00	19.49	7
	MOTA	2038	N	LYS	Α	275	5.882	-13.699	42.841	1.00	12.00	7
10	MOTA	2039	CA	LYS	Α	275	4.726	-14.366	42.195	1.00	11.46	6
	ATOM	2040	C	LYS	Α	275	4.874	-14.299	40.667	1.00	12.56	6
	ATOM	2041	Ó	LYS			4.574	-15.288	40.002	1.00	12.54	8
	ATOM	2042	CB	LYS			3.383	-13.896	42.682	1.00		6
	ATOM	2042	CG	LYS			3.025	-13.902	44.182	1.00		6
- ·				LYS			1.573	-13.451	44.400	1.00		6
15	ATOM	2044	CD									
	ATOM	2045	CE	LYS			1.152	-12.015	44.481	1.00	28.84	6
	MOTA	2046	NZ	LYS			-0.267	-11.496	44.363		26.58	7
	MOTA	2047	N	ALA			5.310	-13.118	40.185		12.51	7
	MOTA	2048	CA	ALA	Α	276	5.385	-13.059	38.706	1.00	10.12	6
20	ATOM	2049	C	ALA	Α	276	6.375	-14.014	38.107	1.00	10.25	6
	ATOM	2050	0	ALA	Α	276	6.048	-14.635	37.070	1.00	10.48	8
	ATOM	2051.	CB	ALA	Α	276	5.743	-11.617	38.304	1.00	11.31	6
	ATOM	2052	N	VAL			7.553	-14.226	38.736	1.00	11.74	7
	ATOM	2053	CA	VAL				-15.041	38.026	1.00		6
25	ATOM	2054	C	VAL			8.167		38.194		14.27	6
25				VAL			8.780	-17.298	37.504	1.00		8
	ATOM	2055	O					-14.842				
	ATOM	2056	CB	VAL			9.970		38.526		12.43	6
	ATOM	2057		VAL				-13.425	38.246		12.15	6
	ATOM	2058	CG2	VAL			10.184	-15.151	40.012	1.00		6
30	MOTA	2059	N	ARG	Α	278	7.190	-16.809	39.071	1.00	12.39	7
	MOTA	2060	$^{\rm CA}$	ARG	Α	278	6.784	-18.223	39.175	1.00	15.11	6
	MOTA	2061	C	ARG	Α	278	5.497	-18.504	38.446	1.00	16.59	6
	ATOM	2062	0	ARG	Α	278	5.089	-19.689	38.350	1.00	20.78	8
	ATOM	2063	CB	ARG			6.542	-18.587	40.655	1.00	15.94	6
35	ATOM	2064	CG	ARG				-18.422	41.383		17.42	6
33	ATOM	2065	CD	ARG			7.595	-18.572	42.905		15.96	6
		2066	NE	ARG				-18.230	43.559		19.66	7
	ATOM											6
	ATOM	2067	CZ	ARG			9.900	-18.901	43.897	1.00		
	ATOM	2068					9.966	-20.223	43.611	1.00	23.93	7
40	MOTA	2069	NH2	ARG			10.918	-18.305	44.529	1.00		7
	MOTA	2070	N			279	4.913	-17.490	37.831	1.00		7
	ATOM	2071	CA	TYR	Α	279	3.644	-17.626	37.129	1.00		6
	ATOM	2072	C	TYR	Α	279	3.850	-18.378	35.829	1.00		6
	ATOM	2073	0	TYR	Α	279	4.901	-18.165	35.189	1.00	24.68	8
45	MOTA	2074	CB	TYR	Α	279	3.005	-16.277	36.932	1.00	13.65	6
	ATOM	2075	CG	TYR	Α	279	1.693	-16.105	36.231	1.00	13.86	6
	ATOM	2076	CD1	TYR			0.452	-16.189	36.858		14.68	6
	ATOM	2077		TYR				-15.872	34.847		15.48	6
	ATOM	2078	CE1	TYR				-16.037	36.103		15.73	6
-0		2079	CE2				0.575	-15.702	34.121		14.88	6
50	ATOM			TYR							15.75	
	ATOM	2080	CZ			279	-0.652		34.740			6
	MOTA	2081	ОН			279	-1.834	-15.612	34.089		17.03	8
	MOTA	2082	OT			279	3.000	-19.258	35.525		24.50	8
	MOTA	2083	C1	${ m GLL}$	Α	296	-3.949	0.135	29.717	1.00	17.61	6
55	MOTA	2084	C2	${\tt GLL}$	Α	296	-4.024	1.580	29.221	1.00	16.18	6
	ATOM	2085	C3	GLL	Α	296	-5.461	2.100	29.213	1.00	18.89	6
	MOTA	2086	01			296	-2.578	-0.308	29.529	1.00	15.42	8
	ATOM	2087	02			296	-3.163	2.400	30.001		15.61	8
	ATOM	2088	03			296	-5.525	3.473	28.806		23.45	8
60	MOTA	2089		WAT		1	25.973	-1.842	43.443		11.05	20
60												
	ATOM		CA	WAT		2	25.647	13.399	23.751		17.24	20
	ATOM	2091		TAW		3	-1.258	1.535	28.929		12.14	11
	MOTA	2092		WAT		4	16.838	2.112	43.195	1.00	9.07	8
	MOTA	2093		WAT		5	13.085	6.361	31.187		10.24	8
65	MOTA	2094				6	18.887	0.537	42.447		10.28	8
	MOTA	2095	OWO	TAW	W	7	14.445	5.591	39.775	1.00	10.40	8
	MOTA	2096	OWO	WAT	W	8	14.210	1.611	47.107	1.00	10.59	8
	MOTA	2097		WAT		9	14.918	3.839	48.721	1.00	10.61	8

10.698 -1.779 53.649 1.00 10.77 MOTA 2098 OWO WAT W 10 5.117 1.00 10.86 8 40.655 MOTA 2099 W TAW OWO 11 -1.751 MOTA 0.687 44.697 1.00 10.99 8 2100 W TAW OWO 12 14.945 1.00 11.25 42.978 -0.327 4.307 8 MOTA 2101 W TAW 0WO 13 1.00 11.76 W TAW OWO 4.023 -3.345 27.168 5 ATOM 2102 14 39.822 1.00 11.88 8 ATOM 2103 W TAW OWO 15 3.256 -8.810 OWO WAT W 18.664 7.646 28.905 1.00 12.48 8 2104 16 MOTA 1.00 12.57 2105 TAW OWO W 17 29.275 -1.039 37.125 8 ATOM 20.255 10.140 -1.402 5.723 11.383 32.574 6.840 4.270 16.914 25.377 16.613 3.879 11.580 8.559 31.655 20.255 15.290 29.790 1.00 12.74 W TAW OWO 2106 18 ATOM 2107 OWO WAT W 19 -8.862 25.520 1.00 12.92 8 10 ATOM 0.794 22.084 W TAW OWO 1.00 13.07 8 2108 20 MOTA -0.410 49.244 1.00 13.11 8 MOTA 2109 OWO WAT W 21 1.00 13.37 49.015 11.383 -11.545 8 MOTA 2110 W TAW OWO 22 1.00 13.78 OWO WAT W 23 -0.530 38.835 8 MOTA 2111 14.824 1.00 13.94 15 ATOM 2112 W TAW OWO 24 6.391 8 -7.073 W TAW OWO 25 46.186 1.00 14.15 MOTA 2113 -1.439 1.00 14.17 W TAW OWO 26 53.452 R MOTA 2114 1.00 14.66 W TAW OWO 27 -6.748 38.454 8 MOTA 2115 OWO WAT W 28 -9.407 30.953 1.00 14.93 8 MOTA 2116 7.957 -4.612 30.204 1.00 14.99 8 W TAW OWO 20 ATOM 2117 29 W TAW OWO 12.085 1.00 15.06 8 MOTA 2118 30 8.55.
31.655 -2.825
5.355 5.671 1:
14.542 5.167 1
15.681 2.641 1
22.959 -5.924 5
17.792 -7.760 2
-5.745 -0.511 3
8.911 8.038 1
0.345 -4.964 1
11.031 -11.431 1
2 13.079 5.575
3 9.891 -5.124
4 5.686 -8.148
5 25.251 13.768
-0.436 1.365
-7.9.577 -3.555
18 30.018 9.014
19 15.370 -7.155
50 20.118 20.536
51 23.269 -5.467
52 18.707 -18.348
53 29.237 2.519
54 -2.442 2.172
55 19.933 -4.327
56 34.473 -1.581
57 12.821 11.824
58 11.503 7.499
59 23.684 -1.037
60 -0.612 -3.323
61 17.007 14.116
62 -0.273 -9.571
63 -1.316 -4.375
64 25.755 -8.111
65 -3.039 -2.281
66 14.409 -8.63
67 -3.784 -5.57
28.701 0.91 22.717 1.00 15.31 8.559 -11.110 MOTA 2119 W TAW OWO 31 8 -2.825 39.954 1.00 15.39 MOTA 2120 OWO WAT W 32 12.382 1.00 15.85 R MOTA 2121 W TAW OWO 25 ATOM 2122 W TAW OWO 15.017 1.00 15.88 1.00 16.11 MOTA 2123 W TAW OWO 14.612 8 W TAW OWO 55.817 1.00 16.14 MOTA 2124 MOTA 2125 W TAW OWO 24.674 1.00 16.20 R 2126 OWO WAT W 32.819 1.00 16.38 8 MOTA 1.00 16.56 2127 W TAW OWO 13.921 8 30 ATOM 25.288 1.00 16.65 8 2128 W TAW OWO MOTA 25.798 1.00 16.84 MOTA 2129 OWO WAT W 1.00 17.00 8 51.582 MOTA 2130 OWO WAT W 1.00 17.04 MOTA 2131 W TAW OWO 53.560 8 1.00 17.09 35 ATOM 2132 OWO WAT W 48.229 8 1.00 17.19 2133 W TAW OWO 26.180 ATOM 1.00 17.45 2134 W TAW OWO 15.687 R ATOM W TAW OWO 38.689 1.00 17.51 8 2135 MOTA 2136 W TAW OWO 37.735 1.00 18.20 8 MOTA 1.00 18.50 29.434 8 40 ATOM 2137 W TAW OWO W TAW OWO 34.111 1.00 18.97 MOTA 2138 51.272 1.00 19.01 8 MOTA 2139 W TAW OWO 1.00 19.39 MOTA 2140 OWO WAT W 45.501 1.00 19.62 48.044 MOTA 2141 W TAW OWO 8 2142 OWO WAT W 47.419 1.00 19.63 45 ATOM 22.737 1.00 19.76 MOTA 2143 W TAW 0WO 8 W TAW 0WO 37.164 1.00 19.96 8 MOTA 2144 1.00 20.13 MOTA 2145 W TAW OWO 47.078 8 1.00 20.21 W TAW OWO 13.241 8 MOTA 2146 W TAW OWO 20.633 1.00 20.22 50 ATOM 2147 1.00 20.28 W TAW OWO 51.692 8 MOTA 2148 MOTA 2149 W TAW OWO 44.269 1.00 20.65 1.00 20.67 27.817 MOTA 2150 OWO WAT W 8 MOTA W TAW 0WO 40.684 1.00 20.73 2151 1.00 20.89 55 ATOM 2152 W TAW OWO 33.313 R W TAW OWO 51.281 1.00 20.99 8 MOTA 2153 66 67 68 69 70 71 W TAW OWO 51.937 1.00 20.99 8 MOTA 2154 1.00 20.99 OWO WAT W 30.454 MOTA 2155 8 MOTA 2156 OWO WAT W 28.701 0.916 24.873 1.00 21.03 1.00 21.11 -2.298 60 ATOM 2157 W TAW OWO 4.090 45.230 2158 30.077 4.491 W TAW OWO 44.090 1.00 21.11 MOTA 6.907 -4.539 7.930 1.00 21.20 MOTA 2159 W TAW OWO 25.235 8 OWO WAT W 1.00 21.38 72 16.602 17.863 ATOM 2160 OWO WAT W 72 7.930 16.602
OWO WAT W 73 25.030 5.431
OWO WAT W 74 21.967 -14.316
OWO WAT W 75 2.376 -6.419
OWO WAT W 76 4.085 10.456
OWO WAT W 77 5.239 -12.232 8 1.00 21.46 MOTA 2161 18.766 1.00 21.78 49.321 8 65 ATOM 2162 MOTA 2163 49.074 1.00 21.92 1.00 22.11 48.716 MOTA 2164 8 MOTA 2165 48.334 1.00 22.25

	ATOM	2166	OMO	WAT	W	78	-4.190	-2.933	30.508	1.00	22.26	8
			OWO	WAT	W	79	8.378	5.587	51.200		22.44	8
	ATOM	2167							20.760		22.55	8
	MOTA	2168	OWO	TAW	W	80	12.983	-5.518				
	MOTA	2169		TAW	W	81	9.499	10.528	14.890		22.84	8
5	ATOM	2170	owo	\mathtt{TAW}	W	82	2.960	-17.253	40.993		23.00	8
	ATOM	2171	OWO	TAW	W	83	6.098	-15.849	34.785	1.00	23.11	8
	ATOM	2172	OWO	WAT	W	84	-9.765	-5.816	36.844	1.00	23.23	8
	ATOM	2173			W	85	17.165	-8.431	51.079	1.00	23.38	8
		2174	OWO	TAW	W	86	26.762	4.780	20.872		23.45	8
	ATOM						-3.582	-0.255	20.689		23.52	8
10	ATOM	2175	OWO		M	87						
	MOTA	2176		TAW	W	88	24.998	-0.493	54.746		23.60	8
	ATOM	2177	owo	\mathtt{TAW}	W	89	15.378	4.977	52.842		23.62	8
	MOTA	2178	OWO	TAW	W	90	-3.290	-9.213	32.314	1.00	23.62	8
	ATOM	2179	OWO	TAW	W	91	-1.217	9.980	21.173	1.00	23.69	8
15	ATOM	2180	OWO		W	92	-4.575	5.139	23.029	1.00	23.74	8
15					W	93	5.660	-20.272	33.874		23.86	8
	ATOM	2181	OWO									8
	MOTA	2182	OWO		W	94	2.570	-19.717	32.700		23.93	
	ATOM	2183	OWO	TAW	W	95	-2.768	8.489	18.967		24.13	8
	ATOM	2184	OWO	\mathtt{WAT}	W	96	-9.884	0.662	45.427	1.00	24.32	8
20	MOTA	2185	OWO	TAW	W	97	5.619	-4.476	51.362	1.00	24.37	8
	ATOM	2186	OWO		W	98	8.421	11.297	38.167	1.00	24.65	8
		2187	OWO		W	99	25.813	-8.535	52.635		24.70	8
	ATOM											8
	ATOM	2188	OWO			100	20.832	19.605	26.661		24.82	
	ATOM	2189	OWO		W	101	16.258	-9.256	21.262		24.86	8
25	ATOM	2190	OWO	TAW	W	102	12.349	13.826	43.372	1.00	24.89	8
	ATOM	2191	OWO	TAW	W	103	13.170	-19.745	35.451	1.00	24.90	8
	MOTA	2192	OWO	TAW	W	104	7.075	17.770	20.578	1.00	24.93	8
	MOTA	2193		TAW		105	22.242	-3.099	22.446		24.94	8
							2.596	-15.349	31.525		25.01	8
	ATOM	2194				106						
30	MOTA	2195	OWO		M	107	13.138	-13.432	26.305	1.00		8
	ATOM	2196	OWO	\mathtt{WAT}	W	108	27.906	13.991	24.255	1.00	25.14	8
	ATOM	2197	OWO	WAT	W	109	6.218	-4.057	14.703	1.00	25.22	8
	ATOM	2198	OWO	\mathtt{WAT}	W	110	10.505	12.665	32.677	1.00	25.29	8
	ATOM	2199	OWO	TAW		111	-3.781	-2.725	27.641	1.00	25.30	8
2.5					W	112	30.677	10.964	34.167		25.31	8
35	MOTA	2200									25.32	8
	MOTA	2201		TAW		113	17.661	-13.781	50.306			
	MOTA	2202			W	114	34.541	6.057	36.868		25.36	8
	ATOM	2203	OWO	\mathtt{WAT}	W	115	23.605	3.174	17.711	1.00	25.38	8
	MOTA	2204	OWO	WAT	W	116	17.497	-13.278	24.578	1.00	25.43	8
40	ATOM	2205	OWO	WAT	W	117	26.337	-11.225	48.970	1.00	25.54	8
-0	ATOM	2206	OWO	WAT		118	-5.239	13.734	29.361	1.00		8
	ATOM					119	-2.765	6.609	16.532		25.61	8
		2207			W							
	MOTA	2208		TAW		120	-0.782	-2.817	17.108		25.71	8
	ATOM	2209		\mathtt{WAT}	W	121	16.158	7.089	14.095	1.00		8
45	ATOM	2210	OWO	TAW	W	122	18.930	12.534	48.368	1.00	26.12	8
	MOTA	2211	OWO	TAW	W	123	24.403	-6.067	53.444	1.00	26.65	8
	ATOM	2212	OWO	WAT	W	124	-3.404	4.730	49.022	1.00	26.81	8
	ATOM	2213	OWO	TAW	W	125	32.619	10.296	29.183	1.00	26.88	8
	ATOM	2214	OWO				-6.804	14.466	42.289		27.19	8
							24.517	14.294	40.806		27.26	8
50	ATOM	2215		TAW								
	MOTA	2216		TAW			-4.697	17.443	41.250		27.26	8
	ATOM	2217	OWO	TAW	W	129	15.601	-5.581	15.252	1.00	27.49	8
	ATOM	2218	OWO	TAW	W	130	19.225	-7.757	52.854	1.00	27.55	8
	ATOM	2219		TAW			20.571	-7.244	23.187	1.00	27.79	8
55	ATOM	2220		WAT			-5.634	12.995	45.863		27.84	8
22								2.015	28.288		27.85	8
	MOTA	2221		TAW			29.455					
	MOTA	2222		TAW			35.253	6.005	33.542		27.91	8
	ATOM	2223	OWO	WAT	W	135	26.528	7.004	17.380	1.00	28.00	8
	ATOM	2224	OWO	TAW	W	136	4.802	-2.134	53.088	1.00	28.06	8
60	ATOM	2225		TAW			7.702	-19.316	35.292		28.29	8
30	ATOM	2226		WAT			33.637	-3.892	43.427		28.32	8
	MOTA	2227		WAT		139	-3.078	-11.204	41.616	1.00	28.34	8
	MOTA	2228		TAW			7.296	-11.855	20.394		28.39	8
	MOTA	2229	OWO	TAW	W	141	-8.355	14.458	38.156		28.47	8
65	ATOM	2230	OWO	WAT	W	142	-3.786	-10.077	45.809		28.51	8
	ATOM	2231		TAW			17.884	8.271	55.001	1.00	28.52	8
	ATOM	2232		WAT			-7.450	9.431	27.023		28.66	8
	ATOM	2233		WAT			25.034	10.848	14.171		28.68	8
	ATOI1		ONO	1177.1	**	T-E-2	25.054	10.010		~.00		-

	MOTA	2234	TAW 0WO	W 146	27.154	14.822	33.256	1.00 28.71	8
	ATOM	2235	TAW 0WO	W 147	3.930	14.554	35.353	1.00 28.86	8
	ATOM	2236	TAW 0WO	W 148	3.832	14.101	17.367	1.00 28.94	8
	ATOM	2237	TAW OWO	W 149	-7.141	6.522	26.433	1.00 28.95	8
5	ATOM	2238	TAW OWO		16.291	15.441	37.748	1.00 28.96	8
,	ATOM	2239		W 151	23.732	-13.472	32.813	1.00 29.06	8
		2240	OWO WAT		31.579	0.528	49.009	1.00 29.17	8
	ATOM				0.948	11.515	50.856	1.00 29.19	8
	ATOM	2241					24.104	1.00 29.61	8
	ATOM	2242	TAW OWO		20.562	20.238			8
10	ATOM	2243	TAW 0WO		14.815	22.549	27.658	1.00 29.72	
	ATOM	2244	TAW OWO		-0.505	13.461	15.844	1.00 29.79	8
	ATOM	2245	TAW 0WO	W 157	27.503	-7.381	36.814	1.00 29.90	8
	MOTA	2246	OWO WAT	W 158	31.766	-7.236	46.577	1.00 29.96	8
	ATOM	2247	OWO WAT	W 159	2.280	5.918	54.243	1.00 30.06	8
15	ATOM	2248	TAW 0WO	W 160	15.109	18.191	36.248	1.00 30.13	8
	ATOM	2249		W 161	4.637	-16.479	32.113	1.00 30.14	8
	ATOM	2250	TAW OWO		17.268	13.651	16.688	1.00 30.17	8
		2251		W 163	19.452	14.125	43.037	1.00 30.18	8
	ATOM				-4.171	13.696	26.886	1.00 30.24	8
	MOTA	2252	OWO WAT					1.00 30.24	8
20	MOTA	2253		W 165	14.909	-15.477	49.534		
	ATOM	2254	TAW 0WO		-8.602	11.318	30.557	1.00 30.42	8
	MOTA	2255		W 167			28.159	1.00 30.52	8
	MOTA	2256	TAW 0WO	W 168	26.601	10.511	46.969	1.00 30.58	8
	MOTA	2257	TAW 0WO	W 169	31.110	-8.170	41.359	1.00 30.61	8
25	MOTA	2258	TAW 0WO	W 170	29.593	8.135	46.349	1.00 30.72	8
	ATOM	2259	TAW 0WO	W 171	-10.368	-1.876	34.504	1.00 30.74	8
	ATOM	2260	TAW OWO	W 172	28.564	-4.100	29.544	1.00 30.83	8
	ATOM	2261	TAW OWO	W 173	-12.777	4.044	45.410	1.00 30.92	8
	ATOM	2262		W 174		-21.931	42.319	1.00 30.96	8
						-10.251	23.688	1.00 30.90	8
30	MOTA	2263		W 175				1.00 31.07	8
	MOTA	2264	TAW 0WO	W 176	0.113	-6.364	50.914		
	MOTA	2265	TAW 0WO	W 177	-3.585	3.671	16.785	1.00 31.12	8
	MOTA	2266	TAW OWO	W 178	4.754	-21.901	38.826	1.00 31.24	8
	MOTA	2267	TAW 0WO	W 179	3.124	-4.459	52.013	1.00 31.30	8
35	MOTA	2268	TAW 0WO	W 180	27.364	15.293	27.098	1.00 31.43	8
	ATOM	2269	TAW 0WO	W 181	19.204	-18.620	42.633	1.00 31.46	8
	ATOM	2270	TAW OWO	W 182	23.808	-11.495	40.059	1.00 31.53	8
	ATOM	2271		W 183	29.332	-1.923	29.953	1.00 31.57	8
	ATOM	2272		W 184	12.448	14.328	33.070	1.00 31.59	8
4.0	ATOM	2273		W 185	1.205	17.345	29.981	1.00 31.67	8
40					-9.791	7.997	34.844	1.00 31.75	8
	MOTA	2274	TAW OWO	W 186		18.408		1.00 31.75	8
	MOTA	2275		W 187	-7.837		38.069		8
	ATOM	2276	TAW OWO	W 188	11.140	-9.008	50.792	1.00 31.95	
	MOTA	2277		W 189	26.511	-2.526	54.760	1.00 32.13	8
45	ATOM	2278	TAW 0WO	W 190	23.093	-7.348	24.192	1.00 32.27	8
	ATOM	2279	TAW 0WO	W 191	-10.284	6.288	39.379	1.00 32.43	8
	MOTA	2280	TAW 0WO	W 192	-7.821	-0.312	31.358	1.00 32.44	8
	MOTA	2281	TAW 0WO	W 193	20.703	-19.058	40.128	1.00 32.50	8
	MOTA	2282	OWO WAT		23.085	18.180	25.298	1.00 32.52	8
50	ATOM	2283	TAW 0WO		18.564	11.924	14.883	1.00 32.61	8
50	ATOM	2284	TAW OWO		19.725		37.227	1.00 32.93	8
	MOTA	2285	TAW 0WO			-12.850	50.029	1.00 33.07	8
						-11.891	39.040	1.00 33.31	8
	MOTA	2286	TAW 0WO					1.00 33.34	8
	MOTA	2287	TAW 0WO		-10.872	11.311	41.622		
55	MOTA	2288	TAW 0WO		24.953	-10.123	51.108	1.00 33.47	8
	MOTA	2289	TAW 0WO		10.234	12.343	37.442	1.00 33.61	8
	MOTA	2290	TAW OWO	W 202	-1.385	9.325	49.590	1.00 33.68	8
	ATOM	2291	TAW 0WO	W 203	13.133	-13.562	50.516	1.00 33.68	8
	MOTA	2292	TAW 0WO	W 204	32.332	3.720	31.230	1.00 33.72	8
60	ATOM	2293	TAW OWO		-4.769	19.603	30.890	1.00 34.01	8
	ATOM	2294	TAW 0WO		-10.676		32.373	1.00 34.14	8
	ATOM	2295	OWO WAT		5.473		47.418	1.00 34.18	8
			TAW OWO		-0.600	-4.653	18.959	1.00 34.35	8
	ATOM	2296					48.979	1.00 34.33	8
	MOTA	2297	OWO WAT		5.122	13.867			
65	ATOM	2298	TAW OWO		-4.776		38.696	1.00 34.40	8
	MOTA	2299	TAW 0WO		22.711		56.151	1.00 34.54	8
	MOTA	2300	TAW 0WO		-5.723		25.199	1.00 34.59	8
	MOTA	2301	TAW 0WO	W 213	-5.854	7.368	47.036	1.00 34.60	8

	3.0014	0000	OFIO E	770 E 7	014	2 162	10 775	15.472	1 00	34.69	8
	ATOM	2302	OWO W			2.162	12.775				8
	MOTA	2303	OWO W			29.086	-4.835	51.244		34.91	
	MOTA	2304	OWO W			29.521	1.500	30.290		35.03	8
	MOTA	2305	OWO W	W TAN	217	9.270	16.229	27.647		35.08	8
5	MOTA	2306	OWO W	W TA	218	-0.559	-13.990	44.942	1.00	35.09	8
	ATOM	2307	OWO W	W TA	219	31.092	12.772	28.102	1.00	35.13	8
	MOTA	2308	OWO W	ש ידענ	220	4.053	17.330	40.649	1.00	35.18	8
	ATOM	2309	OWO W			9.804	12.126	12.806		35.19	8
			OWO W			16.382	10.037	14.084		35.33	8
	ATOM	2310									
10	MOTA	2311	OWO W			34.860	8.861	43.050		35.36	8
	ATOM	2312	OWO W			2.481	-1.469	55.185		35.39	8
	MOTA	2313	OWO W	W TAN	225	27.639	15.901	20.220	1.00	35.45	8
	MOTA	2314	OWO W	W TAN	226	13.522	14.546	22.193	1.00	35.58	8
	ATOM	2315	OWO W	W TA	227	18.759	-16.368	34.341	1.00	35.64	8
15	ATOM	2316	OWO W			29.746	6.054	47.983	1.00	35.88	8
	ATOM	2317	OWO W			1.824	8.703	50.441		35.91	8
			OWO W				-10.212	20.566		36.11	8
	ATOM	2318									
	ATOM	2319	OWO W			25.903	-4.307	53.039		36.25	8
	ATOM	2320	OWO W			30.041	-9.858	50.314		36.32	8
20	ATOM	2321	OWO W	IAT W	233	2.098	9.375	12.724	1.00	36.32	8
	ATOM	2322	OWO W	W TAN	234	-6.517	-10.587	46.846	1.00	36.56	8
	ATOM	2323	OWO W	AT W	235	-6.610	-3.836	30.415	1.00	36.57	8
	ATOM	2324	OWO W			-10.495	12.363	34.899	1.00	36.64	8
	ATOM	2325	OWO W			-9.368	9.062	33.012		36.76	8
25	ATOM	2326	OWO W			19.878	23.075	33.288		36.92	8
25											
	ATOM	2327	OWO W			-4.530	7.046	20.896		36.93	8
	MOTA	2328	OWO W			33.313	6.152	46.202		36.93	8
	MOTA	2329	OWO W			-8.607	4.039	46.924	1.00	37.16	8
	ATOM	2330	OWO W	W TAN	242	-0.158	-8.511	20.728	1.00	37.69	8
30	ATOM	2331	OWO W	W TA	243	5.833	13.274	13.596	1.00	37.75	8
	ATOM	2332	OWO W				-19.503	31.198	1.00	37.77	8
	ATOM	2333	OWO W				-11.125	30.496		37.88	8
			OWO W				-18.250	25.554		37.97	8
	MOTA	2334									
	ATOM	2335	OWO W			-2.981	10.860	22.607		38.01	8
35	MOTA	2336	OWO W	M TAN	248	29.733	2.478	51.185	1.00	38.06	8
	ATOM	2337	OWO W	W TAN	249	-1.876	18.713	35.692	1.00	38.18	8
	ATOM	2338	OWO W	M TAN	250	-0.040	-2.395	54.365	1.00	38.20	8
	ATOM	2339	OWO W	AT W	251	-2.499	-1.254	18.143	1.00	38.26	8
	ATOM	2340	OWO W			1.301	15.936	18.064		38.65	8
40	ATOM	2341	OWO W			-7.703	5.024	28.841		38.66	8
40										38.97	8
	ATOM	2342	OWO W				-10.548	51.105			
	ATOM	2343	OWO M			19.072	-5.777	16.600		39.02	8
	MOTA	2344	OWO W	W TA		-1.755	-6.479	25.704	1.00	39.11	8
	ATOM	2345	OWO W	M TAN	257	15.948	-20.846	38.342	1.00	39.37	8
45	ATOM	2346	OWO W	W TAN	258	-7.884	13.866	29.148	1.00	39.59	8
	MOTA	2347	OWO W	JAT W	259	34.511	11.821	32.723	1.00	39.65	8
	ATOM	2348	OWO W				-16.084	27.952		39.69	8
	ATOM	2349	OWO W			-8.601	2.060	30.456		39.87	8
	ATOM	2350	OWO W			-0.861	17.301	21.849		39.89	8
50	MOTA	2351	OMO M			8.555		47.241		39.93	8
	MOTA	2352	OMO M			24.230	-5.252	22.664		40.00	8
	ATOM	2353	OMO M	W TA	265	-1.056	0.937	53.921	1.00	40.53	8
	ATOM	2354	OWO W	W TAV	266	16.017	-13.902	22.326	1.00	40.63	8
	ATOM	2355	OWO W	W TAV	267	23.066	10.127	50.334	1.00	40.86	8
55	ATOM	2356	OMO M			12.877	15.614	35.023		40.87	8
55	ATOM	2357	OWO W			21.711	-4.797	18.761		40.90	8
	MOTA	2358	OMO M			28.676	-7.905	40.739		41.51	8
	ATOM	2359	OMO M	W TAV	271	21.557	-6.991	52.277		42.05	8
	MOTA	2360	OWO W	W TAV	272	18.619	5.353	14.661	1.00	42.32	8
60	MOTA	2361	OWO W			6.542	-6.740	51.852	1.00	42.53	8
	ATOM	2362	OWO W			13.730	15.335	37.537		42.69	8
	ATOM	2363	OWO W			25.430	5.894	14.816		42.71	8
	ATOM	2364	OWO W			-6.269	3.726	22.288		43.87	8
	ATOM	2365	OMO M			19.099	-16.349	31.912		43.95	8
65	MOTA	2366	OMO M			19.470	8.026	13.818		43.97	8
	MOTA	2367	OMO M			22.549	19.383	22.028		44.26	8
	MOTA	2368	OWO W	W TAV	280	-7.882	-11.624	39.578	1.00	44.88	8
	ATOM	2369	OWO W			12.425	-9.624	21.392	1.00	45.09	8

	ATOM	2370	OWO	TAW	W	282	9.040	-7.996	13.289	1.00	45.24	8
	ATOM	2371	OWO	TAW	W	283	18.170	-7.822	17.373	1.00	45.27	8
	ATOM	2372	OWO	TAW	W	284	20.862	6.192	13.601	1.00	45.89	8
	ATOM	2373	OWO	TAW	W	285	7.780	-19.941	30.094	1.00	46.04	8
5	ATOM	2374	OWO	WAT	W	286	25.580	16.286	35.358	1.00	46.89	8
	ATOM	2375	OWO	WAT	W	287	16.268	22.912	35.142	1.00	47.83	8
	ATOM	2376	OWO	WAT	W	288	7.741	15.092	27.401	1.00	48.86	8
	ATOM	2377	OWO	WAT	W	289	30.772	12.835	22.683	1.00	49.34	8
	ATOM	2378	OWO	WAT	W	290	22.334	12.132	49.136	1.00	49.76	8
1.0	ATOM	2379	OWO	WAT	W	291	-9.173	-1.103	47.956	1.00	50.16	8

Patent Claims

- 1. A polypeptide with reduced immune response, having one or more amino acid residues modified, wherein the C^{α} -atoms of said 5 amino acid residues are located less than 15 Å from a ligand bound to said polypeptide.
 - 2. A polypeptide according to claim 1, wherein the polypeptide has reduced allergenicity.
- 3. The polypeptide according to any of the claims 1 to 2, wherein the $C^\beta\text{-atom}$ of the amino acid residues is located closer to the ligand than the $C^\alpha\text{-atom}.$
- 4. The polypeptide according to any of the claims 1 to 3, wherein the C^{α} -atoms of the amino acid residues are located less than 10 Å from the ligand and said amino acid residues have an accessibility of at least 15%.
 - 5. The polypeptide according to any of the claims 1 to 4, wherein the ligand is a metal or metal ion.
- 6. The polypeptide according to any of the preceding claims, wherein the polypeptide is modified by substitution of amino acid residues.
 - 7. The polypeptide according to any of the claims 1 to 6, wherein the modified polypeptide has been selected from a diverse library of variants.
- 8. The polypeptide according to claim 6, wherein the substituting amino acids contain amino groups in the form of Lysine residues(s), or carboxylic groups in the form of Aspartic acid or Glutamic acid residues, or SH-groups in the form of Cysteine residues.
- 9. The polypeptide according to claim 6, wherein the modification(s) is(are) prepared by a conservative substitution of an amino acid residue, such as an Arginine to Lysine substitution or Aspargine to Aspartate/Glutamate or a Glutamine to Aspartate/Glutamate substitution or Threonine/Serine to Cysteine.
 - 10. The polypeptide according to claims 1-9, wherein the polypeptide is modified by coupling one or more polymeric molecules to said polypeptide, thereby providing a polypeptide-

polymer conjugate.

- 11. The polypeptide according to claim 10, wherein the parent polypeptide moiety of the conjugate has a molecular weight from 1 to 1000 kDa, preferred 4 to 100 kDa, more 5 preferred 12 to 60 kDa.
 - 12. The polypeptide according to claim 10, wherein the polymeric molecules coupled to the polypeptide have a molecular weight from 0.1 to 100, preferably 0.1 to 60 kDa, more preferably 0.3-5 kDa, most preferably 1 to 2 kDa.
- 13. The polypeptide according to any of the preceding claims, wherein said polypeptide or parent polypeptide is an enzyme selected from the group of Oxidoreductases, including laccases and Superoxide dismutase (SOD); Hydrolases, including carbohydrases, amylases, proteases, especially subtilisins;

 15 Transferases, including Transglutaminases (TGases); Isomerases, including Protein disulfide Isomerases (PDI); Lyases, including Pectate lyases.
- 14. The polypeptide according to claim 13, wherein said polypeptide or parent polypeptide is PD498, Savinase®, BPN´, 20 Amylase, Proteinase K, Proteinase R, Subtilisin DY, Lion Y, Rennilase®, JA16, Alcalase®.
- 15. The polypeptide according to claim 14, wherein the polypeptide or parent polypeptide of the conjugate is a PD498 variant with one or more of the following substitutions: The amino acid residues in position 86, 87, 7, 47, 51, 219, 12, 218, 10, 11, 53, 28, 1, 65, 61, 63, 67, 60, 69, 55, 44, 45, 111, 115, 109, 215, 200, 202, 170, 268, 250, 152, 254, 136, 269, 246, 141 is substituted with K, D, E, or C, preferably R250K, R250D, R250E, R250C.
- 16. The polypeptide according to claim 14, wherein the polypeptide or parent polypeptide is a BPN' variant with one or more of the following substitutions: The amino acid residues in position 77, 2, 5, 43, 214, 206, 22, 215, 14, 17, 9, 36, 211, 195, 197, 154, 163, 247, 265, 251, 143, 127, 260, 131, 128, 243 is substituted with K, D, E, or C, preferably R247K, R247D, R247E, R247C.
 - 17. The polypeptide according to claim 14, wherein the polypeptide or parent polypeptide is a Savinase $^{\text{\tiny{0}}}$ variant with

WO 00/22103

one or more of the following substitutions: The amino acid residues in position 75, 2, 42, 208, 200, 14, 22, 17, 189, 241, 125, 125, 141, 245, 259, 237, 254, 157 is substituted with K, D, E, or C, preferably R241K, R241D, R241E, R241C.

- 18. The polypeptide according to claim 14, wherein the polypeptide or parent polypeptide is an amylase variant with one or more of the following substitutions: The amino acid residue in position 124, 126, 128, 159, 160, 166, 185, 186, 189, 190, 193, 194, 195, 196, 198, 201, 202, 203, 209, 210, 214, 242, 244, 247, 296, 298, 299, 302, 303, 304, 306, 307, 308, 310, 311, 314, 345, 347, 405, 406, 407, 408, 409, 433, 434, 435, 436, 437, 475, 476, 477, 478 is substituted with K, D, E, or C.
- 19. The polypeptide according to claims 10 or 12, wherein the polymeric molecule is selected from the group comprising a 15 natural or synthetic homo- and heteropolymers, selected from the group of the synthetic polymeric molecules including Branched poly-vinyl alcohol (PVA), poly-carboxyl acids, poly-(vinylpyrolidone) and poly-D, L-amino acids, or natural occurring polymeric molecules including dextrans, including carboxymethylcelluloses such as methylcellulose, and 20 dextrans, carboxymethylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and hydrolysates of chitosan, starches, such as hydroxyethyl-starches, hydroxypropyl-starches, glycogen, agarose, guar gum, inulin, pullulans, xanthan gums, carrageenin, 25 pectin and alginic acid.
 - 20. The polypeptide according to claim 19, wherein the modified polypeptide is savinase variant R241KbPEG1000 or R241KbPEG2000.
- 21. The polypeptide according to any of claims 1 to 7, wherein the modified polypeptide is savinase variants R241Q, R241E, R241H or R241K.
 - 22. A method for preparing polypeptides with reduced immune response comprising the steps of:
- a) identifying amino acid residues located on the surface of the
 35 3-dimensional structure of the parent polypeptide in question,
 - b) selecting target amino acid residues on the surface of said 3-dimensional structure of said parent polypeptide to be modified,

- c) substituting one or more amino acid residues selected in step
- b) with other amino acid residues, and/or

WO 00/22103

- d) coupling polymeric molecules to the amino acid residues in step b)and/or step c).
- 23. The method according to claim 22, wherein the C^{α} -atoms of the amino acid residues are located less than 15 Å from the ligand bound to said polypeptide.
- 24. The method according to any of claims 22 to 23, wherein the $C^\beta\text{-atoms}$ of the amino acid residues are located closer to the ligand than the $C^\alpha\text{-atom}.$
- 25. The method according to any of the claims 22-24, wherein the C^{α} -atoms of the amino acid residues are located less than 10 Å from the ligand and said amino acid residues have an accessibility of at least 15%, preferable at least 20%, more preferably at least 30%.
- 26. The method according to any of the claims 22-25, wherein the identification of amino acid residues located on the surface on the polypeptide referred to in step a) are performed by a computer program analyzing the 3-dimensional structure of the parent polypeptide in question.
 - 27. The method according to any of the claims 22 to 26, wherein step b) comprises selecting Arginine or Lysine residues on the surface of the parent polypeptide.
- 28. The method according to claim 27, wherein one or more 25 Arginine residues identified in step b) is(are) substituted with a Lysine residue(s) in step c).
 - 29. Use of the modified polypeptide in claims 1 to 21 for reducing the allergenicity of industrial products.
- 30. Use of the modified polypeptide in claims 1 to 21 for reducing the immunogenicity of pharmaceuticals.
 - 31. A composition comprising a modified polypeptide of any of claims 1 to 21 and further comprising ingredients used in industrial products.
- 32. The composition according to claim 31, wherein the industrial product is a detergent, such as a laundry, dish wash or hard surface cleaning product, including bio-film products or a food or feed product or a textile product.

- 33. The composition according to claim 32, comprising a modified polypeptide of any of claims 1 to 21 and further ingredients used in personal care products, especially skin care products.
- 34. A composition comprising a modified polypeptide of any of claims 1 to 21 and further comprising ingredients used in pharmaceuticals.




Fig. 1




Fig. 2

1

SEQUENCE LISTING

(1) GENERAL INFORMATION:

	(i)	API	PLICE	: TNL												
			A) NA					A/S	3							
		•	3) S7													
			c) C1		_											
			E) CC					שת	2000	`						
		•	r) PC 3) TE							,						
		-	i) TE													
	(ii)		TLE C							nols	ment	ide				
			UMBE						-1-04	Por	рор					
	•		MPUT													
	,	(<i>I</i>	A) ME	DIUN	TYI	E: E	lopp	y di	isk							
			3) CC							.e						
			(C) (
		(I) sc	FTW	RE:	Pate	entIr	n Rel	lease	+1.	.0, 7	/ersi	on ‡	‡1.30	(EPO)
					· ·											
(2)			CION													
	(1)	_	OUENC						_							
			4) L E 3) T Y				_		5							
) SI													
) T (,								
	(ii)		ECUI					omio	2)							
			GINA													
		(E	3) SI	TRAIN	1: Ba	acill	lus s	sp. I	PD498	3, NO	CIMB	No.	4048	34		
	(ix)		ATURE													
			A) NA	•												
			3) LC													
	(xi)	SEÇ	QUENC	CE DE	ESCR:	[PTIC	ON: S	SEQ .	ID NO): 1	:					
raa	ጥሮል	CCG	AAT	GAC	ССТ	тΔС	ΤΔΤ	тст	ССТ	ТΔС	CAG	тдт	GGA	CCA	CAA	48
			Asn													10
1	501	10		5		-1-	-1-	201	10	-1-		-1-	1	15		
AAC	ACC	TCA	ACC	CCT	GCT	GCC	TGG	GAT	GTA	ACC	CGT	GGA	AGC	AGC	ACT	96
Asn	Thr	Ser	Thr	Pro	Ala	Ala	Trp	Asp	Val	Thr	Arg	Gly	Ser	Ser	Thr	
			20					25					30			
							~	~~~					~~ ~	~~	a	7.4.4
															GAT -	144
÷1η	Thr		Ala	vaı	ьeu	Asp		GIY	vai	Asp	Tyr	Asn 45	HIS	Pro	Asp	
		35					40					45				
بليلت	GCA	AGA	AAA	ДΤЪ	מידמ	ΔΔΔ	GGG	TAC	GAC	הרת	ATC	GAC	AGG	GAC	AAT	192
			Lys													
	50		-1-			55	1	-1-	1-		60		5			
AAC	CCA	ATG	GAT	CTT	AAC	GGA	CAT	GGT	ACC	CAT	GTT	GCC	GGT	ACT	GTT	240
Asn	${\tt Pro}$	Met	Asp	Leu	Asn	Gly	His	Gly	Thr	His	Val	Ala	Gly	Thr	Val	
65					70					75					80	
						•										
			ACG													288
Ala	Ala	Asp	Thr		Asn	Gly	Ile	Gly		Ala	Gly	Met	Ala		Asp	
				85					90					95		
א כיכו	7 7 A	7 000	CTT	aaa	Citta	ccc	ama	Cutur	C N m	CCC	יים ע ע	CCA	א כזידי	GGC	ጥር አ	336
			Leu													230
T 11T	пλя	TIG	100	ATA	val	mr. 9	val	105	Tap	VIQ	WOII	GIY	110	- T Y	JCI	

			GGT Gly					384
			CTT Leu 135					432
			GCA Ala					480
			GTA Val					528
			GGT Gly					576
			ACG Thr					624
 			CCG Pro 215					672
			CAC His					720
			GTA Val					768
			ACT Thr					816
		_	 AGA Arg					840

(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 280 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Trp Ser Pro Asn Asp Pro Tyr Tyr Ser Ala Tyr Gln Tyr Gly Pro Gln
1 5 10 15

Asn Thr Ser Thr Pro Ala Ala Trp Asp Val Thr Arg Gly Ser Ser Thr 20 25 30

- Gln Thr Val Ala Val Leu Asp Ser Gly Val Asp Tyr Asn His Pro Asp 35 40 45
- Leu Ala Arg Lys Val Ile Lys Gly Tyr Asp Phe Ile Asp Arg Asp Asn 50 55 60
- Asn Pro Met Asp Leu Asn Gly His Gly Thr His Val Ala Gly Thr Val
 65 70 75 80
- Ala Ala Asp Thr Asn Asn Gly Ile Gly Val Ala Gly Met Ala Pro Asp 85 90 95
- Thr Lys Ile Leu Ala Val Arg Val Leu Asp Ala Asn Gly Ser Gly Ser 100 105 110
- Leu Asp Ser Ile Ala Ser Gly Ile Arg Tyr Ala Ala Asp Gln Gly Ala 115 120 125
- Lys Val Leu Asn Leu Ser Leu Gly Cys Glu Cys Asn Ser Thr Thr Leu 130 135 140
- Ala Ala Gly Asn Asp Asn Val Ser Arg Thr Phe Gln Pro Ala Ser Tyr 165 170 175
- Pro Asn Ala Ile Ala Val Gly Ala Ile Asp Ser Asn Asp Arg Lys Ala 180 185 190
- Ser Phe Ser Asn Tyr Gly Thr Trp Val Asp Val Thr Ala Pro Gly Val 195 200 205
- Asn Ile Ala Ser Thr Val Pro Asn Asn Gly Tyr Ser Tyr Met Ser Gly 210 215 220
- Thr Ser Met Ala Ser Pro His Val Ala Gly Leu Ala Ala Leu Leu Ala 225 230 235 240
- Ser Gln Gly Lys Asn Asn Val Gln Ile Arg Gln Ala Ile Glu Gln Thr 245 250 255
- Ala Asp Lys Ile Ser Gly Thr Gly Thr Asn Phe Lys Tyr Gly Lys Ile 260 265 270

Asn Ser Asn Lys Ala Val Arg Tyr 275 280

- (2) INFORMATION FOR SEQ ID NO: 3:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 269 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (vi) ORIGINAL SOURCE:
 - (B) STRAIN: Bacillus lentus
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Ala Gln Ser Val Pro Trp Gly Ile Ser Arg Val Gln Ala Pro Ala Ala

1				5					10					15	
His	Asn	Arg	Gly 20	Leu	Thr	Gly	Ser	Gly 25	Val	Lys	Val	Ala	Val 30	Leu	Asp
Thr	Gly	Ile 35	Ser	Thr	His	Pro	Asp 40	Leu	Asn	Ile	Arg	Gly 45	Gly	Ala	Ser
Phe	Val 50	Pro	Gly	Glu	Pro	Ser 55	Thr	Gln	Asp	Gly	Asn 60	Gly	His	Gly	Thr
His 65	Val	Ala	Gly	Thr	Ile 70	Ala	Ala	Leu	Asn	Asn 75	Ser	Ile	Gly	Val	Leu 80
Gly	Val	Ala	Pro	Ser 85	Ala	Glu	Leu	Tyr	Ala 90	Val	Lys	Val	Leu	Gly 95	Ala
Ser	Gly	Ser	Gly 100	Ser	Val	Ser	Ser	Ile 105	Ala	Gln	Gly	Leu	Glu 110	Trp	Ala
Gly	Asn	Asn 115	Gly	Met	His	Val	Ala 120	Asn	Leu	Ser	Leu	Gly 125	Ser	Pro	Ser
Pro	Ser 130	Ala	Thr	Leu	Glu	Gln 135	Ala	Val	Asn	Ser	Ala 140	Thr	Ser	Arg	Gly
Val 145	Leu	Val	Val	Ala	Ala 150	Ser	Gly	Asn	Ser	Gly 155	Ala	Gly	Ser	Ile	Ser 160
Tyr	Pro	Ala	Arg	Tyr 165	Ala	Asn	Ala	Met	Ala 170	Val	Gly	Ala	Thr	Asp 175	Gln
Asn	Asn	Asn	Arg 180	Ala	Ser	Phe	Ser	Gln 185	Tyr	Gly	Ala	Gly	Leu 190	Asp	Ile
Val	Ala	Pro 195	Gly	Val	Asn	Val	Gln 200	Ser	Thr	Tyr	Pro	Gly 205	Ser	Thr	Tyr
Ala	Ser 210	Leu	Asn	Gly	Thr	Ser 215	Met	Ala	Thr	Pro	His 220	Val	Ala	Gly	Ala
Ala 225	Ala	Leu	Val	Lys	Gln 230	Lys	Asn	Pro	Ser	Trp 235	Ser	Asn	Val	Gln	Ile 240
Arg	Asn	His	Leu	Lys 245	Asn	Thr	Ala	Thr	Ser 250	Leu	Gly	Ser	Thr	Asn 255	Leu
Tyr	Gly	Ser	Gly		Val	Asn		Glu 265		Ala	Thr	Arg			

(2) INFORMATION FOR SEQ ID NO: 4:

WO 00/22103

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1458 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (vi) ORIGINAL SOURCE:

		FEAT	URE: NAM LOC	E/KE	Y: C N:1. CRIP	DS .145	8				349					
cac (ac t	tt c	raa 1	caa t	at	48
		Asn														
1			1	5		2			10		-			15	-	
cta	cca	aat	gac	gga	aac	cat	tgg	aat	aga	tta	agg	tct	gat	gca	agt	96
Leu	Pro	Asn	Asp	Gly	Asn	His	Trp	Asn	Arg	Leu	Arg	Ser	Asp	Ala	Ser	
			20					25					30			
aac	cta	aaa	gat	aaa	999	atc	tca	gcg	gtt	tgg	att	cct	cct	gca	tgg	144
Asn	Leu	Lys	Asp	Lys	Gly	Ile	Ser	Ala	Val	Trp	Ile	Pro	Pro	Ala	Trp	
		35					40					45				
aag	ggt	gcc	tct	caa	aat	gat	gtg	999	tat	ggt	gct	tat	gat	ctg	tat	192
Lys	Gly	Ala	Ser	Gln	Asn	Asp	Val	Gly	Tyr	Gly	Ala	Tyr	Asp	Leu	Tyr	
	50					55					60					
gat	tta	gga	gaa	ttc	aat	caa	aaa	gga	acc	att	cgt	aca	aaa	tat	gga	240
Asp	Leu	Gly	Glu	Phe	Asn	Gln	Lys	Gly	Thr	Ile	Arg	Thr	Lys	Tyr	Gly	
65					70					75					80	
		aat														288
Thr	Arg	Asn	Gln	Leu	Gln	Ala	Ala	Val	Asn	Ala	Leu	Lys	Ser	Asn	Gly	
				85					90					95		
att	caa	gtg	tat	ggc	gat	gtt	gta	atg	aat	cat	aaa	999	gga	gca	gac	336
Ile	Gln	Val	Tyr	Gly	Asp	Val	Val	Met	Asn	His	Lys	Gly	Gly	Ala	Asp	
			100					105					110			
gct	acc	gaa	atg	gtt	agg	gca	gtt	gaa	gta	aac	ccg	aat	aat	aga	aat	384
Ala	Thr	Glu	Met	Val	Arg	Ala	Val	Glu	Val	Asn	Pro	Asn	Asn	Arg	Asn	
		115					120					125				
caa	gaa	gtg	tcc	ggt	gaa	tat	aca	att	gag	gct	tgg	aca	aag	ttt	gac	432
Gln	Glu	Val	Ser	Gly	Glu	Tyr	Thr	Ile	Glu	Ala	Trp	Thr	Lys	Phe	Asp	
	130					135					140					

tt	cca	gga	cga	ggt	aat	act	cat	tca	aac	ttc	aaa	tgg	aga	tgg	tat	480
Phe	Pro	Gly	Arg	Gly	Asn	Thr	His	Ser	Asn	Phe	Lys	Trp	Arg	Trp	Tyr	
145					150					155					160	
cac	ttt	gat	gga	gta	gat	tgg	gat	cag	tca	cgt	aag	ctg	aac	aat	cga	528
His	Phe	Asp	Gly	Val	Asp	Trp	Asp	Gln	Ser	Arg	Lys	Leu	Asn	Asn	Arg	
				165					170					175		
att	tat	aaa	ttt	aga	ggt	gat	gga	aaa	g gg	tgg	gat	tgg	gaa	gtc	gat	576
							Gly									
	_	_	180					185					190			
aca	qaa	aac	ggt	aac	tat	gat	tac	cta	atg	tat	gca	gat	att	gac	atg	624
							Tyr									
		195	•		-	-	200					205				
gat	cac	cca	qaq	qta	ata	aat	gag	cta	aga	aat	tgg	ggt	gtt	tgg	tat	672
_							Glu									
	210					215					220	_				
acq	aat	aca	tta	aac	ctt	qat	ggt	ttt	aga	ata	gat	gca	gta	aaa	cat	720
_							Gly									
225				1	230	_	-		_	235	-			-	240	
ata	aaa	tac	agc	ttt	act	cat	gat	tgg	att	aat	cat	gtt	aga	agt	gca	768
							Asp									
		•		245		-	-	-	250					255		
act	aac	aaa	aat	atq	ttt	aca	gtt	aca	qaa	ttt	tgg	aaa	aat	gat	tta	816
							Val								Leu	
	0-7	-7-	260					265			-	2	270	-		
aat	act	att	gaa	aac	tat	tta	aac	aaa	aca	aac	taa	aac	cat	tca	atc	864
							Asn									
O _± y	1114	275	O.L.u	11011	-7-	200	280	-1-				285				
		د ، ب					200									
+++	ast	a++	מממ	ctc	cac	tat	aac	ct-c	tat	aat	act	tca	aaa	age	gga	912
							Asn									-
FIIC		val	FTO	пеп	HTS		VOII	Leu	+ Y T	POII	300	Der	Ly 6	JU1	- 1	
	290					295					200					

				atg Met						Gly					Arg	960
305					310					315					320	
		_		gct												1008
His	Pro	Met	His	Ala 325	Val	Thr	Phe	Val	330	Asn	His	Asp	ser	335	Pro	
																40E.
_	_	_		gag Glu												1056
0	0_u		340					345				7	350			
.	~~+	++~	202	tta	202	aat	433	C a a	aac	tac	cct	tat	ata	+++	tat	1104
	_			Leu												
		355					360					365				
aa s	ast.	tat	tat	ggc	att	cca	aca	cat	aat	ata	cca	aca	atq	aaa	t.ca	1152
	_			Gly												
	370					375					380					
aaa	att	gac	cca	att	cta	gaa	aca	cat	caa	aaq	tat	qca	tat	gga	aga	1200
		_	_	Ile		_		_		_		_			_	
385					390					395					400	
a 22	aat	asa	tac	tta	asc	cat	cat	aat	atc	atc	aat	taa	aca	cat	gaa	1248
		_		Leu	_											
		_	-	405	_				410					415		
~~~	224	202	aas	cac	aaa	220	taa	aat	<b>+</b> +=	act	act	atc	ata	tcc	gat	1296
			_	His												1270
-			420					425					430			
						+~~	2+~		~++	~~~	aat	22+	222	aat	aat	1344
				aat Asn												1344
1		435	1		. 1.3	-12	440			4		445	4		-	
				gat -												1392
Gln		Trp	Thr	Asp	Пе	Thr 455	GIY	Asn	Arg	Ala	G1y 460	Thr	val	Thr	тте	
	450					433					-0U					

aat	gct	gat	gga	tgg	ggt	aat	ttt	tct	gta	aat	gga	gga	tca	gtt	tct	1440
Asn	Ala	Asp	Gly	Trp	Gly	Asn	Phe	Ser	Val	Asn	Gly	Gly	Ser	Val	Ser	
465					470					475					480	
att	tgg	gta	aac	aaa	taa											1458
Ile	Trp	Val	Asn	Lys	*											
				485												

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00542

#### A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12N 9/96 // C11D 3/386, A61K 47/48
According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

#### IPC7: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

## SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

#### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	WO 9835026 A1 (NOVO NORDISK A/S), 13 August 1998 (13.08.98), page 5; page 22, line 15 - line 17; page 24	1-34
x	WO 9830682 A1 (NOVO NORDISK A/S), 16 July 1998 (16.07.98), claims 1-2	1-34
A	WO 9730148 A1 (NOVO NORDISK A/S), 21 August 1997 (21.08.97)	1-34
	<del></del>	
A	WO 9617929 A1 (NOVO NORDISK A/S), 13 June 1996 (13.06.96)	1-34

- Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" erlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- document referring to an oral disclosure, use, exhibition or other
- document published prior to the international filing date but later than the priority date claimed
- later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of mailing of the international search report Date of the actual completion of the international search **0 7** -02- 2000

## 31 January 2000

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Yvonne Siösteen/EÖ

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No. PCT/DK 99/00542

	101	/ DK 33/00	75-7E	
C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where appropriate, of the relevant p	assages	Relevant to claim No.	
A	WO 9640792 A1 (NOVO NORDISK A/S), 19 December 199 (19.12.96)	6	1-34	
A	Proc. Natl. Acad. Sci., Volume 88, August 1991, Michael S. Hershfield et al, "Use of site-dir mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins w polyethylene glycol" page 7185 - page 7189		1-34	
8				

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No. PCT/DK 99/00542

Patent document cited in search report		Publication date	Patent family member(s)		Publication date		
WO	9835026	A1	13/08/98	AU	5749598	A	26/08/98
WO	9830682	A1	16/07/98	AU EP	5478598 / 0954572 /		03/08/98 10/11/99
WO	9730148	A1	21/08/97	AU CA CN EP	1540697 / 2242488 / 1211278 / 0894128 /	A A	02/09/97 21/08/97 17/03/99 03/02/99
WO	9617929	A1	13/06/96	AU AU BR CA CN EP FI JP US	697440 I 4114496 A 9509976 A 2206852 A 1168694 A 0796324 A 972443 A 10510516 S 5856451 A	A A A A A T A	08/10/98 26/06/96 09/06/98 13/06/96 24/12/97 24/09/97 09/06/97 13/10/98 05/01/99 09/11/99
WO.	9640792	A1	19/12/96	AU	5893796	A	30/12/96